

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 March 2003 (20.03.2003)

PCT

(10) International Publication Number
WO 03/022856 A1

(51) International Patent Classification⁷: **C07D 519/00**,
A61K 31/4025, A61P 25/18

Tartan Circle, Portage, MI 49024 (US). **GROPPI, Vincent, E., Jr.** [US/US]; 318 Sprague Avenue, Kalamazoo, MI 49006 (US).

(21) International Application Number: PCT/US02/25959

(74) Agents: **HOSLEY, Mary, J. et al.**; Global Intellectual Property, Pharmacia & Upjohn Company, 301 Henrietta Street, Kalamazoo, MI 49001 (US).

(22) International Filing Date:
4 September 2002 (04.09.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/322,346 12 September 2001 (12.09.2001) US
60/322,333 12 September 2001 (12.09.2001) US
60/322,100 12 September 2001 (12.09.2001) US
60/399,530 30 July 2002 (30.07.2002) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(71) Applicant (*for all designated States except US*): **PHARMACIA & UPJOHN COMPANY** [US/US]; 301 Henrietta Street, Kalamazoo, MI 49001 (US).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **WISHKA, Donn, G.** [US/US]; 1431 Northampton Road, Kalamazoo, MI 49006-1993 (US). **WALKER, Daniel, Patrick** [US/US]; 9350 Highlandview Drive, Kalamazoo, MI 49009 (US). **CORBETT, Jeffrey, W.** [US/US]; 6427 Pepperidge Circle, Portage, MI 49024 (US). **REITZ, Steven, Charles** [US/US]; 5880 Firethorne Drive, Apt. G, Toledo, OH 43615 (US). **RAUCKHORST, Mark, R.** [US/US]; 3749


Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/022856 A1

(54) Title: SUBSTITUTED 7-AZA[2.2.1] BICYCLOHEPTANES FOR THE TREATMENT OF DISEASES



(I)

(57) Abstract: The invention provides compounds of Formula (I), which may be in the form of pharmaceutical acceptable salts or compositions, are useful in treating diseases or conditions in which $\alpha 7$ nicotinic acetylcholine receptors (nAChRs) are known to be involved.

SUBSTITUTED 7-AZA[2.2.1]BICYCLOHEPTANES FOR THE TREATMENT OF DISEASES

BACKGROUND OF THE INVENTION

5

FIELD OF INVENTION

Nicotinic acetylcholine receptors (nAChRs) play a large role in central nervous system (CNS) activity. Particularly, they are known to be involved in cognition, learning, mood, emotion, and neuroprotection. There are several types of nicotinic acetylcholine receptors, and each one appears to have a different role in regulating CNS function. Nicotine affects all such receptors, and has a variety of activities. Unfortunately, not all of the activities are desirable. In fact, one of the least desirable properties of nicotine is its addictive nature and the low ratio between efficacy and safety. The present invention relates to molecules that have a greater effect upon the $\alpha 7$ nAChRs as compared to other closely related members of this large ligand-gated receptor family. Thus, the invention provides compounds that are active drug molecules with fewer side effects.

BRIEF DESCRIPTION OF RELATED TECHNOLOGY

Cell surface receptors are, in general, excellent and validated drug targets. nAChRs comprise a large family of ligand-gated ion channels that control neuronal activity and brain function. These receptors have a pentameric structure. In mammals, this gene family is composed of nine alpha and four beta subunits that co-assemble to form multiple subtypes of receptors that have a distinctive pharmacology. Acetylcholine is the endogenous regulator of all of the subtypes, while nicotine non-selectively activates all nAChRs.

The $\alpha 7$ nAChR is one receptor system that has proved to be a difficult target for testing. Native $\alpha 7$ nAChR is not routinely able to be stably expressed in most mammalian cell lines (Cooper and Millar, *J. Neurochem.*, 1997, 68(5):2140-51). Another feature that makes functional assays of $\alpha 7$ nAChR challenging is that the receptor is rapidly (100 milliseconds) inactivated. This rapid inactivation greatly limits the functional assays that can be used to measure channel activity.

Recently, Eisele et al. has indicated that a chimeric receptor formed between the N-terminal ligand binding domain of the $\alpha 7$ nAChR (Eisele et al., *Nature*, 366(6454), p 479-83, 1993), and the pore forming C-terminal domain of the 5-HT₃ receptor expressed well in *Xenopus* oocytes while retaining nicotinic agonist sensitivity. Eisele et al. used the N-terminus of the avian (chick) form of the $\alpha 7$ nAChR receptor and the C-terminus of the mouse form of the 5-HT₃ gene. However, under physiological conditions the $\alpha 7$ nAChR is a calcium channel while the 5-HT₃R is a sodium and potassium channel. Indeed, Eisele et al. teaches that the chicken $\alpha 7$ nAChR/ mouse 5-HT₃R behaves quite differently than the native $\alpha 7$ nAChR with the pore element not conducting calcium but actually being blocked by calcium ions. WO 00/73431 A2 reports on assay conditions under which the 5-HT₃R can be made to conduct calcium. This assay may be used to screen for agonist activity at this receptor.

US Patent 6,255,490 discloses 7-azabicyclo[2.2.1]-heptane and -heptene derivatives as cholinergic receptor ligands.

US Patent 6,117,889 discloses 7-azabicyclo[2.2.1]-heptane and -heptene derivatives as analgesics and anti-inflammatory agents.

US Patent 6,060,473 discloses 7-azabicyclo[2.2.1]-heptane and -heptene derivatives as cholinergic receptor ligands.

US Patent 6,054,464 discloses azabicyclic esters of carbamic acids useful in therapy, especially in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders, as well as intermediates and use of intermediates in synthesis.

US Patent 5,977,144 discloses compositions for benzylidene- and cinnamylidene-anabaseines and methods for using these compositions for treating conditions associated with defects or malfunctioning of nicotinic subtypes brain receptors. These compositions target the $\alpha 7$ receptor subtype with little or no activation of the $\alpha 4\beta 2$ or other receptor subtypes.

US Patent 5,830,902 discloses quinuclidine derivatives having tricyclic hetero condensed ring. The compounds are disclosed as having strong squalene synthase inhibiting activity and being useful as a cholesterol lowering agent without causing side effects.

US Patent 5,817,679 discloses 7-azabicyclo[2.2.1]-heptane and -heptene derivatives as cholinergic receptor ligands.

US Patent 5,723,103 discloses substituted benzamides and radioligand analogs and methods of using the compounds for the identification of 5-HT₃ receptors and the
5 detection and treatment of abnormal conditions associated therewith.

US Patent 5,599,937 discloses heteroaromatic quinuclidines used for treating diseases related to muscarinic receptor function.

US Patent 5,576,434 discloses a novel process for preparing 2-(1-azabicyclo[2.2.2]oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz[de]isoquinolin-1-one, the
10 pharmaceutically acceptable salts thereof, which are 5-HT₃ receptor antagonists, and the intermediates thereof.

US Patent 5,561,149 discloses the use of a mono or bicyclic carbocyclic, or heterocyclic carboxylic, acid ester or amide or an imidazolyl carbazol in the manufacture of a medicament suitable for the treatment of stress-related psychiatric
15 disorders, for increasing vigilance, for the treatment of rhinitis or serotonin-induced disorders and/or coadministration with another active agent to increase the bioavailability thereof, or for nasal administration.

US Patent 5,556,851 discloses cinnoline-3-carboxylic acid derivatives having an antagonistic activity against serotonin 5-HT₃ receptor, its pharmaceutically
20 acceptable salts, its N-oxide derivatives or solvates thereof, and pharmaceutical formulations containing the same for the prevention and/or treatment of various disorders such as nausea and/or emesis caused by anticancer drugs or X-ray treatment, central nervous disorders such as anxiety and/or neuropathy, gastroenteric diseases such as indigestion, chronic gastritis, digestive ulcer, irritable bowel syndromes and
25 the like, hemicrania, cluster headache, trigeminal neuralgia, arrhythmia and the like.

US Patent 5,543,426 discloses the use of certain 3,7-disubstituted indole compounds for treating depression or cognitive disorders.

US Patent 5,510,478 discloses a group of 2-arylaminothiazole derivatives which bind to and stimulate central muscarinic acetylcholine receptors and are useful
30 agents for treating symptoms of cognitive disorders, specifically the impaired memory associated with a decrease in the neurotransmitter, acetylcholine. Some of the compounds of this invention also bind to 5HT_{1A} receptors and dopamine D₂ receptors, making them useful as antipsychotic agents.

US Patent 5,491,148 discloses isoquinolinones and dihydroisoquinolinones which are 5-HT₃ receptor antagonists.

US Patent 5,434,161 discloses imidazopyridines as serotonergic 5-HT₃ antagonists.

5 US Patent 5,362,740 discloses dihydrobenzofuran carboxamides useful in treating CNS disorders, but motility disorders, and/or emesis and/or pain in mammals, and/or migraine.

US Patent 5,362,734 discloses certain benzo-quinolizine compounds, derivatives thereof, and acid addition salts and identifies them as being 5-HT₃ antagonists which may be used in, for example, the treatment of neuro-psychiatric disorders.

US Patent 5,352,685 discloses thieno[3,2-b]pyridine derivatives effective for the prevention and therapeutical treatment of the symptoms caused by gastric hypanakinesis, such as heartburn, abdominal distension feeling, anorexia, unpleasant
15 feeling on upper abdomen, abdominalgia, nausea, vomiting, etc. caused by the underlying diseases such as acute and chronic gastritis, stomach and duodenum ulcer, gastroneurosis, gastroparesis, etc.

US Patent 5,342,845 discloses indole derivatives and drugs. The compound of the invention is disclosed as being effective as a gastrointestinal motor activity
20 regulator, antimigraine, antipsychotic or antianxiety drug and for dementia or orthostatic hypotension.

US Patent 5,322,951 discloses certain 1-(2,3-dihydro-indole)carbonyl intermediates useful for preparing 1-(2,3-dihydro)-1-carboxamide final products that possess 5-HT M-receptor antagonist activity.

25 US Patent 5,300,512 discloses benzimidazole compounds as being useful for treating serotonin mediated conditions with pharmaceutical compositions of the disclosed compounds which act as 5-HT₄ agonists or antagonists and/or 5-HT₃ antagonists.

US Patent 5,273,972 discloses novel 2-substituted-3-quinuclidinyl
30 arylcarboxamides and arylthiocarboxamides and corresponding arylcarboxylates which have utility as therapeutic agents which exhibit gastric prokinetic, antiemetic, anxiolytic and 5-HT (serotonin) antagonist effects in warm blooded animals.

US Patent 5,246,942 discloses certain dibenzofurancarboxamides and their use as 5-HT₃ antagonists having unique CNS, anti-emetic and gastric prokinetic activity void of any significant D₂ receptor binding properties.

5 US Patent 5,223,511 discloses benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists.

US Patent 5,217,975 discloses azabicyclic compounds for treating dementia.

US Patent 5,185,333 discloses benzazine compounds useful as drugs for the prophylaxis or treatment of various digestive diseases vomiting and disturbances in central nervous systems and the like.

10 US Patent 5,175,173 discloses carboxamides useful as antiemetic or antipsychotic agents.

US Patent 5,122,528 discloses analgesic use of benzobicyclic carboxamides.

US Patent 5,114,947 discloses method for alleviating anxiety using benzobicyclic carboxamides.

15 US Patent 5,063,231 discloses method of treatment of visceral pain.

US Patent 5,039,680 discloses 5-HT₃ antagonists in preventing or reducing dependency on dependency-inducing agents.

US Patent 5,001,133 discloses benzoic acid derivatives.

20 US Patent 4,985,424 discloses a group of new substituted 1,7-annelated 1H-indazole derivatives being strong and selective antagonists of "neuronal" 5-hydroxytryptamine (5-HT) receptors.

US Patent 4,985,437 discloses the use of certain compounds which act as antagonists of 5-hydroxytryptamine (5-HT) at 5-HT₃ receptors for the treatment of cognitive disorders such as attentional and memory deficits and dementia states.

25 US Patent 4,983,600 discloses heterocyclic compounds useful as 5-HT₃ antagonists.

US Patent 4,973,594 discloses the use of compounds which act as antagonists of 5-hydroxytryptamine (5-HT) at the 5-HT₃ receptors for the treatment of depression.

30 US Patent 4,937,247 discloses 1-acyl indazoles and are disclosed as having 5-HT₃ antagonist activity.

US Patent 4,935,511 discloses benzoxazine and benzoxazepin carboxamide 5-HT₃ antagonists properties including CNS, anti-emetic and gastric prokinetic activity and which are void of any significant D₂ receptor binding affinity.

US Patent 4,933,445 discloses heteroazabenzobicyclic carboxamide 5-HT₃ antagonists properties including CNS, anti-emetic and gastric prokinetic activity.

US Patent 4,921,982 discloses 5-halo-2,3-dihydro-2,2-dimethylbenzofuran-7-carboxylic acids which are useful as intermediates for 5-HT₃ antagonists.

5 US Patent 4,920,227 discloses benzobicyclic carboxamide 5-HT₃ antagonists.

US Patent 4,920,219 discloses substituted saturated and unsaturated indole quinoline and benzazepine carboxamides and their valuable use as 5-HT₃ antagonists having CNS and gastric prokinetic activity void of any significant D₂ receptor binding properties.

10 US Patent 4,920,127 discloses substituted indoles and their use as 5-HT₃ receptor antagonists.

US Patent 4,910,193 discloses treatment of gastrointestinal disorders.

US Patent 4,892,872 discloses benzoxazine compounds exhibiting 5-HT₃ receptor antagonistic activity and being useful as antiemetics and so on.

15 US Patent 4,888,353 discloses carboxamides useful as antiemetic or antipsychotic agents.

US Patent 4,882,327 discloses certain heterocyclic N-substituted carboxamides having 5-HT₃ receptor antagonist activity.

20 US Patent 4,835,162 discloses agonists and antagonists to nicotine as smoking deterrents.

US Patent 4,822,795 discloses pharmaceutically useful esters and amides.

US Patent 4,803,199 discloses pharmaceutically useful heterocyclic acid esters and amides or alkylene bridged piperidines as serotonin M antagonists.

25 US Patent 4,798,829 discloses 1-azabicyclo[3.2.2]nonane derivatives having gastric motility enhancing activity and/or anti-emetic activity and/or 5-HT receptor antagonist activity.

US Patent 4,797,406 discloses amides and esters containing bridged piperidines and use as serotonin M antagonists.

US Patent 4,789,673 discloses heterocyclic carboxylic acid amides and esters.

30 US Patent 4,721,720 discloses a method of treating emesis, anxiety and/or irritable bowel syndrome.

US Patent 4,612,319 discloses bridged quinolizinidinylamides, compositions containing them and methods for their use.

US Patent 4,605,652 discloses a method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes, and the pharmaceutically acceptable acid addition salts, hydrates and alcoholates thereof.

WO 02/30405 A2 discloses the treatment of affective disorders by the
5 combined action of a nicotinic receptor agonist and a monoaminergic substance.

WO 01/60821 discloses novel biarylcarboxamides.

WO 01/36417 A1 discloses novel N-azabicyclo-amide derivatives and use in therapy, especially in the treatment of prophylaxis of psychotic disorders and intellectual impairment disorders.

10 WO 01/29304 discloses quinuclidine acrylamides.

WO 00/73431 A2 discloses two binding assays to directly measure the affinity and selectivity of compounds at the $\alpha 7$ nAChR and the 5-HT₃R. The combined use of these functional and binding assays may be used to identify compounds that are selective agonists of the $\alpha 7$ nAChR.

15 WO 98/01443 discloses indole derivatives for the treatment of osteoporosis.

WO 97/35860 discloses novel benzimidazol derivatives having an affinity for the serotonergic 5-HT₃/5-HT₄ receptors.

WO 97/30998 discloses azabicyclic esters of carbamic acids useful in therapy.

WO 96/33186 discloses substituted dihydrobenzofuran derivatives as 5-HT₄
20 agonists.

WO 95/27490 discloses serotonin antagonists (5-HT₃) for treating fibromyalgia.

WO 95/04742 discloses tropyl 7-azaindol-3-ylcarboxyamides as antitussive agents.

25 WO 95/01793 discloses 5-HT₃ antagonists as topical medicaments for treatment of peripheral disorders associated with pain.

WO 94/20465 discloses indole derivatives as antagonists of excitatory amino acids.

WO 92/10494 discloses novel compounds that are 5-HT₃ receptor antagonists.

30 WO 91/17161 discloses isoquinoline amides and esters as 5-HT₃ receptor antagonists.

WO 91/09593 discloses 5-HT₃ antagonists for treatment of nausea, bradycardia or hypotension associated myocardial instability.

WO 90/14347 A as abstracted in chemical abstract 1991:143,158 discloses N-quinuclidinyl-indolecarboxamide derivatives as being antiemetics.

EP 512 350 A2 discloses 3-(indolyl-2-carboxamido) quinuclidines useful for treating diseases characterized by an excess or enhanced sensitivity to serotonin, e.g., psychosis, nausea, vomiting, dementia or other cognitive diseases, migraine, diabetes. The compound may be used to control anxiety, aggression, depression, and pain. The compounds are disclosed as serotonin 5-HT₃ antagonists.

EP 496 064 A1 discloses a process for the preparation of substituted benzofuran derivatives. The compounds are disclosed as being useful 5-HT₃ receptor antagonists.

EP 483 836 A1 discloses pyrazolo[1,5-a]pyridine-3-carboxylic acid derivatives, their preparation process, and serotonin receptor antagonists containing them as active ingredients.

EP 403 882 A2 discloses indole derivatives which have pharmacological activities such as 5-HT antagonism and the like.

DE 3810552 A1 discloses esters and amides of indolyl-, benzo[b]thiophenyl-, benzo[b]furancarboxylic acids or 4-amino-2 methoxy-benzoic acids with N-heterocyclic or N-heterobicyclic alcohols or amines. The compounds disclosed have activity against pain especially migraine, as an anti-arrhythmic for gastrointestinal disturbances, stomach disturbances, gastritis ulcer, gall bladder, spastic colon, Crohn's disease, ulcerative colitis, carcinoid syndrome, diarrhea of various types. The compounds are also disclosed as speeding stomach emptying, controlling gastro duodenal and gastro esophageal reflux, disturbances of esophageal motility, hiatal hernia, cardiac insufficiency, hypotonic stomach, paralytic ileus, manic depressive psychosis and other psychoses. The compounds are also disclosed as useful for stress related diseases, senility, and enhancement of nasal absorption of other agents, e.g., in the treatment of emesis.

In *Bioorg. & Med. Chem. Lett.* 11 (2001) 319-321, the 5-HT₃ antagonist tropisetron (ICS 205-930) is discussed as a potent and selective $\alpha 7$ nicotinic receptor partial agonist.


In *Behavioral Brain Res.*, 113 (2000) 169-181, it is discussed that the brain $\alpha 7$ nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease using DMXBA which is known as GTS-21.

In *Eur. J. Med. Chem.*, 34 (1999) 415-422, benzimidazole-2-carboxylic acid amides and esters are discussed as a new structural class of 5-HT₃ ligands.

SUMMARY OF THE INVENTION

5 In general, the present invention is directed to methods and compositions useful in treating a disease, disorder, and/or condition in a mammal in need thereof wherein the $\alpha 7$ nAChR is implicated, where the mammal would receive symptomatic relief from the administration of an $\alpha 7$ nicotinic acetylcholine receptor agonist, by using a novel compound disclosed herein.

10 In accordance with the present invention, novel compounds which demonstrate useful biological activity, and particular activity as an $\alpha 7$ nAChR agonist, are provided. More specifically, the invention provides a compound of Formula I:




Formula I

15 wherein the stereochemistry of the of the 7-azabicyclo[2.2.1]heptane ring is 1*S*, 4*R* and the nitrogen substituent at the C-2 carbon has the *exo* orientation and is 2*R*;

X is O or S;

W is



20

A₁ is N;

Each E₁, E₂, G₁, G₂, and T is independently selected from CR₃ and N, provided that no more than two of E₁, E₂, G₁, G₂, and T are N, and further provided

that when E_1 is N, G_1 and E_2 must be CR_3 , and further provided that when E_2 is N, E_1 and G_2 must be CR_3 ;

Each V_8 , V_9 , and V_{10} is independently selected from O, S, NA_5 , and $C(R_3)_2$, provided that when V_8 is $C(R_3)_2$ the R_3 substituents on the carbon atoms adjacent to

5 V_8 are moieties other than H;

Each V_1 , V_2 , V_3 , V_4 , V_5 , V_6 , and V_7 is independently selected from O, S, N, $C(R_3)$, $C(R_3)_2$, or NA_5 , provided that V_1 and V_2 , V_2 and V_3 , V_4 and V_5 , V_5 and V_6 , and V_6 and V_7 are not simultaneously O or S, or combinations of O and S, and further provided that at least one of V_1 , V_2 , and V_3 , at least one of V_4 , V_5 , and V_6 , and at least

10 one of V_5 , V_6 , and V_7 is $C(R_3)$ or $C(R_3)_2$;

Each J , J_1 , J_2 , L , L_1 , L_2 , M , M_1 , M_2 , Q , Q_1 , and Q_2 is independently selected from CR_3 and N; provided that no more than two of J , L , M , and Q , or no more than two of J_1 , L_1 , M_1 , and Q_1 , or no more than two of J_2 , L_2 , M_2 , and Q_2 are N, and provided that at least one of J , L , M , and Q is N when V_1 , V_2 , and V_3 are

15 independently selected from $C(R_3)_2$ and $C(R_3)$, when V_4 , V_5 , V_6 , and V_7 are independently selected from $C(R_3)_2$ and $C(R_3)$, and when V_8 is $C(R_3)_2$, and further provided that at least one of J_1 , L_1 , M_1 , and Q_1 or at least one of J_2 , L_2 , M_2 , and Q_2 is N when V is $C(R_3)_2$ and when V_9 and V_{10} are $C(R_3)_2$;

Each A_5 is independently H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated alkenyl, halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, R_7 , R_9 , $-C(O)R_8$, $-C(S)R_8$, $-C(O)NR_8R_8$, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, phenyl optionally substituted with 1-4 substituents independently selected from F, Cl, Br, I, R_{13} , and R_{15} , naphthyl optionally

25 substituted with 1-4 substituents independently selected from F, Cl, Br, I, R_{13} , and R_{15} , or

A_5 forms a bond to the carbon of the amide or thio amide group bound to the C-2 carbon of the 7-azabicyclo[2.2.1]heptane ring provided that only one of R_3 or A_5 forms a bond to the carbon of the amide or thio amide group;

30 R_1 is H, alkyl, cycloalkyl, halogenated alkyl, or aryl;

R_2 is H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl;

Each R_3 is independently H, F, Cl, Br, I, $-CN$, $-NO_2$, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated alkenyl, halogenated

- alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, -OR₈, -SR₈, -S(O)₂R₈, -S(O)R₈, -OS(O)₂R₈, -NR₈R₈, -C(O)R₈, -C(S)R₈, -C(O)OR₈, -C(O)NR₈R₈, -NR₈C(O)R₈, -NR₈C(O)NR₈R₈, -S(O)₂NR₈R₈,
 5 -NR₈S(O)₂R₈, R₇, R₉, phenyl optionally substituted with 1-4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅, naphthyl optionally substituted with 1-4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅, or


two R₃ groups bound to the same atom together form =O or =S where valency allows, or

- 10 R₃ forms a bond to the carbon of the amide or thio amide group bound to the C-2 carbon of the 7-azabicyclo[2.2.1]heptane ring provided that only one of R₃ or A₅ forms a bond to the carbon of the amide or thio amide group;


Each R₄ is independently H, alkyl, and substituted alkyl;

- R₆ is H, alkyl, an amino protecting group, or an alkyl group having 1-3
 15 substituents selected from F, Cl, Br, I, -OH, -CN, -NH₂, -NH(alkyl), and -N(alkyl)₂;

- R₇ is 5-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms independently selected from the group consisting of =N-, -N(R₁₈)-, -O-, and -S-, and having 0-1 substituent selected from R₁₇ and further having
 20 0-3 substituents independently selected from F, Cl, Br, or I, or R₇ is 9-membered fused-ring moieties having a 6-membered ring fused to a 5-membered ring including the formula




wherein Z₁ is O, S or NR₁₈,



25

wherein Z is C(R₁₄) or N, and Z₂ and Z₃ are independently selected from C(R₁₄)₂, C(R₁₄), O, S, N, and N(R₁₈), provided that both Z₂ and Z₃ are not simultaneously O, simultaneously S, or simultaneously O and S, or



wherein Z is C(R₁₄) or N, and Z₂ and Z₃ are independently selected from C(R₁₄)₂, C(R₁₄), O, S, N, and N(R₁₈), and Z is CR₁₄ or N, each 9-membered bicyclic ring having 0-1 substituent selected from R₁₇ and 0-3 substituents independently selected from F, Cl, Br, or I, wherein the R₇ moiety attaches to other substituents as defined in Formula I at any position on either ring as valency allows;

Each R₈ is independently H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl, R₇, R₉, phenyl optionally substituted with 1-4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅, or naphthyl optionally substituted with 1-4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅;

R₉ is 6-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms selected from =N- and having 0-1 substituent selected from R₁₅ and 0-3 substituent(s) independently selected from F, Cl, Br, or I, or R₉ is 10-membered heteroaromatic bi-cyclic moieties containing within one or both rings 1-3 heteroatoms selected from =N-, including, but not limited to, quinolinyl or isoquinolinyl, each 10-membered fused-ring moiety having 0-1 substituent selected from R₁₇ and 0-3 substituent(s) independently selected from F, Cl, Br, or I, wherein the R₉ moiety attaches to other substituents as defined in formula I at any position on either ring as valency allows;

Each R₁₀ is independently H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from R₁₃, cycloalkyl substituted with 1 substituent selected from R₁₃, heterocycloalkyl substituted with 1 substituent selected from R₁₃, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, or phenyl optionally substituted with 1-4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅;

Each R₁₁ is independently H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, or halogenated heterocycloalkyl;

R_{12} is alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, $-OR_{11}$, $-SR_{11}$, $-S(O)_2R_{11}$, $-S(O)R_{11}$, $-OS(O)_2R_{11}$, $-NR_{11}R_{11}$, $-C(O)R_{11}$, $-C(S)R_{11}$, $-NO_2$, $-C(O)NR_{11}R_{11}$, $-CN$, $-NR_{11}C(O)R_{11}$, $-NR_{11}C(O)NR_{11}R_{11}$, $-S(O)_2NR_{11}R_{11}$, or $-NR_{11}S(O)_2R_{11}$;

R_{13} is $-OR_{11}$, $-SR_{11}$, $-NR_{11}R_{11}$, $-C(O)R_{11}$, $-C(S)R_{11}$, $-C(O)NR_{11}R_{11}$, $-CN$, $-CF_3$, $-NR_{11}C(O)R_{11}$, $-NR_{11}C(O)NR_{11}R_{11}$, $-S(O)_2NR_{11}R_{11}$, $-NR_{11}S(O)_2R_{11}$, or $-NO_2$;

R_{14} is H or a substituent selected from alkyl, cycloalkyl, phenyl, or naphthyl, each optionally substituted with 1-4 substituents independently selected from F, Cl, Br, I, $-OR_{16}$, $-SR_{16}$, $-S(O)_2R_{16}$, $-S(O)R_{16}$, $-OS(O)_2R_{16}$, $-NR_{16}R_{16}$, $-C(O)R_{16}$, $-C(S)R_{16}$, $-NO_2$, $-C(O)NR_{16}R_{16}$, $-CN$, $-NR_{16}C(O)R_{16}$, $-NR_{16}C(O)NR_{16}R_{16}$, $-S(O)_2NR_{16}R_{16}$, and $-NR_{16}S(O)_2R_{16}$, and the cycloalkyl also being further optionally substituted with $=O$ or $=S$;

R_{15} is alkyl, cycloalkyl, heterocycloalkyl, heteroaryl, phenyl, or naphthyl, each optionally substituted with 1-4 substituents independently selected from F, Cl, Br, I, $-CN$, $-NO_2$, $-OR_{16}$, $-SR_{16}$, $-S(O)_2R_{16}$, $-S(O)R_{16}$, $-OS(O)_2R_{16}$, $-NR_{16}R_{16}$, $-C(O)R_{16}$, $-C(S)R_{16}$, $-C(O)NR_{16}R_{16}$, $-NR_{16}C(O)R_{16}$, $-NR_{16}C(O)NR_{16}R_{16}$, $-S(O)_2NR_{16}R_{16}$, and $-NR_{16}S(O)_2R_{16}$, and the cycloalkyl and heterocycloalkyl also being further optionally substituted with $=O$ or $=S$;

Each R_{16} is independently H, alkyl, cycloalkyl, halogenated alkyl, or halogenated cycloalkyl;

Each R_{17} is independently H, F, Cl, Br, I, R_7 , R_9 , $-CN$, $-NO_2$, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated alkenyl, halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, $-OR_8$, $-SR_8$, $-S(O)_2R_8$, $-S(O)R_8$, $-OS(O)_2R_8$, $-NR_8R_8$, $-C(O)R_8$, $-C(S)R_8$, $-C(O)NR_8R_8$, $-NR_8C(O)R_8$, $-NR_8C(O)NR_8R_8$, $-S(O)_2NR_8R_8$, $-NR_8S(O)_2R_8$, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, phenyl optionally substituted with 1-4 substituents independently selected from F, Cl, Br, I, R_{13} , and R_{15} , and naphthyl optionally substituted with 1-4 substituents independently selected from F, Cl, Br, I, R_{13} , and R_{15} ;

R_{18} is H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, phenyl, $-SO_2R_8$, or phenyl having 1 substituent

selected from R₁₂ and further having 0-3 substituents independently selected from F, Cl, Br, or I; or pharmaceutically acceptable salt thereof.

The compounds of the present invention are used to treat or prevent diseases, disorders, and/or conditions wherein the diseases, disorders, and/or condition is any one or more or combination of the following: cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, depression, anxiety, general anxiety disorder, post traumatic stress disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems in general and associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, Parkinson's disease, tardive dyskinesia, Pick's disease, dysregulation of food intake including bulimia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependant drug cessation, Gilles de la Tourette's Syndrome, age-related macular degeneration, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain.

Embodiments of the invention may include one or more or combination of the following.

One embodiment of the present invention provides a method comprising administering a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof or pharmaceutical composition containing said compound or salt thereof, to the mammal.

The compound of Formula I, wherein X is O.

The compound of Formula I, where X is S.

The compound of Formula I, where W is any one or more or combination of (a), (b), (c), (d), (e), or (f), any of which is optionally substituted with up to 4 substituents independently selected from F, Cl, Br, -CN, -NO₂, alkyl, substituted alkyl, halogenated alkyl, alkenyl, substituted alkenyl, halogenated alkenyl, alkynyl, substituted alkynyl, halogenated alkynyl, heterocycloalkyl, substituted heterocycloalkyl, halogenated heterocycloalkyl, -OR₈, -SR₈, -NR₈R₈, -NR₈C(O)R₈, or phenyl optionally substituted with up to 4 substituents independently selected from F,

Cl, Br, I, R₁₃, and R₁₅. One of ordinary skill in the art can identify where substitution occurs and at which position on the W moiety the attachment to the core molecule occurs by comparing the identified moieties with W.

The compound of Formula I, where each A₅ is independently H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated alkenyl, halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, R₇, R₉, -C(O)R₈, -C(S)R₈, -C(O)NR₈R₈, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, phenyl optionally substituted with 1-4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅, or naphthyl optionally substituted with 1-4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅.

The compound of Formula I, where A₅ forms a bond to the carbon of the amide or thio amide group bound to the C-2 carbon of the 7-azabicyclo[2.2.1]heptane ring provided that only one of R₃ or A₅ forms a bond to the carbon of the amide or thio amide group.

The compound of Formula I, where each R₃ is independently any of the following: H, F, Cl, Br, I, -CN, -NO₂, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated alkenyl, halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, -OR₈, -SR₈, -S(O)₂R₈, -S(O)R₈, -OS(O)₂R₈, -NR₈R₈, -C(O)R₈, -C(S)R₈, -C(O)OR₈, -C(O)NR₈R₈, -NR₈C(O)R₈, -NR₈C(O)NR₈R₈, -S(O)₂NR₈R₈, -NR₈S(O)₂R₈, R₇, R₉, phenyl optionally substituted with 1-4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅, or naphthyl optionally substituted with 1-4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅.

The compound of Formula I, where two R₃ groups bound to the same atom together form =O or =S where valency allows.

The compound of Formula I, where R₃ forms a bond to the carbon of the amide or thio amide group bound to the C-2 carbon of the 7-azabicyclo[2.2.1]heptane ring provided that only one of R₃ or A₅ forms a bond to the carbon of the amide or thio amide group.

The compound of Formula I, where R₁ is H, alkyl, or cycloalkyl, and wherein R₂ is H, alkyl, substituted alkyl, cycloalkyl, halogenated alkyl, or aryl.

The compound of Formula I, where (b) is any one or more or combination of the following: thieno[2,3-b]pyridin-2-yl, thieno[2,3-b]pyridin-5-yl, thieno[2,3-b]pyridin-6-yl, thieno[2,3-c]pyridin-2-yl, furo[3,2-c]pyridin-2-yl, thieno[3,2-b]pyridin-2-yl, furo[2,3-b]pyridin-2-yl, thieno[3,2-b]pyridin-5-yl, thieno[3,2-b]pyridin-6-yl, furo[2,3-c]pyridin-5-yl, thieno[3,2-c]pyridin-2-yl, 2,3-dihydrofuro[2,3-c]pyridin-5-yl, thieno[2,3-c]pyridin-5-yl, furo[2,3-c]pyridin-2-yl, thieno[3,2-c]pyridin-6-yl, 1H-pyrrolo[2,3-c]pyridin-5-yl, furo[3,2-c]pyridin-6-yl, 1-benzofuran-5-yl, 1-benzofuran-6-yl, 1-benzofuran-2-yl, 1-benzothiophene-5-yl, 1-benzothiophen-6-yl, 1-benzothiophen-2-yl, indol-5-yl, indol-6-yl, indol-2-yl, 1,3-benzothiazole-6-yl, 1,3-benzothiazole-5-yl, 1,3-benzoxazole-6-yl, 1,3-benzoxazole-5-yl, benzimidazole-6-yl, benzimidazole-5-yl, 1,3-benzodioxole-5-yl, 1H-indazole-5-yl, 1H-indazole-6-yl, 1,2-benzisothiazole-6-yl, 1,2-benzisothiazole-6-yl, 1,3-benzothiazole-5-yl, 1,3-benzothiazole-6-yl, 1,3-benzodioxole-5-yl, 1,3-benzodioxole-6-yl, 2H-isoindole-5-yl, 2H-isoindole-6-yl, 1H-benzimidazole-5-yl, 1H-benzimidazole-6-yl, [1,3]thiazolo[5,4-c]pyridine-6-yl, [1,3]thiazolo[4,5-c]pyridine-6-yl, [1,3]dioxolo[4,5-c]pyridine-6-yl, or [1,3]oxazolo[4,5-c]pyridine-6-yl, any of which is optionally substituted with up to 4 substituents independently selected from F, Cl, Br, -CN, -NO₂, alkyl, substituted alkyl, halogenated alkyl, alkenyl, substituted alkenyl, halogenated alkenyl, alkynyl, substituted alkynyl, halogenated alkynyl, heterocycloalkyl, substituted heterocycloalkyl, halogenated heterocycloalkyl, -OR₈, -SR₈, -NR₈R₈, -NR₈C(O)R₈, or phenyl optionally substituted with up to 4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅.

The compound of Formula I, where each R₄ is independently H, lower alkyl, or substituted lower alkyl.

The compound of Formula I, where R₆ is an amino protecting group.

The compound of Formula I, where R₆ is H, or lower alkyl optionally substituted with up to 3 substituents independently selected from F, Cl, Br, I, -OH, -CN, -NH₂, -NH(alkyl), or -N(alkyl)₂.

The compound of Formula I, where R₁ is H or lower alkyl, and where R₂ is H or lower alkyl.

- The compound of Formula I, where at least one R_4 is H and one R_4 is H or lower alkyl optionally substituted with 1 substituent selected from $-OR_{10}$, $-SR_{10}$, $-S(O)R_{10}$, $-S(O)_2R_{10}$, $-OS(O)_2R_{10}$, $-NR_{10}R_{10}$, $-C(O)R_{10}$, $-C(O)OR_{10}$, $-C(S)R_{10}$, $-C(O)NR_{10}R_{10}$, $-CN$, $-NR_{10}C(O)R_{10}$, $-NR_{10}C(O)NR_{10}R_{10}$, $-S(O)_2NR_{10}R_{10}$, $-NR_{10}S(O)_2R_{10}$, $-NO_2$, or phenyl optionally substituted with up to 4 substituents independently selected from F, Cl, Br, I, R_{13} , and R_{15} , provided that when said lower alkyl is optionally substituted, said lower alkyl can be further optionally substituted with up to 3 substituents independently selected from F, Cl, Br, and I, wherein R_{10} is H, lower alkyl, or halogenated lower alkyl. This allows the lower alkyl to be substituted with one substituent selected from $-OR_{10}$, $-SR_{10}$, $-S(O)R_{10}$, $-S(O)_2R_{10}$, $-OS(O)_2R_{10}$, $-NR_{10}R_{10}$, $-C(O)R_{10}$, $-C(O)OR_{10}$, $-C(S)R_{10}$, $-C(O)NR_{10}R_{10}$, $-CN$, $-NR_{10}C(O)R_{10}$, $-NR_{10}C(O)NR_{10}R_{10}$, $-S(O)_2NR_{10}R_{10}$, $-NR_{10}S(O)_2R_{10}$, $-NO_2$, or phenyl optionally substituted with up to 4 substituents independently selected from F, Cl, Br, I, R_{13} , and R_{15} , and further optionally substituted with up to 3 substituents independently selected from F, Cl, Br, and I on any carbon with sufficient valency for said substitution.

The compound of Formula I, where R_1 , R_2 , and each R_4 are H.

- The compound of Formula I, where the compound is any one or more or combination of the following as the free base, or pharmaceutically acceptable salt thereof:
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-methylfuro[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,2-c]pyridine-6-carboxamide;
- N-[(2R)-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethylfuro[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-isopropyl-furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1H-pyrrolo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1,3-benzodioxole-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1H-pyrrolo[2,3-c]pyridine-2-carboxamide;
- N-[(1S, 2R, 4R)-7-methyl-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-methyl-7-azabicyclo[2.2.1]hept-2-yl]-1-benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1-benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1-benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-bromofuro[2,3-c]pyridine-5-
- 10 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1-benzofuran-2-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-chlorofuro[2,3-c]pyridine-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-methyl-1-benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-methyl-1-benzofuran-6-carboxamide;
- 20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-isopropyl-1-benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-methyl-1-benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-bromo-1-benzofuran-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethynyl-1-benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-prop-1-ynyl-1-benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-bromothieno[2,3-c]pyridine-5-
- 30 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1H-indole-2-carboxamide;
- N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-1-benzothiophene-2-carboxamide; or

N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-methyl-1-benzofuran-5-carboxamide.

The compound of Formula I, where the compound is any one or more or
 5 combination of the following as the free base, or pharmaceutically acceptable salt thereof:

- 7-methyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-5-carboxamide;
- 7-methylthio-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-5-carboxamide;
- 10 7-methoxy-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-5-carboxamide;
- 7-chloro-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-vinylbenzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-ethynylbenzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-prop-1-ynylbenzofuran-5-
- 15 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-hydroxyprop-1-ynyl)benzofuran-5-carboxamide;
- methyl 3-(5-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl) benzofuran-2-yl)prop-2-ynoate;
- 20 2-(5-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl) benzofuran-2-yl)prop-2-ynoic acid;
- 2-(3-amino-3-oxoprop-1-ynyl)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-cyanobenzofuran-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-chlorobenzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-fluorobenzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-iodobenzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-trifluoromethylbenzofuran-5-carboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-mercaptobenzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylthio)benzofuran-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylamino)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(formylamino)benzofuran-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[formyl(methyl)amino]benzofuran-5-carboxamide;
- 2-(acetylamino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-5-carboxamide;
- 2-(acetyl(methyl)amino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-5-
- 10 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(trifluoroacetyl)amino]benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(benzoylamino)benzofuran-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(diethylamino)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(diisopropylamino)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(pyrrolidin-1-yl)benzofuran-5-
- 20 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopyrrolidin-1-yl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperidin-1-yl)benzofuran-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopiperidin-1-yl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(morpholin-4-yl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxomorpholin-4-yl)benzofuran-5-
- 30 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(thiomorpholin-4-yl)benzofuran-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxothiomorpholin-4-yl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperazin-1-yl)benzofuran-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopiperazin-1-yl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methylpiperazin-1-yl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methyl-2-oxopiperazin-1-yl)benzofuran-5-carboxamide;
- 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxopiperazin-1-yl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methyl-3-oxopiperazin-1-yl)benzofuran-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(cyclopropylamino)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[dimethylamino]benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-pyrrole-1-yl)benzofuran-5-carboxamide;
- 20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-imidazol-1-yl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-1,2,4-triazol-1-yl)benzofuran-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-1,2,3-triazol-1-yl)benzofuran-5-carboxamide;
- N-5-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-2,5-dicarboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(pyrrolidin-1-ylcarbonyl)benzofuran-5-carboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperidin-1-ylcarbonyl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperazin-1-ylcarbonyl)benzofuran-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(4-methylpiperazin-1-yl)carbonyl]benzofuran-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(morpholin-4-ylcarbonyl)benzofuran-5-carboxamide;
5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(thiomorpholin-4-ylcarbonyl)benzofuran-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(aziridin-1-ylcarbonyl)benzofuran-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(azetidin-1-ylcarbonyl)benzofuran-5-
10 carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-formylbenzofuran-5-carboxamide;
2-acetyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(trifluoroacetyl)benzofuran-5-carboxamide;
15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(phenyl)sulfonyl]benzofuran-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylsulfonyl)benzofuran-5-carboxamide;
5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl} benzofuran -2-
20 carboxylic acid;
methyl 5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}benzofuran-2-carboxylate;
isopropyl 5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}benzofuran-2-carboxylate;
25 2,2,2-trifluoroethyl 5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}benzofuran-2-carboxylate;

N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-vinylbenzofuran-6-carboxamide;
4-methyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-6-carboxamide;
30 4-methylthio-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-6-carboxamide;
4-methoxy-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-6-carboxamide;
4-chloro-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-6-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-ethynylbenzofuran-6-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-prop-1-ynylbenzofuran-6-
carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-hydroxyprop-1-ynyl)benzofuran-
5 6-carboxamide;
methyl 3-(6-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl) benzofuran-
2-yl)prop-2-ynoate;
2-(6-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl) benzofuran-2-
yl)prop-2-ynoic acid;
10 2-(3-amino-3-oxoprop-1-ynyl)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-
yl]benzofuran-6-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-cyanobenzofuran-6-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-chlorobenzofuran-6-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-fluorobenzofuran-6-carboxamide;
15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-iodobenzofuran-6-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-trifluoromethylbenzofuran-6-
carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-mercaptobenzofuran-6-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylthio)benzofuran-6-
20 carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylamino)benzofuran-6-
carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(formylamino)benzofuran-6-
carboxamide;
25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[formyl(methyl)amino]benzofuran-6-
carboxamide;
2-(acetylamino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-6-
carboxamide;
2-(acetyl(methyl)amino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-6-
30 carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(trifluoroacetyl)amino]benzofuran-
6-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(benzoylamino)benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(diethylamino)benzofuran-6-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(diisopropylamino)benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(pyrrolidin-1-yl)benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopyrrolidin-1-yl)benzofuran-6-
- 10 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperidin-1-yl)benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopiperidin-1-yl)benzofuran-6-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(morpholin-4-yl)benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxomorpholin-4-yl)benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(thiomorpholin-4-yl)benzofuran-6-
- 20 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxothiomorpholin-4-yl)benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperazin-1-yl)benzofuran-6-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopiperazin-1-yl)benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methylpiperazin-1-yl)benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methyl-2-oxopiperazin-
- 30 1-yl)benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxopiperazin-1-yl)benzofuran-6-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methyl-3-oxopiperazin-1-yl)benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(cyclopropylamino)benzofuran-6-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[dimethylamino]benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-pyrrole-1-yl)benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-imidazol-1-yl)benzofuran-6-carboxamide;
- 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-1,2,4-triazol-1-yl)benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-1,2,3-triazol-1-yl)benzofuran-6-carboxamide;
- 15 N-6-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-2,6-dicarboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(pyrrolidin-1-ylcarbonyl)benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperidin-1-ylcarbonyl)benzofuran-6-carboxamide;
- 20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperazin-1-ylcarbonyl)benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(4-methylpiperazin-1-yl)carbonyl]benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(morpholin-4-ylcarbonyl)benzofuran-6-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(thiomorpholin-4-ylcarbonyl)benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(aziridin-1-ylcarbonyl)benzofuran-6-carboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(azetidin-1-ylcarbonyl)benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-formylbenzofuran-6-carboxamide;
- 2-acetyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-6-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(trifluoroacetyl)benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(phenyl)sulfonyl]benzofuran-6-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylsulfonyl)benzofuran-6-carboxamide;
- 6-[[[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl] benzofuran-2-carboxylic acid;
- methyl 6-[[[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl] benzofuran-2-
- 10 carboxylate;
- isopropyl 6-[[[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl] benzofuran-2-carboxylate;
- 2,2,2-trifluoroethyl 6-[[[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl] benzofuran-2-carboxylate;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-vinylbenzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethynylbenzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-prop-1-ynylbenzofuran-5-carboxamide;
- 20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(3-hydroxyprop-1-ynyl)benzofuran-5-carboxamide;
- methyl 3-(5-[[[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl] benzofuran-3-yl)prop-2-ynoate;
- 3-(5-[[[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl] benzofuran-3-
- 25 yl)prop-2-ynoic acid;
- 3-(3-amino-3-oxoprop-1-ynyl)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-cyanobenzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-chlorobenzofuran-5-carboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-fluorobenzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-iodobenzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-trifluoromethylbenzofuran-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-mercaptobenzofuran-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(methylthio)benzofuran-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(methylamino)benzofuran-5-carboxamide;
5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(formylamino)benzofuran-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[formyl(methyl)amino]benzofuran-5-carboxamide;
10 3-(acetylamino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-5-carboxamide;
3-(acetyl(methyl)amino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[(trifluoroacetyl)amino]benzofuran-5-carboxamide;
15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(benzoylamino)benzofuran-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(diethylamino)benzofuran-5-carboxamide;
20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(diisopropylamino)benzofuran-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(pyrrolidin-1-yl)benzofuran-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(2-oxopyrrolidin-1-yl)benzofuran-5-carboxamide;
25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(piperidin-1-yl)benzofuran-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(2-oxopiperidin-1-yl)benzofuran-5-carboxamide;
30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(morpholin-4-yl)benzofuran-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(3-oxomorpholin-4-yl)benzofuran-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(thiomorpholin-4-yl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(3-oxothiomorpholin-4-yl)benzofuran-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(piperazin-1-yl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(2-oxopiperazin-1-yl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(4-methylpiperazin-1-yl)benzofuran-
- 10 5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(4-methyl-2-oxopiperazin-1-yl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(3-oxopiperazin-1-yl)benzofuran-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(4-methyl-3-oxopiperazin-1-yl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(cyclopropylamino)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[dimethylamino]benzofuran-5-
- 20 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(1H-pyrrole-1-yl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(1H-imidazol-1-yl)benzofuran-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(1H-1,2,4-triazol-1-yl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(1H-1,2,3-triazol-1-yl)benzofuran-5-carboxamide;
- N-5-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-3,5-dicarboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(pyrrolidin-1-ylcarbonyl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(piperidin-1-ylcarbonyl)benzofuran-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(piperazin-1-ylcarbonyl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[(4-methylpiperazin-1-yl)carbonyl]benzofuran-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(morpholin-4-ylcarbonyl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(thiomorpholin-4-ylcarbonyl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(aziridin-1-ylcarbonyl)benzofuran-5-
- 10 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(azetidin-1-ylcarbonyl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-formylbenzofuran-5-carboxamide;
- 3-acetyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(trifluoroacetyl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[(phenyl)sulfonyl]benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(methylsulfonyl)benzofuran-5-
- 20 carboxamide;
- 5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl} benzofuran -3-carboxylic acid;
- methyl 5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}benzofuran-3-carboxylate;
- 25 isopropyl 5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}benzofuran-3-carboxylate; or
- 2,2,2-trifluoroethyl 5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}benzofuran-3-carboxylate.

30 The compound of Formula I, where the compound is any one or more or combination of the following as the free base, or pharmaceutically acceptable salt thereof:

N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-vinylbenzothiophene-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-ethynylbenzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-prop-1-ynylbenzothiophene-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-hydroxyprop-1-ynyl)benzothiophene-5-carboxamide;
- methyl 3-(5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}benzothiophen-2-yl)prop-2-ynoate;
- 3-(5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl} benzothiophen-2-yl)prop-2-ynoic acid;
- 10 2-(3-amino-3-oxoprop-1-ynyl)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-cyanobenzothiophene-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-chlorobenzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-fluorobenzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-iodobenzothiophene-5-carboxamide;
- 20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-trifluoromethylbenzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-mercaptobenzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylthio)benzothiophene-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylamino)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(formylamino)benzothiophene-5-carboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[formyl(methyl)amino]benzothiophene-5-carboxamide;
- 2-(acetylamino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-5-carboxamide;

- 2-(acetyl(methyl)amino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(trifluoroacetyl)amino]benzothiophene-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(benzoylamino)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(diethylamino)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(diisopropylamino)benzothiophene-
- 10 5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(pyrrolidin-1-yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopyrrolidin-1-yl)benzothiophene-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperidin-1-yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopiperidin-1-yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(morpholin-4-yl)benzothiophene-5-
- 20 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxomorpholin-4-yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(thiomorpholin-4-yl)benzothiophene-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxothiomorpholin-4-yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperazin-1-yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopiperazin-1-yl)benzothiophene-
- 30 5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methylpiperazin-1-yl)benzothiophene-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methyl-2-oxopiperazin-1-yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxopiperazin-1-yl)benzothiophene-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methyl-3-oxopiperazin-1-yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(cyclopropylamino)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[dimethylamino]benzothiophene-5-carboxamide;
- 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-pyrrole-1-yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-imidazol-1-yl)benzothiophene-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-1,2,4-triazol-1-yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-1,2,3-triazol-1-yl)benzothiophene-5-carboxamide;
- N-5-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-2,5-dicarboxamide;
- 20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(pyrrolidin-1-ylcarbonyl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperidin-1-ylcarbonyl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperazin-1-ylcarbonyl)benzothiophene-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(4-methylpiperazin-1-yl)carbonyl]benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(morpholin-4-ylcarbonyl)benzothiophene-5-carboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(thiomorpholin-4-ylcarbonyl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(aziridin-1-ylcarbonyl)benzothiophene-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(azetidin-1-ylcarbonyl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-formylbenzothiophene-5-carboxamide;
- 5 2-acetyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(trifluoroacetyl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(phenyl)sulfonyl]benzothiophene-10 5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylsulfonyl)benzothiophene-5-carboxamide;
- 5-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl} benzothiophene-2-carboxylic acid;
- 15 methyl 5-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl} benzothiophene-2-carboxylate;
- isopropyl 5-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl} benzothiophene-2-carboxylate;
- 2,2,2-trifluoroethyl 5-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl} benzothiophene-2-carboxylate;
- 20 2,2,2-trifluoroethyl 5-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl} benzothiophene-2-carboxylate;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-vinylbenzothiophene-6-carboxamide;
- 4-methyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-6-carboxamide;
- 25 4-methylthio-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-6-carboxamide;
- 4-methoxy-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-6-carboxamide;
- 4-chloro-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-6-carboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-ethynylbenzothiophene-6-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-prop-1-ynylbenzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-hydroxyprop-1-ynyl)benzothiophene-6-carboxamide;
- 5 methyl 3-(6-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl)benzothiophene-2-yl)prop-2-ynoate;
- 2-(6-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl) benzothiophen-2-yl)prop-2-ynoic acid;
- 2-(3-amino-3-oxoprop-1-ynyl)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-6-carboxamide;
- 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-cyanobenzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-chlorobenzothiophene-6-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-fluorobenzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-iodobenzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-trifluoromethylbenzothiophene-6-carboxamide;
- 20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-mercaptobenzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylthio)benzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylamino)benzothiophene-6-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(formylamino)benzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[formyl(methyl)amino]benzothiophene-6-carboxamide;
- 30 2-(acetylamino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-6-carboxamide;
- 2-(acetyl(methyl)amino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-6-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-
[(trifluoroacetyl)amino]benzothiophene-6-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(benzoylamino)benzothiophene-6-
carboxamide;
5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(diethylamino)benzothiophene-6-
carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(diisopropylamino)benzothiophene-
6-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(pyrrolidin-1-yl)benzothiophene-6-
10 carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopyrrolidin-1-yl)benzothiophene-
6-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperidin-1-yl)benzothiophene-6-
carboxamide;
15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopiperidin-1-yl)benzothiophene-
6-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(morpholin-4-yl)benzothiophene-6-
carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxomorpholin-
20 4yl)benzothiophene-6-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(thiomorpholin-4yl)benzothiophene-
6-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxothiomorpholin-
4yl)benzothiophene-6-carboxamide;
25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperazin-1-yl)benzothiophene-6-
carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopiperazin-1-yl)benzothiophene-
6-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methylpiperazin-1-
30 yl)benzothiophene-6-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methyl-2-oxopiperazin-
1yl)benzothiophene-6-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxopiperazin-1-yl)benzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methyl-3-oxopiperazin-1-yl)benzothiophene-6-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(cyclopropylamino)benzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[dimethylamino]benzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-pyrrole-1-yl)benzothiophene-6-
- 10 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-imidazol-1-yl)benzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-1,2,4-triazol-1-yl)benzothiophene-6-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-1,2,3-triazol-1-yl)benzothiophene-6-carboxamide;
- N-6-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-2,6-dicarboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(pyrrolidin-1-ylcarbonyl)benzothiophene-6-carboxamide;
- 20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperidin-1-ylcarbonyl)benzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperazin-1-ylcarbonyl)benzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(4-methylpiperazin-1-
- 25 yl)carbonyl]benzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(morpholin-4-ylcarbonyl)benzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(thiomorpholin-4-ylcarbonyl)benzothiophene-6-carboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(aziridin-1-ylcarbonyl)benzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(azetidin-1-ylcarbonyl)benzothiophene-6-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-formylbenzothiophene-6-carboxamide;
- 2-acetyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-6-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(trifluoroacetyl)benzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(phenyl)sulfonyl]benzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylsulfonyl)benzothiophene-6-
- 10 carboxamide;
- 6-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl) benzothiophene-2-carboxylic acid;
- methyl 6-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl) benzothiophene-2-carboxylate;
- 15 isopropyl 6-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl) benzothiophene-2-carboxylate;
- 2,2,2-trifluoroethyl 6-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl) benzothiophene-2-carboxylate;
- 20 7-methyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-5-carboxamide;
- 7-methylthio-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-5-carboxamide;
- 7-methoxy-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-5-
- 25 carboxamide;
- 7-chloro-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-vinylbenzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethynylbenzothiophene-5-
- 30 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-prop-1-ynylbenzothiophene-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(3-hydroxyprop-1-ynyl)benzothiophene-5-carboxamide;
methyl 3-(5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}benzothiophen-3-yl)prop-2-ynoate;
- 5 3-(5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl} benzothiophen-3-yl)prop-2-ynoic acid;
3-(3-amino-3-oxoprop-1-ynyl)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-cyanobenzothiophene-5-
- 10 carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-chlorobenzothiophene-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-fluorobenzothiophene-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-iodobenzothiophene-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-trifluoromethylbenzothiophene-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-mercaptopbenzothiophene-5-carboxamide;
- 20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(methylthio)benzothiophene-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(methylamino)benzothiophene-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(formylamino)benzothiophene-5-
- 25 carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[formyl(methyl)amino]benzothiophene-5-carboxamide;
3-(acetylamino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-5-carboxamide;
- 30 3-(acetyl(methyl)amino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[(trifluoroacetyl)amino]benzothiophene-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(benzoylamino)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(diethylamino)benzothiophene-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(diisopropylamino)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(pyrrolidin-1-yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(2-oxopyrrolidin-1-yl)benzothiophene-5-carboxamide;
- 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(piperidin-1-yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(2-oxopiperidin-1-yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(morpholin-4-yl)benzothiophene-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(3-oxomorpholin-4-yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(thiomorpholin-4-yl)benzothiophene-5-carboxamide;
- 20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(3-oxothiomorpholin-4-yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(piperazin-1-yl)benzothiophene-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(2-oxopiperazin-1-yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(4-methylpiperazin-1-yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(4-methyl-2-oxopiperazin-1-yl)benzothiophene-5-carboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(3-oxopiperazin-1-yl)benzothiophene-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(4-methyl-3-oxopiperazin-1-yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(cyclopropylamino)benzothiophene-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[dimethylamino]benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(1H-pyrrole-1-yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(1H-imidazol-1-yl)benzothiophene-5-carboxamide;
- 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(1H-1,2,4-triazol-1-yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(1H-1,2,3-triazol-1-yl)benzothiophene-5-carboxamide;
- 15 N-5-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-3,5-dicarboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(pyrrolidin-1-ylcarbonyl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(piperidin-1-ylcarbonyl)benzothiophene-5-carboxamide;
- 20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(piperazin-1-ylcarbonyl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[(4-methylpiperazin-1-yl)carbonyl]benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(morpholin-4-ylcarbonyl)benzothiophene-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(thiomorpholin-4-ylcarbonyl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(aziridin-1-ylcarbonyl)benzothiophene-5-carboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(azetidin-1-ylcarbonyl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-formylbenzothiophene-5-carboxamide;

- 3-acetyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(trifluoroacetyl)benzothiophene-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[(phenyl)sulfonyl]benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(methylsulfonyl)benzothiophene-5-carboxamide;
- 5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl} benzothiophene-3-
- 10 carboxylic acid;
- methyl 5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl} benzothiophene-3-carboxylate;
- isopropyl 5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl} benzothiophene-3-carboxylate; or
- 15 2,2,2-trifluoroethyl 5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl} benzothiophene-3-carboxylate.

- The compound of Formula I, where the compound is any one or more or combination of the following as the free base, or pharmaceutally acceptable salt
- 20 thereof:
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-vinylfuro[2,3-c]pyridine-5-carboxamide;
- 7-methyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-carboxamide;
- 25 7-methylthio-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-carboxamide;
- 7-chloro-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-carboxamide;
- 7-methoxy-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-
- 30 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethynylfuro[2,3-c]pyridine-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-prop-1-ynylfuro[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(3-hydroxyprop-1-ynyl)furo[2,3-c]pyridine-5-carboxamide;
- 5 methyl 3-(5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}furo[2,3-c]pyridin-3-yl)prop-2-ynoate;
- 3-(5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}furo[2,3-c]pyridin-3-yl)prop-2-ynoic acid;
- 3-(3-amino-3-oxoprop-1-ynyl)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-carboxamide;
- 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-cyanofuro[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-fluorofuro[2,3-c]pyridine-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-iodofuro[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-trifluoromethylfuro[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-mercaptofuro[2,3-c]pyridine-5-
- 20 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(methylthio)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(methylamino)furo[2,3-c]pyridine-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(formylamino)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[formyl(methyl)amino]furo[2,3-c]pyridine-5-carboxamide;
- 3-(acetylamino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-
- 30 carboxamide;
- 3-(acetyl(methyl)amino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[(trifluoroacetyl)amino]furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(benzoylamino)furo[2,3-c]pyridine-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(diethylamino)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(diisopropylamino)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(pyrrolidin-1-yl)furo[2,3-c]pyridine-10 5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(2-oxopyrrolidin-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(piperidin-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(2-oxopiperidin-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(morpholin-4-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(3-oxomorpholin-4-yl)furo[2,3-c]pyridine-5-carboxamide;
- 20 c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(thiomorpholin-4-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(3-oxothiomorpholin-4-yl)furo[2,3-c]pyridine-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(piperazin-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(2-oxopiperazin-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(4-methylpiperazin-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- 30 c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(4-methyl-2-oxopiperazin-1-yl)furo[2,3-c]pyridine-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(3-oxopiperazin-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(4-methyl-3-oxopiperazin-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(cyclopropylamino)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[dimethylamino]furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(1H-pyrrole-1-yl)furo[2,3-c]pyridine-
- 10 5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(1H-imidazol-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(1H-1,2,4-triazol-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(1H-1,2,3-triazol-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-5-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-3,5-dicarboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(pyrrolidin-1-ylcarbonyl)furo[2,3-
- 20 c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(piperidin-1-ylcarbonyl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(piperazin-1-ylcarbonyl)furo[2,3-c]pyridine-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[(4-methylpiperazin-1-yl)carbonyl]furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(morpholin-4-ylcarbonyl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(thiomorpholin-4-
- 30 ylcarbonyl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(aziridin-1-ylcarbonyl)furo[2,3-c]pyridine-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(azetidin-1-ylcarbonyl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-formylfuro[2,3-c]pyridine-5-carboxamide;
- 5 3-acetyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(trifluoroacetyl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[(phenyl)sulfonyl]furo[2,3-c]pyridine-5-carboxamide;
- 10 c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(methylsulfonyl)furo[2,3-c]pyridine-5-carboxamide;
- 5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}furo[2,3-c]pyridine-3-carboxylic acid;
- 15 methyl 5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}furo[2,3-c]pyridine-3-carboxylate;
- isopropyl 5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}furo[2,3-c]pyridine-3-carboxylate;
- 2,2,2-trifluoroethyl 5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}furo[2,3-c]pyridine-3-carboxylate;
- 20 ylamino]carbonyl}furo[2,3-c]pyridine-3-carboxylate;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-vinylfuro[3,2-c]pyridine-6-carboxamide;
- 4-methyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[3,2-c]pyridine-6-carboxamide;
- 25 4-methylthio-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[3,2-c]pyridine-6-carboxamide;
- 4-methoxy-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[3,2-c]pyridine-6-carboxamide;
- 30 4-chloro-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-ethynylfuro[3,2-c]pyridine-6-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-prop-1-ynylfuro[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-hydroxyprop-1-ynyl)furo[3,2-c]pyridine-6-carboxamide;
- 5 methyl 3-(6-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}furo[3,2-c]pyridin-2-yl)prop-2-ynoate;
- 2-(6-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}furo[3,2-c]pyridin-2-yl)prop-2-ynoic acid;
- 2-(3-amino-3-oxoprop-1-ynyl)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[3,2-c]pyridine-6-carboxamide;
- 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-cyanofuro[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-chlorofuro[3,2-c]pyridine-6-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-fluorofuro[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-iodofuro[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-trifluoromethylfuro[3,2-c]pyridine-6-carboxamide;
- 20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-mercaptofuro[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylthio)furo[3,2-c]pyridine-6-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylamino)furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(formylamino)furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[formyl(methyl)amino]furo[3,2-c]pyridine-6-carboxamide;
- 30 2-(acetylamino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[3,2-c]pyridine-6-carboxamide;

- 2-(acetyl(methyl)amino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(trifluoroacetyl)amino]furo[3,2-c]pyridine-6-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(benzoylamino)furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(diethylamino)furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(diisopropylamino)furo[3,2-c]pyridine-6-carboxamide;
- 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(pyrrolidin-1-yl)furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopyrrolidin-1-yl)furo[3,2-c]pyridine-6-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperidin-1-yl)furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopiperidin-1-yl)furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(morpholin-4-yl)furo[3,2-c]pyridine-6-carboxamide;
- 20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxomorpholin-4-yl)furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(thiomorpholin-4-yl)furo[3,2-c]pyridine-6-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxothiomorpholin-4-yl)furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperazin-1-yl)furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopiperazin-1-yl)furo[3,2-c]pyridine-6-carboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methylpiperazin-1-yl)furo[3,2-c]pyridine-6-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methyl-2-oxopiperazin-1-yl)furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxopiperazin-1-yl)furo[3,2-c]pyridine-6-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methyl-3-oxopiperazin-1-yl)furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(cyclopropylamino)furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[dimethylamino]furo[3,2-c]pyridine-
- 10 6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-pyrrole-1-yl)furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-imidazol-1-yl)furo[3,2-c]pyridine-6-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-1,2,4-triazol-1-yl)furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-1,2,3-triazol-1-yl)furo[3,2-c]pyridine-6-carboxamide;
- N-6-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[3,2-c]pyridine-2,6-
- 20 dicarboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(pyrrolidin-1-ylcarbonyl)furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperidin-1-ylcarbonyl)furo[3,2-c]pyridine-6-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperazin-1-ylcarbonyl)furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(4-methylpiperazin-1-yl)carbonyl]furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(morpholin-4-ylcarbonyl)furo[3,2-
- 30 c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(thiomorpholin-4-ylcarbonyl)furo[3,2-c]pyridine-6-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(aziridin-1-ylcarbonyl)furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(azetidin-1-ylcarbonyl)furo[3,2-c]pyridine-6-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-formylfuro[3,2-c]pyridine-6-carboxamide;
- 2-acetyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(trifluoroacetyl)furo[3,2-c]pyridine-
- 10 6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(phenyl)sulfonyl]furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylsulfonyl)furo[3,2-c]pyridine-
- 15 6-[[[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl]furo[3,2-c]pyridine-2-carboxylic acid;
- methyl 6-[[[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl]furo[3,2-c]pyridine-2-carboxylate;
- isopropyl 6-[[[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl]furo[3,2-
- 20 c]pyridine-2-carboxylate;
- 2,2,2-trifluoroethyl 6-[[[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl]furo[3,2-c]pyridine-2-carboxylate;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-vinylfuro[2,3-c]pyridine-5-
- 25 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-ethynylfuro[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-prop-1-ynylfuro[2,3-c]pyridine-5-carboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-hydroxyprop-1-ynyl)furo[2,3-c]pyridine-5-carboxamide;
- methyl 3-(5-[[[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl]furo[2,3-c]pyridine-2-yl)prop-2-ynoate;

- 2-(5-{{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}furo[2,3-c]pyridin-2-yl}prop-2-ynoic acid;
2-(3-amino-3-oxoprop-1-ynyl)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-cyanofuro[2,3-c]pyridine-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-chlorofuro[2,3-c]pyridine-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-fluorofuro[2,3-c]pyridine-5-
- 10 carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-iodofuro[2,3-c]pyridine-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-trifluoromethylfuro[2,3-c]pyridine-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-mercaptofuro[2,3-c]pyridine-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylthio)furo[2,3-c]pyridine-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylamino)furo[2,3-c]pyridine-5-
- 20 carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(formylamino)furo[2,3-c]pyridine-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[formyl(methyl)amino]furo[2,3-c]pyridine-5-carboxamide;
- 25 2-(acetylamino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-carboxamide;
2-(acetyl(methyl)amino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(trifluoroacetyl)amino]furo[2,3-
- 30 c]pyridine-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(benzoylamino)furo[2,3-c]pyridine-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(diethylamino)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(diisopropylamino)furo[2,3-c]pyridine-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(pyrrolidin-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopyrrolidin-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperidin-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopiperidin-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(morpholin-4-yl)furo[2,3-c]pyridine-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxomorpholin-4-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(thiomorpholin-4-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxothiomorpholin-4-yl)furo[2,3-c]pyridine-5-carboxamide;
- 20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperazin-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopiperazin-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methylpiperazin-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methyl-2-oxopiperazin-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxopiperazin-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methyl-3-oxopiperazin-1-yl)furo[2,3-c]pyridine-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(cyclopropylamino)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[dimethylamino]furo[2,3-c]pyridine-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-pyrrole-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-imidazol-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-1,2,4-triazol-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- 10 c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-1,2,3-triazol-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-5-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[3,2-c]pyridine-2,5-dicarboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(pyrrolidin-1-ylcarbonyl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperidin-1-ylcarbonyl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperazin-1-ylcarbonyl)furo[2,3-c]pyridine-5-carboxamide;
- 20 c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(4-methylpiperazin-1-yl)carbonyl]furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(morpholin-4-ylcarbonyl)furo[2,3-c]pyridine-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(thiomorpholin-4-ylcarbonyl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(aziridin-1-ylcarbonyl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(azetidin-1-ylcarbonyl)furo[2,3-c]pyridine-5-carboxamide;
- 30 c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-formylfuro[2,3-c]pyridine-5-carboxamide;

- 2-acetyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(trifluoroacetyl)furo[2,3-c]pyridine-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(phenyl)sulfonyl]furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylsulfonyl)furo[2,3-c]pyridine-5-carboxamide;
- 5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}furo[2,3-c]pyridine-2-
- 10 carboxylic acid;
- methyl 5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}furo[2,3-c]pyridine-2-carboxylate;
- isopropyl 5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}furo[3,2-c]pyridine-2-carboxylate;
- 15 2,2,2-trifluoroethyl 5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}furo[2,3-c]pyridine-2-carboxylate; and a pharmaceutically acceptable salt thereof.

- The compound of Formula I, where the compound is any one or more or
- 20 combination of the following as the free base, or pharmaceutically acceptable salt thereof:
- 7-methyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[2,3-c]pyridine-5-carboxamide;
- 7-methylthio-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[2,3-c]pyridine-5-
- 25 carboxamide;
- 7-methoxy-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[2,3-c]pyridine-5-carboxamide;
- 7-chloro-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[2,3-c]pyridine-5-carboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-vinylthieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethynylthieno[2,3-c]pyridine-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-prop-1-ynylthieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(3-hydroxyprop-1-ynyl)thieno[2,3-c]pyridine-5-carboxamide;
- 5 methyl 3-(5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}thieno[2,3-c]pyridin-3-yl)prop-2-ynoate;
- 3-(5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}thieno[2,3-c]pyridin-3-yl)prop-2-ynoic acid;
- 3-(3-amino-3-oxoprop-1-ynyl)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[2,3-c]pyridine-5-carboxamide;
- 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-cyanothieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-chlorothieno[2,3-c]pyridine-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-fluorothieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-iodothieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-trifluoromethylthieno[2,3-c]pyridine-5-carboxamide;
- 20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-mercaptothieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(methylthio)thieno[2,3-c]pyridine-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(methylamino)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(formylamino)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[formyl(methyl)amino]thieno[2,3-c]pyridine-5-carboxamide;
- 30 3-(acetylamino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[2,3-c]pyridine-5-carboxamide;

- 3-(acetyl(methyl)amino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[(trifluoroacetyl)amino]thieno[2,3-c]pyridine-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(benzoylamino)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(diethylamino)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(diisopropylamino)thieno[2,3-c]pyridine-5-carboxamide;
- 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(pyrrolidin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(2-oxopyrrolidin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(piperidin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(2-oxopiperidin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(morpholin-4-yl)thieno[2,3-c]pyridine-5-carboxamide;
- 20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(3-oxomorpholin-4-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(thiomorpholin-4-yl)thieno[2,3-c]pyridine-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(3-oxothiomorpholin-4-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(piperazin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(2-oxopiperazin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(4-methylpiperazin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(4-methyl-2-oxopiperazin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(3-oxopiperazin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(4-methyl-3-oxopiperazin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(cyclopropylamino)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[dimethylamino]thieno[2,3-c]pyridine-5-carboxamide;
- 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(1H-pyrrole-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(1H-imidazol-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(1H-1,2,4-triazol-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(1H-1,2,3-triazol-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-5-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[2,3-c]pyridine-3,5-dicarboxamide;
- 20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(pyrrolidin-1-ylcarbonyl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(piperidin-1-ylcarbonyl)thieno[2,3-c]pyridine-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(piperazin-1-ylcarbonyl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[(4-methylpiperazin-1-yl)carbonyl]thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(morpholin-4-ylcarbonyl)thieno[2,3-c]pyridine-5-carboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(thiomorpholin-4-ylcarbonyl)thieno[2,3-c]pyridine-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(aziridin-1-ylcarbonyl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(azetidin-1-ylcarbonyl)thieno[2,3-c]pyridine-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-formylthieno[2,3-c]pyridine-5-carboxamide;
- 3-acetyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(trifluoroacetyl)thieno[2,3-c]pyridine-5-carboxamide;
- 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[(phenyl)sulfonyl]thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(methylsulfonyl)thieno[2,3-c]pyridine-5-carboxamide;
- 15 5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}thieno[2,3-c]pyridine-3-carboxylic acid;
- methyl 5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}thieno[2,3-c]pyridine-3-carboxylate;
- isopropyl 5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}thieno[2,3-c]pyridine-3-carboxylate;
- 20 2,2,2-trifluoroethyl 5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}thieno[2,3-c]pyridine-3-carboxylate;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-vinylthieno[2,3-c]pyridine-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-ethynylthieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-prop-1-ynylthieno[2,3-c]pyridine-5-carboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-hydroxyprop-1-ynyl)thieno[2,3-c]pyridine-5-carboxamide;
- methyl 3-(5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}thieno[2,3-c]pyridin-2-yl)prop-2-ynoate;

- 2-(5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}thieno[2,3-c]pyridin-2-yl)prop-2-ynoic acid;
- 2-(3-amino-3-oxoprop-1-ynyl)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[2,3-c]pyridine-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-cyanothieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-chlorothieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-fluorothieno[2,3-c]pyridine-5-
- 10 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-iodothieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-trifluoromethylthieno[2,3-c]pyridine-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-mercaptothieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylthio)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylamino)thieno[2,3-c]pyridine-
- 20 5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(formylamino)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[formyl(methyl)amino]thieno[2,3-c]pyridine-5-carboxamide;
- 25 2-(acetylamino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[2,3-c]pyridine-5-carboxamide;
- 2-(acetyl(methyl)amino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(trifluoroacetyl)amino]thieno[2,3-
- 30 c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(benzoylamino)thieno[2,3-c]pyridine-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(diethylamino)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(diisopropylamino)thieno[2,3-c]pyridine-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(pyrrolidin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopyrrolidin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperidin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopiperidin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(morpholin-4-yl)thieno[2,3-c]pyridine-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxomorpholin-4-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(thiomorpholin-4-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxothiomorpholin-4-yl)thieno[2,3-c]pyridine-5-carboxamide;
- 20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperazin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopiperazin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methylpiperazin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methyl-2-oxopiperazin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxopiperazin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methyl-3-oxopiperazin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(cyclopropylamino)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[dimethylamino]thieno[2,3-c]pyridine-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-pyrrole-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-imidazol-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-1,2,4-triazol-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-1,2,3-triazol-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-5-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,2-c]pyridine-2,5-dicarboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(pyrrolidin-1-ylcarbonyl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperidin-1-ylcarbonyl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperazin-1-ylcarbonyl)thieno[2,3-c]pyridine-5-carboxamide;
- 20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(4-methylpiperazin-1-yl)carbonyl]thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(morpholin-4-ylcarbonyl)thieno[2,3-c]pyridine-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(thiomorpholin-4-ylcarbonyl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(aziridin-1-ylcarbonyl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(azetidin-1-ylcarbonyl)thieno[2,3-c]pyridine-5-carboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-formylthieno[2,3-c]pyridine-5-carboxamide;

- 2-acetyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(trifluoroacetyl)thieno[2,3-c]pyridine-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(phenyl)sulfonyl]thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylsulfonyl)thieno[2,3-c]pyridine-5-carboxamide;
- 5-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl)thieno[2,3-c]pyridine-10 2-carboxylic acid;
- methyl 5-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl)thieno[2,3-c]pyridine-2-carboxylate;
- isopropyl 5-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl)thieno[2,3-c]pyridine-2-carboxylate;
- 15 2,2,2-trifluoroethyl 5-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl)thieno[2,3-c]pyridine-2-carboxylate;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-vinylthieno[3,2-c]pyridine-6-carboxamide;
- 20 4-methyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,2-c]pyridine-6-carboxamide;
- 4-methylthio-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,2-c]pyridine-6-carboxamide;
- 4-methoxy-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,2-c]pyridine-6-25 carboxamide;
- 4-chloro-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-ethynylthieno[3,2-c]pyridine-6-carboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-prop-1-ynylthieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-hydroxyprop-1-ynyl)thieno[3,2-c]pyridine-6-carboxamide;

- methyl 3-(6-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl)thieno[3,2-c]pyridin-2-yl)prop-2-ynoate;
2-(6-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl)thieno[3,2-c]pyridin-2-yl)prop-2-ynoic acid;
- 5 2-(3-amino-3-oxoprop-1-ynyl)-N-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,2-c]pyridine-6-carboxamide;
N-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-cyanothieno[3,2-c]pyridine-6-carboxamide;
N-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-chlorothieno[3,2-c]pyridine-6-
- 10 carboxamide;
N-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-fluorothieno[3,2-c]pyridine-6-carboxamide;
N-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-iodothieno[3,2-c]pyridine-6-carboxamide;
- 15 N-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-trifluoromethylthieno[3,2-c]pyridine-6-carboxamide;
N-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-mercaptothieno[3,2-c]pyridine-6-carboxamide;
N-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylthio)thieno[3,2-c]pyridine-6-
- 20 carboxamide;
N-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylamino)thieno[3,2-c]pyridine-6-carboxamide;
N-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(formylamino)thieno[3,2-c]pyridine-6-carboxamide;
- 25 N-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[formyl(methyl)amino]thieno[3,2-c]pyridine-6-carboxamide;
2-(acetyl(amino))-N-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,2-c]pyridine-6-carboxamide;
2-(acetyl(methyl)amino)-N-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,2-
- 30 c]pyridine-6-carboxamide;
N-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(trifluoroacetyl)amino]thieno[3,2-c]pyridine-6-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(benzoylamino)thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(diethylamino)thieno[3,2-c]pyridine-6-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(diisopropylamino)thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(pyrrolidin-1-yl)thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopyrrolidin-1-yl)thieno[3,2-c]pyridine-6-carboxamide;
- 10 c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperidin-1-yl)thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopiperidin-1-yl)thieno[3,2-c]pyridine-6-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(morpholin-4-yl)thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxomorpholin-4-yl)thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(thiomorpholin-4-yl)thieno[3,2-c]pyridine-6-carboxamide;
- 20 c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxothiomorpholin-4-yl)thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperazin-1-yl)thieno[3,2-c]pyridine-6-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopiperazin-1-yl)thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methylpiperazin-1-yl)thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methyl-2-oxopiperazin-1-yl)thieno[3,2-c]pyridine-6-carboxamide;
- 30 1yl)thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxopiperazin-1-yl)thieno[3,2-c]pyridine-6-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methyl-3-oxopiperazin-1-yl)thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(cyclopropylamino)thieno[3,2-c]pyridine-6-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[dimethylamino]thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-pyrrole-1-yl)thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-imidazol-1-yl)thieno[3,2-c]pyridine-6-carboxamide;
- 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-1,2,4-triazol-1-yl)thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-1,2,3-triazol-1-yl)thieno[3,2-c]pyridine-6-carboxamide;
- 15 N-6-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,2-c]pyridine-2,6-dicarboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(pyrrolidin-1-ylcarbonyl)thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperidin-1-ylcarbonyl)thieno[3,2-c]pyridine-6-carboxamide;
- 20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperazin-1-ylcarbonyl)thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(4-methylpiperazin-1-yl)carbonyl]thieno[3,2-c]pyridine-6-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(morpholin-4-ylcarbonyl)thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(thiomorpholin-4-ylcarbonyl)thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(aziridin-1-ylcarbonyl)thieno[3,2-c]pyridine-6-carboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(azetidin-1-ylcarbonyl)thieno[3,2-c]pyridine-6-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-formylthieno[3,2-c]pyridine-6-carboxamide;
- 2-acetyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,2-c]pyridine-6-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(trifluoroacetyl)thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(phenyl)sulfonyl]thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylsulfonyl)thieno[3,2-c]pyridine-6-carboxamide;
- 10 6-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}thieno[3,2-c]pyridine-2-carboxylic acid;
- methyl 6-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}thieno[3,2-c]pyridine-2-carboxylate;
- 15 isopropyl 6-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}thieno[3,2-c]pyridine-2-carboxylate; or
- 2,2,2-trifluoroethyl 6-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}thieno[3,2-c]pyridine-2-carboxylate.

20 The compound of Formula I, where the compound is any one or more or combination of the following as the free base, or pharmaceutally acceptable salt thereof:

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1H-indazole-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1H-indazole-6-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-methyl-1H-indazole-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-methyl-1H-indazole-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethyl-1H-indazole-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethyl-1H-indazole-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1,2-benzisothiazole-6-carboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1,2-benzisothiazole-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethyl-1,2-benzisothiazole-6-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethyl-1,2-benzisothiazole-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-methyl-1,2-benzisothiazole-6-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-methyl-1,2-benzisothiazole-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-methyl-1,3-benzothiazole-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-methyl-1,3-benzothiazole-5-
- 10 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-ethyl-1,3-benzothiazole-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-ethyl-1,3-benzothiazole-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-methyl-1,3-benzodioxole-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-ethyl-1,3-benzodioxole-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2,2-dimethyl-1,3-benzodioxole-5-
- 20 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2H-isoindole-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2H-isoindole-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1H-benzimidazole-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1H-benzimidazole-6-carboxamide;
- 25 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl][1,3]thiazolo[5,4-c]pyridine-6-carboxamide;
- N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl][1,3]thiazolo[4,5-c]pyridine-6-carboxamide;
- N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl][1,3]dioxolo[4,5-c]pyridine-6-carboxamide;
- N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl][1,3]oxazolo[4,5-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1H-imidazo[4,5-c]pyridine-6-
- 30 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1,3-benzothiazole-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-bromo-1,3-benzothiazole-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-chloro-1,3-benzothiazole-5-carboxamide;
- 5 2-amino-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1,3-benzothiazole-5-carboxamide;
- 2-(acetylamino-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1,3-benzothiazole-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-methoxy-1,3-benzothiazole-5-
- 10 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-phenoxy-1,3-benzothiazole-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(phenylthio)-1,3-benzothiazole-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylthio)-1,3-benzothiazole-5-carboxamide;
- 2-anilino-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1,3-benzothiazole-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-morpholin-4-yl-1,3-benzothiazole-5-
- 20 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-piperazin-1-yl-1,3-benzothiazole-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1,3-benzothiazole-6-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-bromo-1,3-benzothiazole-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-chloro-1,3-benzothiazole-6-carboxamide;
- 2-amino-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1,3-benzothiazole-6-
- 30 carboxamide;
- 2-(acetylamino-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1,3-benzothiazole-6-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-methoxy-1,3-benzothiazole-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-phenoxy-1,3-benzothiazole-6-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(phenylthio)-1,3-benzothiazole-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylthio)-1,3-benzothiazole-6-carboxamide;
- 2-anilino-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1,3-benzothiazole-6-
- 10 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-morpholin-4-yl-1,3-benzothiazole-6-carboxamide; or
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-piperazin-1-yl-1,3-benzothiazole-6-carboxamide.

15

- The compound of Formula I, where (c) is any one or more or combination of the following: isoquinolin-3-yl, quinoline-3-yl, 2,3-dihydro[1,4]dioxino[2,3-c]pyridine-7-yl, 2,3-dihydro-1,4-benzodioxine-6-yl, chromane-6-yl, 2H-chromene-6-yl, 2H-pyrano[2,3-c]pyridine-6-yl, 2H-pyrano[2,3-c]pyridine-7-yl, 3,4-dihydro-2H-
- 20 pyrano[2,3-c]pyridine-6-yl, or 3,4-dihydro-2H-pyrano[2,3-c]pyridine-7-yl, any of which is optionally substituted with up to 4 substituents independently selected from F, Cl, Br, -CN, -NO₂, alkyl, substituted alkyl, halogenated alkyl, alkenyl, substituted alkenyl, halogenated alkenyl, alkynyl, substituted alkynyl, halogenated alkynyl, heterocycloalkyl, substituted heterocycloalkyl, halogenated heterocycloalkyl, -OR₈,
- 25 -SR₈, -NR₈R₈, -NR₈C(O)R₈, or phenyl optionally substituted with up to 4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅.

The compound of Formula I, where the compound is N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]isoquinoline-3-carboxamide; or a pharmaceutically acceptable salt thereof.

- 30 The compound of Formula I, where the compound is any one or more or combination of the following as the free base, or pharmaceutically acceptable salt thereof:

N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-methylisoquinoline-3-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-methylisoquinoline-3-carboxamide;
 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-methoxyisoquinoline-3-carboxamide;
 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-trifluoromethylisoquinoline-3-carboxamide;
 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-chloroisoquinoline-3-carboxamide;
 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-bromoisoquinoline-3-carboxamide;
 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-fluoroisoquinoline-3-carboxamide;
 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-iodoisoquinoline-3-carboxamide;
 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-ethynylisoquinoline-3-carboxamide;
 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-cyanoisoquinoline-3-carboxamide;
 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-ethenylisoquinoline-3-carboxamide;
 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-nitroisoquinoline-3-carboxamide;
 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2,3-dihydro-1,4-benzodioxane-6-carboxamide;
 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]chromane-6-carboxamide; or a pharmaceutically acceptable salt thereof.

- The compound of Formula I, where (d) is thieno[3,4-c]pyridin-6-yl, furo[3,4-c]pyridin-6-yl, 2-benzothiophen-5-yl, 2-benzothiophen-6-yl, 2-benzofuran-5-yl, or 2-benzofuran-6-yl, any of which is optionally substituted with up to 4 substituents independently selected from F, Cl, Br, -CN, -NO₂, alkyl, substituted alkyl, halogenated alkyl, alkenyl, substituted alkenyl, halogenated alkenyl, alkynyl, substituted alkynyl, halogenated alkynyl, heterocycloalkyl, substituted heterocycloalkyl, halogenated heterocycloalkyl, -OR₈, -SR₈, -NR₈R₈, -NR₈C(O)R₈, or phenyl optionally substituted with up to 4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅.

The compound of Formula I, where the compound is N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,4-c]pyridine-6-carboxamide; or a pharmaceutically acceptable salt thereof.

- 30 The compound of Formula I, where the compound is any one or more or combination of the following as the free base, or pharmaceutically acceptable salt thereof: N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[3,4-c]pyridine-6-carboxamide, N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-benzofuran-5-

carboxamide; or N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-benzothiophen-5-carboxamide.

The compound of Formula I, where (e) is any one or more or combination of the following: [1]benzothieno[2,3-c]pyridin-3-yl, [1]benzothieno[3,2-c]pyridin-3-yl, 5 [1]benzofuro[3,2-c]pyridin-3-yl, [1]benzofuro[2,3-c]pyridin-3-yl, dibenzo[b,d]thiophen-2-yl, or dibenzo[b,d]furan-2-yl, any of which is optionally substituted with up to 4 substituents independently selected from F, Cl, Br, -CN, -NO₂, alkyl, substituted alkyl, halogenated alkyl, alkenyl, substituted alkenyl, halogenated alkenyl, alkynyl, substituted alkynyl, halogenated alkynyl, 10 heterocycloalkyl, substituted heterocycloalkyl, halogenated heterocycloalkyl, -OR₈, -SR₈, -NR₈R₈, -NR₈C(O)R₈, or phenyl optionally substituted with up to 4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅.

The compound of Formula I, where the compound is any one or more or combination of the following as the free base, or pharmaceutically acceptable salt thereof: N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]dibenzo[b,d]thiophene-2- 15 carboxamide; N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothieno[2,3-c]pyridine-3-carboxamide; N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothieno[3,2-c]pyridine-3-carboxamide; N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]dibenzo[b,d]furan-2-carboxamide; N-[(1S, 2R, 4R)-7- 20 azabicyclo[2.2.1]hept-2-yl]benzofuro[3,2-c]pyridine-3-carboxamide; N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuro[2,3-c]pyridine-3-carboxamide; or a pharmaceutically acceptable salt thereof.

The present invention also includes a pharmaceutical composition comprising 25 a compound of Formula I or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient. The pharmaceutical composition is administered rectally, topically, orally, sublingually, or parenterally for a therapeutically effective interval. The pharmaceutical composition is administered to deliver a compound of Formula I in an amount of from about 0.001 to about 30 100mg/kg of body weight of said mammal per day. The pharmaceutical composition is also administered to deliver a compound of Formula I in an amount of from about 0.1 to about 50mg/kg of body weight of said mammal per day.

A pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, an anti-psychotic agent, and a pharmaceutically acceptable excipient. The pharmaceutical composition is administered to independently administer said compound and said agent rectally, topically, orally, sublingually, or parenterally for a therapeutically effective interval. The pharmaceutical composition is administered to deliver a compound of Formula I in an amount of from about 0.001 to about 100mg/kg of body weight of said mammal per day. The pharmaceutical composition is also administered to deliver a compound of Formula I in an amount of from about 0.1 to about 50mg/kg of body weight of said mammal per day.

The present invention also includes a use of a compound according to Formula I or pharmaceutically acceptable salt thereof for the preparation of a medicament for treating a disease or condition, wherein the mammal would receive symptomatic relief from the administration of a therapeutically effective amount of $\alpha 7$ nicotinic acetylcholine receptor agonist.

The present invention also includes a use of a compound according to Formula I or pharmaceutically acceptable salt thereof for the preparation of a medicament for treating a disease or condition, wherein the mammal would receive symptomatic relief from the administration of a therapeutically effective amount of $\alpha 7$ nicotinic acetylcholine receptor agonist, wherein the disease, or condition is any one or more or combination of the following: cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, depression, anxiety, general anxiety disorder, post traumatic stress disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems in general and associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, Parkinson's disease, tardive dyskinesia, Pick's disease, dysregulation of food intake including bulimia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependant drug cessation, Gilles de la Tourette's Syndrome, age-related

macular degeneration, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain.


The present invention also includes a method for treating a disease or condition in a mammal in need thereof, wherein the mammal would receive symptomatic relief from the administration of an $\alpha 7$ nicotinic acetylcholine receptor agonist comprising administering to the mammal a therapeutically effective amount of a compound according to Formula I or pharmaceutically acceptable salt thereof.

The present invention also includes a method for treating a disease or condition in a mammal in need thereof comprising administering to the mammal a therapeutically effective amount of a compound according to Formula I or pharmaceutically acceptable salt thereof, wherein the disease or condition is any one or more or combination of the following: cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, depression, anxiety, general anxiety disorder, post traumatic stress disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems in general and associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, Parkinson's disease, tardive dyskinesia, Pick's disease, dysregulation of food intake including bulimia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependant drug cessation, Gilles de la Tourette's Syndrome, age-related macular degeneration, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain.

Further aspects and embodiments of the invention may become apparent to those skilled in the art from a review of the following detailed description, taken in conjunction with the examples and the appended claims. While the invention is susceptible of embodiments in various forms, described hereafter are specific embodiments of the invention with the understanding that the present disclosure is intended as illustrative, and is not intended to limit the invention to the specific embodiments described herein.

DETAILED DESCRIPTION OF THE INVENTION

Surprisingly, we have found that compounds of the Formula I:




Formula I

- 5 wherein the stereochemistry of the of the 7-azabicyclo[2.2.1]heptane ring is 1*S*, 4*R* and the nitrogen substituent at the C-2 carbon has the *exo* orientation and is *R*;

X is O or S;

W is



- 10 A₁ is N;

Each E₁, E₂, G₁, G₂, and T is independently selected from CR₃ and N, provided that no more than two of E₁, E₂, G₁, G₂, and T are N, and further provided that when E₁ is N, G₁ and E₂ must be CR₃, and further provided that when E₂ is N, E₁ and G₂ must be CR₃;

- 15 Each V, V₈, V₉, and V₁₀ is independently selected from O, S, NA₅, and C(R₃)₂, provided that when V₈ is C(R₃)₂ the R₃ substituents on the carbon atoms adjacent to V₈ are moieties other than H;

- Each V₁, V₂, V₃, V₄, V₅, V₆, and V₇ is independently selected from O, S, N, C(R₃), C(R₃)₂, or NA₅, provided that V₁ and V₂, V₂ and V₃, V₄ and V₅, V₅ and V₆, and V₆ and V₇ are not simultaneously O or S, or combinations of O and S, and further provided that at least one of V₁, V₂, and V₃, at least one of V₄, V₅, and V₆, and at least one of V₅, V₆, and V₇ is C(R₃) or C(R₃)₂;

Each J, J₁, J₂, L, L₁, L₂, M, M₁, M₂, Q, Q₁, and Q₂ is independently selected from CR₃ and N, provided that no more than two of J, L, M, and Q, or no more than two of J₁, L₁, M₁, and Q₁, or no more than two of J₂, L₂, M₂, and Q₂ are N, and provided that at least one of J, L, M, and Q is N when V₁, V₂, and V₃ are
 5 independently selected from C(R₃)₂ and C(R₃), when V₄, V₅, V₆, and V₇ are independently selected from C(R₃)₂ and C(R₃), and when V₈ is C(R₃)₂, and further provided that at least one of J₁, L₁, M₁, and Q₁ or at least one of J₂, L₂, M₂, and Q₂ is N when V is C(R₃)₂ and when V₉ and V₁₀ are C(R₃)₂;

Each A₅ is independently H, alkyl, alkenyl, alkynyl, cycloalkyl,
 10 heterocycloalkyl, halogenated alkyl, halogenated alkenyl, halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, R₇, R₉, -C(O)R₈, -C(S)R₈, -C(O)NR₈R₈, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, phenyl optionally substituted with 1-4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅, naphthyl optionally
 15 substituted with 1-4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅, or

A₅ forms a bond to the carbon of the amide or thio amide group bound to the C-2 carbon of the 7-azabicyclo[2.2.1]heptane ring provided that only one of R₃ or A₅ forms a bond to the carbon of the amide or thio amide group;

20 R₁ is H, alkyl, cycloalkyl, halogenated alkyl, or aryl;
 Aryl is phenyl, substituted phenyl, naphthyl, or substituted naphthyl;
 Alkyl is both straight- and branched-chain moieties having from 1-6 carbon atoms;

Halogenated alkyl is an alkyl moiety having from 1-6 carbon atoms and having
 25 1 to (2n+1) substituent(s) independently selected from F, Cl, Br, or I where n is the maximum number of carbon atoms in the moiety;

Cycloalkyl is a cyclic alkyl moiety having from 3-6 carbon atoms;

Substituted phenyl is a phenyl having 1-4 substituents independently selected from F, Cl, Br, I, or R₁₇;

30 Substituted naphthyl is a naphthalene moiety having 1-4 substituents independently selected from F, Cl, Br, I, or R₁₇;

R₂ is H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl;

Substituted alkyl is an alkyl moiety having from 1-6 carbon atoms and having 0-3 substituents independently selected from F, Cl, Br, or I and further having 1 substituent selected from R₇, R₉, -CN, -NO₂, -OR₁₀, -SR₁₀, -S(O)R₁₀, -S(O)₂R₁₀, -OS(O)₂R₁₀, -NR₁₀R₁₀, -C(O)R₁₀, -C(O)OR₁₀, -C(S)R₁₀, -C(O)NR₁₀R₁₀,
 5 -NR₁₀C(O)R₁₀, -NR₁₀C(O)NR₁₀R₁₀, -S(O)₂NR₁₀R₁₀, -NR₁₀S(O)₂R₁₀, or phenyl optionally substituted with 1-4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅;

Each R₃ is independently H, F, Cl, Br, I, -CN, -NO₂, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated alkenyl, halogenated
 10 alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, -OR₈, -SR₈, -S(O)₂R₈, -S(O)R₈, -OS(O)₂R₈, -NR₈R₈, -C(O)R₈, -C(S)R₈, -C(O)OR₈, -C(O)NR₈R₈, -NR₈C(O)R₈, -NR₈C(O)NR₈R₈, -S(O)₂NR₈R₈, -NR₈S(O)₂R₈, R₇, R₉, phenyl optionally substituted with 1-4 substituents
 15 independently selected from F, Cl, Br, I, R₁₃, and R₁₅, naphthyl optionally substituted with 1-4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅, or

two R₃ groups bound to the same atom together form =O or =S where valency allows, or

R₃ forms a bond to the carbon of the amide or thio amide group bound
 20 to the C-2 carbon of the 7-azabicyclo[2.2.1]heptane ring provided that only one of R₃ or A₅ forms a bond to the carbon of the amide or thio amide group;

Alkenyl is straight- and branched-chain moieties having from 2-6 carbon atoms and having at least one carbon-carbon double bond;

Halogenated alkenyl is an unsaturated alkenyl moiety having from 2-6 carbon
 25 atoms and having 1 to (2n-1) substituent(s) independently selected from F, Cl, Br, or I where n is the maximum number of carbon atoms in the moiety;

Substituted alkenyl is an unsaturated alkenyl moiety having from 2-6 carbon atoms and having 0-3 substituents independently selected from F, Cl, Br, or I, and further having 1 substituent selected from R₇, R₉, -OR₁₀, -SR₁₀, -S(O)R₁₀, -S(O)₂R₁₀,
 30 -OS(O)₂R₁₀, -NR₁₀R₁₀, -C(O)R₁₀, C(O)OR₁₀, -C(S)R₁₀, -C(O)NR₁₀R₁₀, -CN, -NR₁₀C(O)R₁₀, -NR₁₀C(O)NR₁₀R₁₀, -S(O)₂NR₁₀R₁₀, -NR₁₀S(O)₂R₁₀, -NO₂, and phenyl optionally substituted with 1-4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅;

Alkynyl is straight- and branched-chained moieties having from 2-6 carbon atoms and having at least one carbon-carbon triple bond;

Halogenated alkynyl is an unsaturated alkynyl moiety having from 3-6 carbon atoms and having 1 to (2n-3) substituent(s) independently selected from F, Cl, Br, or I
 5 where n is the maximum number of carbon atoms in the moiety;

Substituted alkynyl is an unsaturated alkynyl moiety having from 3-6 carbon atoms and having 0-3 substituents independently selected from F, Cl, Br, or I, and further having 1 substituent selected from R₇, R₉, -OR₁₀, -SR₁₀, -S(O)R₁₀, -S(O)₂R₁₀, -OS(O)₂R₁₀, -NR₁₀R₁₀, -C(O)R₁₀, -C(O)OR₁₀, -C(S)R₁₀, -C(O)NR₁₀R₁₀, -CN,
 10 -NR₁₀C(O)R₁₀, -NR₁₀C(O)NR₁₀R₁₀, -S(O)₂NR₁₀R₁₀, -NR₁₀S(O)₂R₁₀, -NO₂, and phenyl optionally substituted with 1-4 substituents independently selected F, Cl, Br, I, R₁₃, and R₁₅;

Halogenated cycloalkyl is a cyclic moiety having from 3-6 carbon atoms and having 1-4 substituents independently selected from F, Cl, Br, or I;

15 Substituted cycloalkyl is a cyclic moiety having from 3-6 carbon atoms and having 0-3 substituents independently selected from F, Cl, Br, or I, and further having 1 substituent selected from =O, =S, R₇, R₉, -OR₁₀, -SR₁₀, -S(O)R₁₀, -S(O)₂R₁₀, -OS(O)₂R₁₀, -NR₁₀R₁₀, -C(O)R₁₀, -C(O)R₁₀, -C(S)R₁₀, -C(O)NR₁₀R₁₀, -CN, -NR₁₀C(O)R₁₀, -NR₁₀C(O)NR₁₀R₁₀, -S(O)₂NR₁₀R₁₀, -NR₁₀S(O)₂R₁₀, -NO₂, and
 20 phenyl optionally substituted with 1-4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅;

Heterocycloalkyl is a cyclic moiety having 4-7 atoms with 1-2 atoms within the ring being -S-, -N(R₁₈)-, or -O-;

Halogenated heterocycloalkyl is a cyclic moiety having from 4-7 atoms with 1-
 25 2 atoms within the ring being -S-, -N(R₁₈)-, or -O-, and having 1-4 substituents independently selected from F, Cl, Br, or I;

Substituted heterocycloalkyl is a cyclic moiety having from 4-7 atoms with 1-2 atoms within the ring being -S-, -N(R₁₈)-, or -O- and having 0-3 substituents independently selected from F, Cl, Br, or I, and further having 1 substituent selected
 30 from =O, =S, R₇, R₉, -OR₁₀, -SR₁₀, -S(O)R₁₀, -S(O)₂R₁₀, -OS(O)₂R₁₀, -NR₁₀R₁₀, -C(O)R₁₀, -C(O)R₁₀, -C(S)R₁₀, -C(O)NR₁₀R₁₀, -CN, -NR₁₀C(O)R₁₀,


-NR₁₀C(O)NR₁₀R₁₀, -S(O)₂NR₁₀R₁₀, -NR₁₀S(O)₂R₁₀, -NO₂, and phenyl optionally substituted with 1-4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅;

Each R₄ is independently H, alkyl, and substituted alkyl;


5 R₆ is H, alkyl, an amino protecting group, or an alkyl group having 1-3 substituents selected from F, Cl, Br, I, -OH, -CN, -NH₂, -NH(alkyl), and -N(alkyl)₂;

Heteroaryl is a 5 membered mono-cyclic aromatic ring, a 6 membered mono-cyclic aromatic ring, a 9 membered bicyclic aromatic ring, or a 10 membered bi-cyclic aromatic ring, in which each mono-cyclic or bicyclic ring contains 1-3 hetero atoms selected from =N-, -N(R₁₈)-, O, and S;

R₇ is 5-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms independently selected from the group consisting of =N-, -N(R₁₈)-, -O-, and -S-, and having 0-1 substituent selected from R₁₇ and further having 15 0-3 substituents independently selected from F, Cl, Br, or I, or R₇ is 9-membered fused-ring moieties having a 6-membered ring fused to a 5-membered ring including the formula




wherein Z₁ is O, S or NR₁₈,



20

wherein Z is C(R₁₄) or N, and Z₂ and Z₃ are independently selected from C(R₁₄)₂, C(R₁₄), O, S, N, and N(R₁₈), provided that both Z₂ and Z₃ are not simultaneously O, simultaneously S, or simultaneously O and S, or



25 wherein Z is C(R₁₄) or N, and Z₂ and Z₃ are independently selected from C(R₁₄)₂, C(R₁₄), O, S, N, and N(R₁₈), and Z is CR₁₄ or N, each 9-membered bicyclic ring having 0-1 substituent selected from R₁₇ and 0-3 substituents independently selected

from F, Cl, Br, or I, wherein the R₇ moiety attaches to other substituents as defined in Formula I at any position on either ring as valency allows;

Each R₈ is independently H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl, R₇, R₉, phenyl optionally substituted with 1-4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅, or naphthyl optionally substituted with 1-4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅;

R₉ is 6-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms selected from =N- and having 0-1 substituent selected from R₁₅ and 0-3 substituent(s) independently selected from F, Cl, Br, or I, or R₉ is 10-membered heteroaromatic bi-cyclic moieties containing within one or both rings 1-3 heteroatoms selected from =N-, including, but not limited to, quinolinyl or isoquinolinyl, each 10-membered fused-ring moiety having 0-1 substituent selected from R₁₇ and 0-3 substituent(s) independently selected from F, Cl, Br, or I, wherein the R₉ moiety attaches to other substituents as defined in formula I at any position on either ring as valency allows;

Each R₁₀ is independently H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from R₁₃, cycloalkyl substituted with 1 substituent selected from R₁₃, heterocycloalkyl substituted with 1 substituent selected from R₁₃, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, or phenyl optionally substituted with 1-4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅;

Each R₁₁ is independently H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, or halogenated heterocycloalkyl;

R₁₂ is alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -OR₁₁, -SR₁₁, -S(O)₂R₁₁, -S(O)R₁₁, -OS(O)₂R₁₁, -NR₁₁R₁₁, -C(O)R₁₁, -C(S)R₁₁, -NO₂, -C(O)NR₁₁R₁₁, -CN, -NR₁₁C(O)R₁₁, -NR₁₁C(O)NR₁₁R₁₁, -S(O)₂NR₁₁R₁₁, or -NR₁₁S(O)₂R₁₁;

R₁₃ is -OR₁₁, -SR₁₁, -NR₁₁R₁₁, -C(O)R₁₁, -C(S)R₁₁, -C(O)NR₁₁R₁₁, -CN, -CF₃, -NR₁₁C(O)R₁₁, -NR₁₁C(O)NR₁₁R₁₁, -S(O)₂NR₁₁R₁₁, -NR₁₁S(O)₂R₁₁, or -NO₂;

R_{14} is H or a substituent selected from alkyl, cycloalkyl, phenyl, or naphthyl, each optionally substituted with 1-4 substituents independently selected from F, Cl, Br, I, $-OR_{16}$, $-SR_{16}$, $-S(O)_2R_{16}$, $-S(O)R_{16}$, $-OS(O)_2R_{16}$, $-NR_{16}R_{16}$, $-C(O)R_{16}$, $-C(S)R_{16}$, $-NO_2$, $-C(O)NR_{16}R_{16}$, $-CN$, $-NR_{16}C(O)R_{16}$, $-NR_{16}C(O)NR_{16}R_{16}$, $-S(O)_2NR_{16}R_{16}$, and $-NR_{16}S(O)_2R_{16}$, and the cycloalkyl also being further optionally substituted with $=O$ or $=S$;

R_{15} is alkyl, cycloalkyl, heterocycloalkyl, heteroaryl, phenyl, or naphthyl, each optionally substituted with 1-4 substituents independently selected from F, Cl, Br, I, $-CN$, $-NO_2$, $-OR_{16}$, $-SR_{16}$, $-S(O)_2R_{16}$, $-S(O)R_{16}$, $-OS(O)_2R_{16}$, $-NR_{16}R_{16}$, $-C(O)R_{16}$, $-C(S)R_{16}$, $-C(O)NR_{16}R_{16}$, $-NR_{16}C(O)R_{16}$, $-NR_{16}C(O)NR_{16}R_{16}$, $-S(O)_2NR_{16}R_{16}$, and $-NR_{16}S(O)_2R_{16}$, and the cycloalkyl and heterocycloalkyl also being further optionally substituted with $=O$ or $=S$;

Each R_{16} is independently H, alkyl, cycloalkyl, halogenated alkyl, or halogenated cycloalkyl;

Each R_{17} is independently H, F, Cl, Br, I, R_7 , R_9 , $-CN$, $-NO_2$, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated alkenyl, halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, $-OR_8$, $-SR_8$, $-S(O)_2R_8$, $-S(O)R_8$, $-OS(O)_2R_8$, $-NR_8R_8$, $-C(O)R_8$, $-C(S)R_8$, $-C(O)NR_8R_8$, $-NR_8C(O)R_8$, $-NR_8C(O)NR_8R_8$, $-S(O)_2NR_8R_8$, $-NR_8S(O)_2R_8$, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, phenyl optionally substituted with 1-4 substituents independently selected from F, Cl, Br, I, R_{13} , and R_{15} , and naphthyl optionally substituted with 1-4 substituents independently selected from F, Cl, Br, I, R_{13} , and R_{15} ;

R_{18} is H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, phenyl, $-SO_2R_8$, or phenyl having 1 substituent selected from R_{12} and further having 0-3 substituents independently selected from F, Cl, Br, or I;

or pharmaceutically acceptable salts are useful to treat any one or more or combination of the following: cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, depression, anxiety, general anxiety disorder, post traumatic stress disorder, mood and

5 affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems in general and associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, Parkinson's disease, tardive dyskinesia, Pick's disease, dysregulation of food intake including bulimia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependant drug cessation, Gilles de la Tourette's Syndrome, age-related macular degeneration, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain.

10 In another aspect, the invention includes methods of treating a mammal suffering from schizophrenia or psychosis by administering compounds of Formula I or pharmaceutically acceptable salt thereof in conjunction with antipsychotic drugs. The compounds of Formula I and the antipsychotic drugs can be administered simultaneously or at separate intervals. When administered simultaneously the
15 compounds of Formula I and the antipsychotic drugs can be incorporated into a single pharmaceutical composition. Alternatively, two separate compositions, i.e., one containing compounds of Formula I and the other containing antipsychotic drugs, can be administered simultaneously.

The compounds of Formula I have optically active centers on the 7-
20 azabicyclo[2.2.1]heptane ring which can exhibit a number of stereochemical configurations. The terms *exo* and *endo* are stereochemical prefixes that describe the relative configuration of a substituent on a bridge (not a bridgehead) of a bicyclic system. If a substituent is oriented toward the larger of the other bridges, it is *endo*. If a substituent is oriented toward the smaller bridge it is *exo*. Depending on the
25 substitution on the carbon atoms, the *endo* and *exo* orientations can give rise to different stereoisomers. For instance, when carbons 1 and 4 are substituted with hydrogen and carbon 2 is bonded to a nitrogen containing species, the *endo* orientation gives rise to the possibility of a pair of enantiomers: either the 1*S*, 2*S*, 4*R* isomer or its enantiomer, the 1*R*, 2*R*, 4*S* isomer. Likewise, the *exo* orientation gives rise to the
30 possibility of another pair of stereoisomers which are diastereomeric and C-2 epimers with respect to the *endo* isomers: either the 1*R*, 2*S*, 4*S* isomer or its enantiomer, the 1*S*, 2*R*, 4*R* isomer. The compounds of this invention exist in the *exo* orientation. For

example, when $R_2 = R_4 = H$, the absolute stereochemistry is (1*S*, 2*R*, 4*R*) for the compounds in Formula I.

Stereoselective syntheses and/or subjecting the reaction product to appropriate purification steps produces substantially optically pure materials. Suitable

5 stereoselective synthetic procedures for producing optically pure materials are well known in the art, as are procedures for purifying racemic mixtures into optically pure fractions.

The compounds of the present invention have the *exo* orientation at the C-2 carbon and *S* configuration at the C-1 carbon and the *R* configuration at the C-2 and
10 the C-4 carbons of the 7-azabicyclo[2.2.1]heptane ring. Unexpectedly, the inventive compounds exhibit much higher activity relative to compounds lacking the 1*S*, 2*R*, and 4*R* stereochemistry within the 7-azabicyclo[2.2.1]heptane ring system. For example, the ratio of activities for compounds having the 1*S*, 2*R*, and 4*R* configuration to other stereochemical configurations of the 7-azabicyclo[2.2.1]heptane ring system
15 may be greater than about 100. Surprisingly, the compounds with the 1*S*, 2*R*, and 4*R* stereochemistry exhibit preferred toxicology. Although it is desirable that the stereochemical purity be as high as possible, absolute purity is not required. For example, pharmaceutical compositions can include one or more compounds, each having an 1*S*, 2*R*, and 4*R* configuration, or mixtures of compounds having 1*S*, 2*R*, and
20 4*R* and other configurations. In mixtures of compounds, those species possessing stereochemical configurations other than 1*S*, 2*R*, and 4*R* act as diluents and tend to lower the activity of the pharmaceutical composition. Typically, pharmaceutical compositions including mixtures of compounds possess a larger percentage of species having the 1*S*, 2*R*, and 4*R* configuration relative to other configurations.

25

Abbreviations which are well known to one of ordinary skill in the art may be used (e.g., "Ph" for phenyl, "Me" for methyl, "Et" for ethyl, "h" for hour or hours, min for minute or minutes, and "rt" or "RT" for room temperature).

All temperatures are in degrees Centigrade.

30 Room temperature is within the range of 15-25 degrees Celsius.

AChR refers to acetylcholine receptor.

nAChR refers to nicotinic acetylcholine receptor.

Pre-senile dementia is also known as mild cognitive impairment.

5HT₃R refers to the serotonin-type 3 receptor.

α -btx refers to α -bungarotoxin.

FLIPR refers to a device marketed by Molecular Devices, Inc. designed to precisely measure cellular fluorescence in a high throughput whole-cell assay.

5 (Schroeder et. al., *J. Biomolecular Screening*, 1(2), p 75-80, 1996).

TLC refers to thin-layer chromatography.

HPLC refers to high pressure liquid chromatography.

MeOH refers to methanol.

IPA refers to isopropyl alcohol.

10 THF refers to tetrahydrofuran.

DMSO refers to dimethylsulfoxide.

DMF refers to dimethylformamide.

EtOAc refers to ethyl acetate.

TMS refers to tetramethylsilane.

15 TEA refers to triethylamine.

DIEA refers to diisopropylethylamine.

MLA refers to methyllycaconitine.

Ether refers to diethyl ether.

20 HATU refers to O-(7-azabenzotriazol-1-yl)-N,N,N', N'-tetramethyluronium hexafluorophosphate.

DBU refers to 1,8-diazabicyclo[5.4.0]undec-7-ene.

When potassium carbonate (K₂CO₃), magnesium sulfate (MgSO₄), and sodium sulfate (Na₂SO₄) are used as a drying agent, the agent is anhydrous.

25 The carbon atom content of various hydrocarbon-containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, i.e., the prefix C_{i-j} indicates a moiety of the integer "i" to the integer "j" carbon atoms, inclusive. Thus, for example, C₁₋₆ alkyl refers to alkyl of one to six carbon atoms.

30 Lower alkyl is both straight- and branched-chain moieties having 1-4 carbon atoms.


Halogenated lower alkyl is lower alkyl having 1 to (2n+1) substituent(s) independently selected from F, Cl, Br, or I where n is the maximum number of carbon atoms in the moiety.

Substituted lower alkyl is lower alkyl having 0-3 substituents independently selected from F, Cl, Br, or I and further having 1 substituent selected from R₇, R₉, -CN, -NO₂, -OR₁₀, -SR₁₀, -S(O)R₁₀, -S(O)₂R₁₀, -OS(O)₂R₁₀, -NR₁₀R₁₀, -C(O)R₁₀, -C(O)OR₁₀, -C(S)R₁₀, -C(O)NR₁₀R₁₀, -NR₁₀C(O)R₁₀, -NR₁₀C(O)NR₁₀R₁₀,
 5 -S(O)₂NR₁₀R₁₀, -NR₁₀S(O)₂R₁₀, or phenyl optionally substituted with 1-4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅.

Non-inclusive examples of heteroaryl compounds that fall within the definition of R₇ and R₉ include, but are not limited to, thienyl, benzothienyl, pyridyl, thiazolyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl,
 10 benzothiazolyl, isothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, indolyl, benzoxazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, oxazolyl, pyrrolyl, isoquinolinyl, cinnolinyl, indazolyl, indoliziny, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, purinyl, oxadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, quinazolinyl, quinoxalinyl, naphthridinyl, furopyridinyl,
 15 pyrrolopyridinyl, or thienopyridinyl. All isomeric forms of the non-inclusive named moieties are included, e.g., benzofuranyl includes 1-benzofuran-2-yl, 1-benzofuran-3-yl, 1-benzofuran-4-yl, 1-benzofuran-5-yl, 1-benzofuran-6-yl, 1-benzofuran-7-yl, 2-benzofuran-1-yl, 2-benzofuran-2-yl, 2-benzofuran-3-yl, 2-benzofuran-4-yl, or 2-benzofuran-5-yl. The non-inclusive examples of R₇ and R₉ may be substituted as
 20 allowed within the respective definition of R₇ and R₉ as valency allows. One of ordinary skill in the art can identify the allowed substitution by comparing the non-inclusive examples with the respective definitions of R₇ and R₉.

Non-inclusive examples of heterocycloalkyl include, but are not limited to, tetrahydrofurano, tetrahydropyrano, morpholino, pyrrolidino, piperidino, piperazine,
 25 azetidino, azetidinono, oxindolo, dihydroimidazolo, pyrrolidino, or isoxazolinyl.

The core molecule refers to the amide or thio amide group bound to the C-2 carbon of the 7-azabicyclo[2.2.1]heptane ring:



A bond to the core molecule refers to the bond from W to the carbon of the amide or thio amide group of the core molecule.

Halogen or halo is F, Cl, Br, or I.

Amino protecting group includes, but is not limited to, carbobenzyloxy (CBz),
5 1,1 dimethylcarbamate, *tert* butoxy carbonyl (BOC) and the like. Examples of other
suitable amino protecting groups are known to person skilled in the art and can be
found in "Protective Groups in Organic synthesis," 3rd Edition, authored by Theodora
Greene and Peter Wuts.

Mammal denotes human and other mammals.

10 Brine refers to an aqueous saturated sodium chloride solution.

IR refers to infrared spectroscopy.

Lv refers to leaving groups within a molecule, including Br, Cl, -OH, PhSO₂,
-Oalkyl, -Oaryl, or mixed anhydride.

NMR refers to nuclear (proton) magnetic resonance spectroscopy, chemical
15 shifts are reported in ppm (δ) downfield from TMS.

MS refers to mass spectrometry expressed as m/e or mass/charge unit. HRMS
refers to high resolution mass spectrometry expressed as m/e or mass/charge unit.

M+H⁺ refers to the positive ion of a parent plus a hydrogen atom. M-H⁻ refers to the
negative ion of a parent minus a hydrogen atom. M+Na⁺ refers to the positive ion of a
20 parent plus a sodium atom. M+K⁺ refers to the positive ion of a parent plus a
potassium atom. EI refers to electron impact. ESI refers to electrospray ionization.
CI refers to chemical ionization. FAB refers to fast atom bombardment.

Compounds of the present invention may be in the form of pharmaceutically
acceptable salts. The term "pharmaceutically acceptable salts" refers to salts prepared
25 from pharmaceutically acceptable non-toxic bases including inorganic bases and
organic bases, and salts prepared from inorganic acids, and organic acids. Salts
derived from inorganic bases include aluminum, ammonium, calcium, ferric, ferrous,
lithium, magnesium, potassium, sodium, zinc, and the like. Salts derived from
pharmaceutically acceptable organic non-toxic bases include salts of primary,
30 secondary, and tertiary amines, substituted amines including naturally occurring
substituted amines, cyclic amines, such as arginine, betaine, caffeine, choline, N, N-
dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylamino-
ethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine,

glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, and the like. Salts derived from inorganic acids include salts of hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, phosphorous acid and the like. Salts derived from pharmaceutically acceptable organic non-toxic acids include salts of C₁₋₆ alkyl carboxylic acids, di-carboxylic acids, and tri-carboxylic acids such as acetic acid, propionic acid, fumaric acid, succinic acid, tartaric acid, maleic acid, adipic acid, and citric acid, and aryl and alkyl sulfonic acids such as toluene sulfonic acids and the like.

By the term "effective amount" of a compound as provided herein is meant a nontoxic but sufficient amount of the compound(s) to provide the desired effect. As pointed out below, the exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the disease that is being treated, the particular compound(s) used, the mode of administration, and the like. Thus, it is not possible to specify an exact "effective amount." However, an appropriate effective amount may be determined by one of ordinary skill in the art using only routine experimentation.

The amount of therapeutically effective compound(s) that is administered and the dosage regimen for treating a disease condition with the compounds and/or compositions of this invention depends on a variety of factors, including the age, weight, sex and medical condition of the subject, the severity of the disease, the route and frequency of administration, and the particular compound(s) employed, and thus may vary widely. The compositions contain well known carriers and excipients in addition to a therapeutically effective amount of compounds of Formula I. The pharmaceutical compositions may contain active ingredient in the range of about 0.001 to 100 mg/kg/day for an adult, preferably in the range of about 0.1 to 50 mg/kg/day for an adult. A total daily dose of about 1 to 1000 mg of active ingredient may be appropriate for an adult. The daily dose can be administered in one to four doses per day.

In addition to the compound(s) of Formula I, the composition for therapeutic use may also comprise one or more non-toxic, pharmaceutically acceptable carrier materials or excipients. The term "carrier" material or "excipient" herein means any

substance, not itself a therapeutic agent, used as a carrier and/or diluent and/or adjuvant, or vehicle for delivery of a therapeutic agent to a subject or added to a pharmaceutical composition to improve its handling or storage properties or to permit or facilitate formation of a dose unit of the composition into a discrete article such as a capsule or tablet suitable for oral administration. Excipients can include, by way of illustration and not limitation, diluents, disintegrants, binding agents, adhesives, wetting agents, polymers, lubricants, glidants, substances added to mask or counteract a disagreeable taste or odor, flavors, dyes, fragrances, and substances added to improve appearance of the composition. Acceptable excipients include lactose, sucrose, starch powder, cellulose esters of alkanolic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active compound in hydroxypropylmethyl cellulose, or other methods known to those skilled in the art. For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid. If desired, other active ingredients may be included in the composition.

In addition to the oral dosing, noted above, the compositions of the present invention may be administered by any suitable route, in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. The compositions may, for example, be administered parenterally, e.g., intravascularly, intraperitoneally, subcutaneously, or intramuscularly. For parenteral administration, saline solution, dextrose solution, or water may be used as a suitable carrier. Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. The compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.

The serotonin type 3 receptor (5HT₃R) is a member of a superfamily of ligand-gated ion channels, which includes the muscle and neuronal nAChR, the glycine receptor, and the γ -aminobutyric acid type A receptor. Like the other members of this receptor superfamily, the 5HT₃R exhibits a large degree of sequence homology with $\alpha 7$ nAChR but functionally the two ligand-gated ion channels are very different. For example, $\alpha 7$ nAChR is rapidly inactivated, is highly permeable to calcium and is activated by acetylcholine and nicotine. On the other hand, 5HT₃R is inactivated slowly, is relatively impermeable to calcium and is activated by serotonin. These experiments suggest that the $\alpha 7$ nAChR and 5HT₃R proteins have some degree of homology, but function very differently. Indeed the pharmacology of the channels is very different. For example, Ondansetron, a highly selective 5HT₃R antagonist, has little activity at the $\alpha 7$ nAChR. The converse is also true. For example, GTS-21, a highly selective $\alpha 7$ nAChR agonist, has little activity at the 5HT₃R.

$\alpha 7$ nAChR is a ligand-gated Ca⁺⁺ channel formed by a homopentamer of $\alpha 7$ subunits. Previous studies have established that α -bungarotoxin (α -btx) binds selectively to this homopentameric, $\alpha 7$ nAChR subtype, and that $\alpha 7$ nAChR has a high affinity binding site for both α -btx and methyllycaconitine (MLA). $\alpha 7$ nAChR is expressed at high levels in the hippocampus, ventral tegmental area and ascending cholinergic projections from nucleus basalis to thalamocortical areas. $\alpha 7$ nAChR agonists increase neurotransmitter release, and increase cognition, arousal, attention, learning and memory.

Data from human and animal pharmacological studies establish that nicotinic cholinergic neuronal pathways control many important aspects of cognitive function including attention, learning and memory (Levin, E.D., *Psychopharmacology*, 108:417-31, 1992; Levin, E.D. and Simon B.B., *Psychopharmacology*, 138:217-30, 1998). For example, it is well known that nicotine increases cognition and attention in humans. ABT-418, a compound that activates $\alpha 4\beta 2$ and $\alpha 7$ nAChR, improves cognition and attention in clinical trials of Alzheimer's disease and attention-deficit disorders (Potter, A. et. al., *Psychopharmacology (Berl.)*, 142(4):334-42, Mar. 1999; Wilens, T. E. et. al., *Am. J. Psychiatry*, 156(12):1931-7, Dec. 1999). It is also clear that nicotine and selective but weak $\alpha 7$ nAChR agonists increase cognition and attention in rodents and non-human primates.

Schizophrenia is a complex multifactorial illness caused by genetic and non-genetic risk factors that produce a constellation of positive and negative symptoms. The positive symptoms include delusions and hallucinations and the negative symptoms include deficits in affect, attention, cognition and information processing.

5 No single biological element has emerged as a dominant pathogenic factor in this disease. Indeed, it is likely that schizophrenia is a syndrome that is produced by the combination of many low penetrance risk factors. Pharmacological studies established that dopamine receptor antagonists are efficacious in treating the overt psychotic features (positive symptoms) of schizophrenia such as hallucinations and

10 delusions. Clozapine, an "atypical" antipsychotic drug, is novel because it is effective in treating both the positive and some of the negative symptoms of this disease. Clozapine's utility as a drug is greatly limited because continued use leads to an increased risk of agranulocytosis and seizure. No other antipsychotic drug is effective in treating the negative symptoms of schizophrenia. This is significant because the

15 restoration of cognitive functioning is the best predictor of a successful clinical and functional outcome of schizophrenic patients (Green, M.F., *Am J Psychiatry*, 153:321-30, 1996). By extension, it is clear that better drugs are needed to treat the cognitive disorders of schizophrenia in order to restore a better state of mental health to patients with this disorder.

20 One aspect of the cognitive deficit of schizophrenia can be measured by using the auditory event-related potential (P50) test of sensory gating. In this test, electroencephalographic (EEG) recordings of neuronal activity of the hippocampus are used to measure the subject's response to a series of auditory "clicks" (Adler, L.E. et. al., *Biol. Psychiatry*, 46:8-18, 1999). Normal individuals respond to the first click

25 with greater degree than to the second click. In general, schizophrenics and schizotypal patients respond to both clicks nearly the same (Cullum, C.M. et. al., *Schizophr. Res.*, 10:131-41, 1993). These data reflect a schizophrenic's inability to "filter" or ignore unimportant information. The sensory gating deficit appears to be one of the key pathological features of this disease (Cadenhead, K.S. et. al., *Am. J. Psychiatry*, 157:55-9, 2000). Multiple studies show that nicotine normalizes the

30 sensory deficit of schizophrenia (Adler, L.E. et. al., *Am. J. Psychiatry*, 150:1856-61, 1993). Pharmacological studies indicate that nicotine's effect on sensory gating is via the $\alpha 7$ nAChR (Adler, L.E. et. al., *Schizophr. Bull.*, 24:189-202, 1998). Indeed, the

biochemical data indicate that schizophrenics have 50% fewer of $\alpha 7$ nAChR receptors in the hippocampus, thus giving a rationale to partial loss of $\alpha 7$ nAChR functionality (Freedman, R. et. al., *Biol. Psychiatry*, 38:22-33, 1995). Interestingly, genetic data indicate that a polymorphism in the promoter region of the $\alpha 7$ nAChR gene is strongly associated with the sensory gating deficit in schizophrenia (Freedman, R. et. al., *Proc. Nat'l Acad. Sci. USA*, 94(2):587-92, 1997; Myles-Worsley, M. et. al., *Am. J. Med. Genet*, 88(5):544-50, 1999). To date, no mutation in the coding region of the $\alpha 7$ nAChR has been identified. Thus, schizophrenics express the same $\alpha 7$ nAChR as non-schizophrenics.

Selective $\alpha 7$ nAChR agonists may be found using a functional assay on FLIPR (see WO 00/73431 A2). FLIPR is designed to read the fluorescent signal from each well of a 96 or 384 well plate as fast as twice a second for up to 30 minutes. This assay may be used to accurately measure the functional pharmacology of $\alpha 7$ nAChR and 5HT₃R. To conduct such an assay, one uses cell lines that expressed functional forms of the $\alpha 7$ nAChR using the $\alpha 7/5$ -HT₃ channel as the drug target and cell lines that expressed functional 5HT₃R. In both cases, the ligand-gated ion channel was expressed in SH-EP1 cells. Both ion channels can produce robust signal in the FLIPR assay.

The compounds of the present invention are $\alpha 7$ nAChR agonists and may be used to treat a wide variety of diseases. For example, they may be used in treating schizophrenia, or psychosis.

Schizophrenia is a disease having multiple aspects. Currently available drugs are generally aimed at controlling the positive aspects of schizophrenia, such as delusions. One drug, Clozapine, is aimed at a broader spectrum of symptoms associated with schizophrenia. This drug has many side effects and is thus not suitable for many patients. Thus, there is a need for a drug to treat the cognitive and attention deficits associated with schizophrenia. Similarly, there is a need for a drug to treat the cognitive and attention deficits associated with schizoaffective disorders, or similar symptoms found in the relatives of schizophrenic patients.

Psychosis is a mental disorder characterized by gross impairment in the patient's perception of reality. The patient may suffer from delusions, and hallucinations, and may be incoherent in speech. His behavior may be agitated and is often incomprehensible to those around him. In the past, the term psychosis has been

applied to many conditions that do not meet the stricter definition given above. For example, mood disorders were named as psychoses.

There are a variety of antipsychotic drugs. The conventional antipsychotic drugs include Chlorpromazine, Fluphenazine, Haloperidol, Loxapine, Mesoridazine, 5 Molindone, Perphenazine, Pimozide, Thioridazine, Thiothixene, and Trifluoperazine. These drugs all have an affinity for the dopamine 2 receptor.

These conventional antipsychotic drugs have several side effects, including sedation, weight gain, tremors, elevated prolactin levels, akathisia (motor restlessness), dystonia and muscle stiffness. These drugs may also cause tardive 10 dyskinesia. Unfortunately, only about 70% of patients with schizophrenia respond to conventional antipsychotic drugs. For these patients, atypical antipsychotic drugs are available.

Atypical antipsychotic drugs generally are able to alleviate positive symptoms of psychosis while also improving negative symptoms of the psychosis to a greater 15 degree than conventional antipsychotics. These drugs may improve neurocognitive deficits. Extrapyramidal (motor) side effects are not as likely to occur with the atypical antipsychotic drugs, and thus, these atypical antipsychotic drugs have a lower risk of producing tardive dyskinesia. Finally these atypical antipsychotic drugs cause little or no elevation of prolactin. Unfortunately, these drugs are not free of side 20 effects. Although these drugs each produce different side effects, as a group the side effects include: agranulocytosis; increased risk of seizures, weight gain, somnolence, dizziness, tachycardia, decreased ejaculatory volume, and mild prolongation of QTc interval.

In a combination therapy to treat multiple symptoms of diseases such as 25 schizophrenia, the compounds of Formula I and the anti-psychotic drugs can be administered simultaneously or at separate intervals. When administered simultaneously the compounds of Formula I and the anti-psychotic drugs can be incorporated into a single pharmaceutical composition, e.g., a pharmaceutical combination therapy composition. Alternatively, two separate compositions, i.e., one 30 containing compounds of Formula I and the other containing anti-psychotic drugs, can be administered simultaneously. Examples of anti-psychotic drugs, in addition to those listed above, include, but are not limited to, Thorazine, Mellaril, Trilafon, Navane, Stelazine, Permitil, Prolixin, Risperdal, Zyprexa, Seroquel, ZELDOX,

Acetophenazine, Carphenazine, Chlorprothixene, Droperidol, Loxapine, Mesoridazine, Molindone, Ondansetron, Pimozide, Prochlorperazine, and Promazine.

A pharmaceutical combination therapy composition can include therapeutically effective amounts of the compounds of Formula I, noted above, and a therapeutically effective amount of anti-psychotic drugs (also called agents). These compositions may be formulated with common excipients, diluents or carriers, and compressed into tablets, or formulated elixirs or solutions for convenient oral administration or administered by intramuscular intravenous routes. The compounds can be administered rectally, topically, orally, sublingually, or parenterally and maybe formulated as sustained relief dosage forms and the like.

When separately administered, therapeutically effective amounts of compositions containing compounds of Formula I and anti-psychotic drugs are administered on a different schedule. One may be administered before the other as long as the time between the two administrations falls within a therapeutically effective interval. A therapeutically effective interval is a period of time beginning when one of either (a) the compounds of Formula I, or (b) the anti-psychotic drugs is administered to a human and ending at the limit of the beneficial effect in the treatment of schizophrenia or psychosis of the combination of (a) and (b). The methods of administration of the compounds of Formula I and the anti-psychotic drugs may vary. Thus, either agent or both agents may be administered rectally, topically, orally, sublingually, or parenterally.

As discussed, the compounds of the present invention are $\alpha 7$ nAChR agonists. Therefore, as another aspect of the present invention, the compounds of the present invention may be used to treat a variety of diseases including cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (also known as mild cognitive impairment), and senile dementia.

Alzheimer's disease has many aspects, including cognitive and attention deficits. Currently, these deficits are treated with cholinesterase inhibitors. These inhibitors slow the break down of acetylcholine, and thereby provide a general nonspecific increase in the activity of the cholinergic nervous system. Since the drugs are nonspecific, they have a wide variety of side effects. Thus, there is a need for a

drug that stimulates a portion of the cholinergic pathways and thereby provides improvement in the cognitive and attention deficits associated with Alzheimer's disease without the side effects created by nonspecific stimulation of the cholinergic pathways.

5 Neurodegeneration is a common problem associated with diseases such as Alzheimer's disease. While the current drugs treat some of the symptoms of this disease, they do not control the underlying pathology of the disease. Accordingly, it would be desirable to provide a drug that can slow the progress of Alzheimer's disease.

10 Pre-senile dementia (mild cognitive impairment) concerns memory impairment rather than attention deficit problems and otherwise unimpaired cognitive functioning. Mild cognitive impairment is distinguished from senile dementia in that mild cognitive impairment involves a more persistent and troublesome problem of memory loss for the age of the patient. There currently is no medication specifically
15 identified for treatment of mild cognitive impairment, due somewhat to the newness of identifying the disease. Therefore, there is a need for a drug to treat the memory problems associated with mild cognitive impairment.

Senile dementia is not a single disease state. However, the conditions classified under this name frequently include cognitive and attention deficits.

20 Generally, these deficits are not treated. Accordingly, there is a need for a drug that provides improvement in the cognitive and attention deficits associated with senile dementia.

As discussed, the compounds of the present invention are $\alpha 7$ nAChR agonists.
25 Therefore, yet other diseases to be treated with compounds of the present invention include treating the cognitive and attention deficits as well as the neurodegeneration associated with any one or more or combination of the following: attention deficit disorder, attention deficit hyperactivity disorder, depression, anxiety, general anxiety disorder, post traumatic stress disorder, mood and affective disorders, amyotrophic
30 lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, Parkinson's disease, tardive dyskinesia, Pick's disease,

dysregulation of food intake including bulimia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependant drug cessation, Gilles de la Tourette's Syndrome, age-related macular degeneration, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain.

5 Attention deficit disorder is generally treated with methylphenidate, an amphetamine-like molecule that has some potential for abuse. Accordingly, it would be desirable to provide a drug that treats attention deficit disorder while having fewer side effects than the currently used drug.

10 Attention deficit hyperactivity disorder, otherwise known as ADHD, is a neurobehavioral disorder affecting 3-5% of all American children. ADHD concerns cognitive alone or both cognitive and behavioral actions by interfering with a person's ability to stay on a task and to exercise age-appropriate inhibition. Several types of ADHD exist: a predominantly inattentive subtype, a predominantly hyperactive-impulsive subtype, and a combined subtype. Treatment may include medications such
15 as methylphenidate, dextroamphetamine, or pemoline, which act to decrease impulsivity and hyperactivity and to increase attention. No "cure" for ADHD currently exists. Children with the disorder seldom outgrow it; therefore, there is a need for appropriate medicaments.

20 Depression is a mood disorder of varying lengths of normally several months to more than two years and of varying degrees of feelings involving sadness, despair, and discouragement. The heterocyclic antidepressants (HCA's) are currently the largest class of antidepressants, but monoamine oxidase inhibitors (MAOI's) are used in particular types of depression. Common side effects from HCA's are sedation and weight gain. In elderly patients with organic brain disease, the side effects from
25 HCA's can also include seizures and behavioral symptoms. The main side effects from using MAOI's occur from dietary and drug interactions. Therefore, agents with fewer side effects would be useful.

30 Anxiety disorders (disorders with prominent anxiety or phobic avoidance), represent an area of unmet medical needs in the treatment of psychiatric illness. See Diagnostic & Statistical Manual of Mental Disorders, IV (1994), pp 393-394, for various disease forms of anxiety.

 General anxiety disorder (GAD) occurs when a person worries about things such as family, health, or work when there is no reason to worry and is unable not to

worry. About 3 to 4% of the U.S. population has GAD during the course of a year. GAD most often strikes people in childhood or adolescence, but can begin in adulthood, too. It affects women more often than men. Currently, treatment involves cognitive-behavioral therapy, relaxation techniques, and biofeedback to control muscle tension and medications such as benzodiazepines, imipramine, and buspirone. These drugs are effective but all have side-effect liabilities. Therefore, there is a need of a pharmaceutical agent to address the symptoms with fewer side effects.

Anxiety also includes post-traumatic stress disorder (PTSD), which is a form of anxiety triggered by memories of a traumatic event that directly affected the patient or that the patient may have witnessed. The disorder commonly affects survivors of traumatic events including sexual assault, physical assault, war, torture, natural disasters, an automobile accident, an airplane crash, a hostage situation, or a death camp. The affliction also can affect rescue workers at an airplane crash or a mass shooting, someone who witnessed a tragic accident or someone who has unexpectedly lost a loved one. Treatment for PTSD includes cognitive-behavioral therapy, group psychotherapy, and medications such as Clonazepam, Lorazepam and selective serotonin-reuptake inhibitors such as Fluoxetine, Sertraline, Paroxetine, Citalopram and Fluvoxamine. These medications help control anxiety as well as depression. Various forms of exposure therapy (such as systemic desensitization and imaginal flooding) have all been used with PTSD patients. Exposure treatment for PTSD involves repeated reliving of the trauma, under controlled conditions, with the aim of facilitating the processing of the trauma. Therefore, there is a need for better pharmaceutical agents to treat post traumatic stress disorder.

Mood and affective disorders fall within a large group of diseases, including monopolar depression and bi-polar mood disorder. These diseases are treated with three major classes of compounds. The first group is the heterocyclic antidepressant (HCA's). This group includes the well-known tricyclic antidepressants. The second group of compounds used to treat mood disorders is the monoamine oxidase inhibitors (MAOI's) that are used in particular types of diseases. The third drug is lithium. Common side effects from HCA's are sedation and weight gain. In elderly patients with organic brain disease, the side effects of HCA's can also include seizures and behavioral symptoms. The main side effects from using MAOI's occur from dietary and drug interactions. Benign side effects from the use of lithium include, but are not

limited to, weight gain, nausea, diarrhea, polyuria, polydipsia, and tremor. Toxic side effects from lithium can include persistent headache, mental confusion, and may reach seizures and cardiac arrhythmias. Therefore, agents with less side effects or interactions with food or other medications would be useful.

5 Borderline personality disorder, although not as well known as bipolar disorder, is more common. People having borderline personality disorder suffer from a disorder of emotion regulation. Pharmaceutical agents are used to treat specific symptoms, such as depression or thinking distortions.

10 Acquired immune deficiency syndrome (AIDS) results from an infection with the human immunodeficiency virus (HIV). This virus attacks selected cells and impairs the proper function of the immune, nervous, and other systems. HIV infection can cause other problems such as, but not limited to, difficulties in thinking, otherwise known as AIDS dementia complex. Therefore, there is a need to drugs to relieve the confusion and mental decline of persons with AIDS.

15 Amyotrophic lateral sclerosis, also known as Lou Gehrig's disease, belongs to a class of disorders known as motor neuron diseases wherein specific nerve cells in the brain and spinal cord gradually degenerate to negatively affect the control of voluntary movement. Currently, there is no cure for amyotrophic lateral sclerosis although patients may receive treatment from some of their symptoms and although
20 Riluzole has been shown to prolong the survival of patients. Therefore, there is a need for a pharmaceutical agent to treat this disease.

 Traumatic brain injury occurs when the brain is damaged from a sudden physical assault on the head. Symptoms of the traumatic brain injury include confusion and other cognitive problems. Therefore, there is a need to address the
25 symptoms of confusion and other cognitive problems.

 Brain tumors are abnormal growths of tissue found inside of the skull. Symptoms of brain tumors include behavioral and cognitive problems. Surgery, radiation, and chemotherapy are used to treat the tumor, but other agents are necessary to address associated symptoms. Therefore, there is a need to address the symptoms
30 of behavioral and cognitive problems.

 Persons with Down's syndrome have in all or at least some of their cells an extra, critical portion of the number 21 chromosome. Adults who have Down's syndrome are known to be at risk for Alzheimer-type dementia. Currently, there is no

proven treatment for Down's syndrome. Therefore, there is a need to address the dementia associated with Down's syndrome.

Genetically programmed degeneration of neurons in certain areas of the brain cause Huntington's disease. Early symptoms of Huntington's disease include mood swings, or trouble learning new things or remembering a fact. Most drugs used to treat the symptoms of Huntington's disease have side effects such as fatigue, restlessness, or hyperexcitability. Currently, there is no treatment to stop or reverse the progression of Huntington's disease. Therefore, there is a need of a pharmaceutical agent to address the symptoms with fewer side effects.

Dementia with Lewy Bodies is a neurodegenerative disorder involving abnormal structures known as Lewy bodies found in certain areas of the brain. Symptoms of dementia with Lewy bodies include, but are not limited to, fluctuating cognitive impairment with episodic delirium. Currently, treatment concerns addressing the parkinsonian and psychiatric symptoms. However, medicine to control tremors or loss of muscle movement may actually accentuate the underlying disease of dementia with Lewy bodies. Therefore, there is a need of a pharmaceutical agent to treat dementia with Lewy bodies.

Parkinson's disease is a neurological disorder characterized by tremor, hypokinesia, and muscular rigidity. Currently, there is no treatment to stop the progression of the disease. Therefore, there is a need of a pharmaceutical agent to address Parkinson's.

Tardive dyskinesia is associated with the use of conventional antipsychotic drugs. This disease is characterized by involuntary movements most often manifested by puckering of the lips and tongue and/or writhing of the arms or legs. The incidence of tardive dyskinesia is about 5% per year of drug exposure among patients taking conventional antipsychotic drugs. In about 2% of persons with the disease, tardive dyskinesia is severely disfiguring. Currently, there is no generalized treatment for tardive dyskinesia. Furthermore, the removal of the effect-causing drugs is not always an option due to underlying problems. Therefore, there is a need for a pharmaceutical agent to address the symptoms of tardive dyskinesia.

Pick's disease results from a slowly progressive deterioration of social skills and changes in personality with the resulting symptoms being impairment of intellect, memory, and language. Common symptoms include memory loss, lack of

spontaneity, difficulty in thinking or concentrating, and speech disturbances.

Currently, there is no specific treatment or cure for Pick's disease but some symptoms can be treated with cholinergic and serotonin-boosting antidepressants. In addition, antipsychotic medications may alleviate symptoms in FTD patients who are
5 experiencing delusions or hallucinations. Therefore, there is a need for a pharmaceutical agent to treat the progressive deterioration of social skills and changes in personality and to address the symptoms with fewer side effects.

Dysregulation of food intake associated with eating disease, including bulimia nervosa and anorexia nervosa, involve neurophysiological pathways. Anorexia
10 nervosa is hard to treat due to patients not entering or remaining in after entering programs. Currently, there is no effective treatment for persons suffering from severe anorexia nervosa. Cognitive behavioral therapy has helped patients suffering from bulimia nervosa; however, the response rate is only about 50% and current treatment does not adequately address emotional regulation. Therefore, there is a need for
15 pharmaceutical agents to address neurophysiological problems underlying diseases of dysregulation of food intake.

Cigarette smoking has been recognized as a major public health problem for a long time. However, in spite of the public awareness of health hazard, the smoking habit remains extraordinarily persistent and difficult to break. There are many
20 treatment methods available, and yet people continue to smoke. Administration of nicotine transdermally, or in a chewing gum base is common treatments. However, nicotine has a large number of actions in the body, and thus can have many side effects. It is clear that there is both a need and a demand of long standing for a convenient and relatively easy method for aiding smokers in reducing or eliminating
25 cigarette consumption. A drug that could selectively stimulate only certain of the nicotinic receptors would be useful in smoke cessation programs.

Smoke cessation programs may involve oral dosing of the drug of choice. The drug may be in the form of tablets. However, it is preferred to administer the daily dose over the waking hours, by administration of a series of incremental doses during
30 the day. The preferred method of such administration is a slowly dissolving lozenge, troche, or chewing gum, in which the drug is dispersed. Another drug in treating nicotine addiction is Zyban. This is not a nicotine replacement, as are the gum and patch. Rather, this works on other areas of the brain, and its effectiveness is to help

control nicotine craving or thoughts about cigarette use in people trying to quit. Zyban is not very effective and effective drugs are needed to assist smokers in their desire to stop smoking. These drugs may be administered transdermally through the use of skin patches. In certain cases, the drugs may be administered by subcutaneous
5 injection, especially if sustained release formulations are used.

Drug use and dependence is a complex phenomenon, which cannot be encapsulated within a single definition. Different drugs have different effects, and therefore different types of dependence. Drug dependence has two basic causes, that is, tolerance and physical dependence. Tolerance exists when the user must take
10 progressively larger doses to produce the effect originally achieved with smaller doses. Physical dependence exists when the user has developed a state of physiologic adaptation to a drug, and there is a withdrawal (abstinence) syndrome when the drug is no longer taken. A withdrawal syndrome can occur either when the drug is discontinued or when an antagonist displaces the drug from its binding site on cell
15 receptors, thereby counteracting its effect. Drug dependence does not always require physical dependence.

In addition drug dependence often involves psychological dependence, that is, a feeling of pleasure or satisfaction when taking the drug. These feelings lead the user to repeat the drug experience or to avoid the displeasure of being deprived of the drug.
20 Drugs that produce strong physical dependence, such as nicotine, heroin and alcohol are often abused, and the pattern of dependence is difficult to break. Drugs that produce dependence act on the CNS and generally reduce anxiety and tension; produce elation, euphoria, or other pleasurable mood changes; provide the user feelings of increased mental and physical ability; or alter sensory perception in some
25 pleasurable manner. Among the drugs that are commonly abused are ethyl alcohol, opioids, anxiolytics, hypnotics, cannabis (marijuana), cocaine, amphetamines, and hallucinogens. The current treatment for drug-addicted people often involves a combination of behavioral therapies and medications. Medications, such as methadone or LAAM (levo-alpha-acetyl-methadol), are effective in suppressing the
30 withdrawal symptoms and drug craving associated with narcotic addiction, thus reducing illicit drug use and improving the chances of the individual remaining in treatment. The primary medically assisted withdrawal method for narcotic addiction is to switch the patient to a comparable drug that produces milder withdrawal

symptoms, and then gradually taper off the substitute medication. The medication used most often is methadone, taken orally once a day. Patients are started on the lowest dose that prevents the more severe signs of withdrawal and then the dose is gradually reduced. Substitutes can be used also for withdrawal from sedatives.

- 5 Patients can be switched to long-acting sedatives, such as diazepam or phenobarbital, which are then gradually reduced.

Gilles de la Tourette's Syndrome is an inherited neurological disorder. The disorder is characterized by uncontrollable vocal sounds called tics and involuntary movements. The symptoms generally manifest in an individual before the person is
10 18 years of age. The movement disorder may begin with simple tics that progress to multiple complex tics, including respiratory and vocal ones. Vocal tics may begin as grunting or barking noises and evolve into compulsive utterances. Coprolalia (involuntary scatologic utterances) occurs in 50% of patients. Severe tics and coprolalia may be physically and socially disabling. Tics tend to be more complex
15 than myoclonus, but less flowing than choreic movements, from which they must be differentiated. The patient may voluntarily suppress them for seconds or minutes.

Currently simple tics are often treated with benzodiazepines. For simple and complex tics, Clonidine may be used. Long-term use of Clonidine does not cause tardive dyskinesia; its limiting adverse effect is hypotension. In more severe cases,
20 antipsychotics, such as Haloperidol may be required, but side effects of dysphoria, parkinsonism, akathisia, and tardive dyskinesia may limit use of such antipsychotics. There is a need for safe and effective methods for treating this syndrome.

Age-related macular degeneration (AMD) is a common eye disease of the macula which is a tiny area in the retina that helps produce sharp, central vision
25 required for "straight ahead" activities that include reading and driving. Persons with AMD lose their clear, central vision. AMD takes two forms: wet and dry. In dry AMD, there is a slow breakdown of light-sensing cells in the macula. There currently is no cure for dry AMD. In wet AMD, new, fragile blood vessels growing beneath the macula as dry AMD worsens and these vessels often leak blood and fluid to cause
30 rapid damage to the macula quickly leading to the loss of central vision. Laser surgery can treat some cases of wet AMD. Therefore, there is a need of a pharmaceutical agent to address AMD.

Glaucoma is within a group of diseases occurs from an increase in intraocular pressure causing pathological changes in the optical disk and negatively affects the field of vision. Medicaments to treat glaucoma either decrease the amount of fluid entering the eye or increase drainage of fluids from the eye in order to decrease
5 intraocular pressure. However, current drugs have drawbacks such as not working over time or causing side effects so the eye-care professional has to either prescribe other drugs or modify the prescription of the drug being used. There is a need for safe and effective methods for treating problems manifesting into glaucoma.


Ischemic periods in glaucoma cause release of excitotoxic amino acids and
10 stimulate inducible form of nitric oxide synthase (iNOS) leading to neurodegeneration. Alpha 7 nicotinic agonists may stimulate the release of inhibitory amino acids such as GABA which will dampen hyperexcitability. Alpha 7 nicotinic agonists are also directly neuroprotective on neuronal cell bodies. Thus alpha 7 nicotinic agonists have the potential to be neuroprotective in glaucoma.

15 Persons afflicted with pain often have what is referred to as the "terrible triad" of suffering from the pain, resulting in sleeplessness and sadness, all of which are hard on the afflicted individual and that individual's family. Pain can manifest itself in various forms, including, but not limited to, headaches of all severity, back pain, neurogenic, and pain from other ailments such as arthritis and cancer from its
20 existence or from therapy to irradiate it. Pain can be either chronic (persistent pain for months or years) or acute (short-lived, immediate pain to inform the person of possible injury and need of treatment). Persons suffering from pain respond differently to individual therapies with varying degrees of success. There is a need for safe and effective methods for treating pain.

25 Finally, the compounds of the present invention may be used in combination therapy with typical and atypical anti-psychotic drugs. All compounds within the present invention are useful for and may also be used in combination with each other to prepare pharmaceutical compositions. Such combination therapy lowers the effective dose of the anti-psychotic drug and thereby reduces the side effects of the
30 anti-psychotic drugs. Some typical anti-psychotic drugs that may be used in the practice of the invention include Haldol. Some atypical anti-psychotic drugs include Ziprasidone, Olanzapine, Risperidone, and Quetiapine.

Compounds of Formula I can be prepared as shown in Scheme 1. Starting materials can be prepared by procedures described below or by procedures that would be well known to one of ordinary skill in organic chemistry. The variables used in Scheme 1 are defined below or as in the claims. The key step in the preparation of this class of compounds is the coupling of *tert*-butyl (1*S*, 2*R*, 4*R*)-(+)-2-amino-7-azabicyclo[2.2.1]heptane-7-carboxylate ((2*R*)-7-aza-[2.2.1]-Amine) with the requisite acid chloride (Lv = Cl), mixed anhydride (e.g., Lv = diphenyl phosphoryl, bis(2-oxo-3-oxazolidinyl)phosphinyl, or acyloxy of the general formula of O-C(O)-R_{Lv}, where R_{Lv} includes phenyl or *t*-butyl), ester (e.g., Lv = alkyl, aryl, or electron deficient aryl), or carboxylic acid (Lv = OH) in the presence of an activating agent. Suitable activating reagents are well known in the art, for examples see Kiso, Y., Yajima, H. "Peptides" pp. 39-91, San Diego, CA, Academic Press, (1995), and include, but are not limited to, agents such as carbodiimides, phosphonium and uronium salts (such as uronium salt HATU).

Scheme 1




Preferably, (2*R*)-7-aza-[2.2.1]-Amine can be coupled to the acid in the presence of an appropriate base, such as DIEA, and a uronium salt, such as HATU, in an aprotic medium, such as DMF, to give the desired amides. Alternatively, the acid is converted into a mixed anhydride by treatment with bis (2-oxo-3-oxazolidinyl) phosphinic chloride in the presence of TEA with CH₂Cl₂ or CHCl₃ as the solvent. The resulting anhydride solution is directly reacted with (2*R*)-7-aza-[2.2.1]-Amine added neat or using CH₂Cl₂ or CHCl₃ as solvent. Furthermore, condensation of the amine with an ester (W-C(O)-O-alkyl or W-C(O)-O-(electron-deficient aryl)) in an alcoholic solvent such as ethanol at an elevated temperature will yield desired amides.

Treatment of the carboxamide with a sulfurating agent such as Lawesson's Reagent (2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide) in, for instance, dioxane at an appropriate temperature provides the corresponding thioamide, e.g., X in formula I is S. See Lawesson et. al. in *Bull. Soc. Chim. Belg.*, 229 (1978)),

or P_4S_{10} (see *Chem. Rev.*, 45 (1961). Alternatively, one can react a dithiocarboxylic ester with the corresponding azbicyclo moiety to form the same thioamide.

There are various methods for the construction of the optionally substituted 7-azabicyclo[2.2.1]heptane ring system. For example, the independent work of Trudell ($R_4 = H$, Zhang, C., Trudell, M.L., *J. Org. Chem.*, 61, 7189-7191, 1996), and Schultz ($R_4 = Me$, Schultz, A.G., Shen, M.S., *Tetrahedron Lett.*, 22, 3347-3350, 1981) describes the utility of a Diels-Alder approach toward preparing this ring system with functionality suitable for further elaboration to the desired 2-amino-7-azabicyclo[2.2.1]heptane (Scheme 2). For instance, Trudell reports (Zhang, C., Trudell, M.L., *Tetrahedron*, 54, 8349-8354, 1998) that Diels-Alder adduct **1a** (where $R_6 =$ methylcarbamate, $R_4 = H$, and $Le = Br$) could readily be functionalized at C-3 via reaction with organocopper species to introduce the substituent R_2 in **2a,b**. Likewise, hydrogenolysis of adduct **1a,b** or **2a,b** followed by isomerization of the *endo* products as described by Singh (Singh, S., Basmadjian, G.P., *Tetrahedron Lett.*, 38, 6829-6830, 1997) could provide access to the required *exo* acid **3a-d**. Treatment of **3** with diphenylphosphoryl azide in the presence of a tertiary amine base (e.g., Et_3N) in a suitable solvent such as toluene, followed by warming of the intermediate acylazide in the presence of a suitable alcohol (e.g., benzyl alcohol) would effect the well-known Curtius rearrangement to provide a differentially protected *bis* carbamate which could be cleaved under typical hydrogenolysis conditions (e.g., 10% Pd/C, EtOH, H_2 , ambient to 50 psi) to give the desired amine **4**. Alternatively, the differentially protected *bis* carbamate might provide an attractive point of intervention for the chromatographic resolution of the individual 2-*exo* isomers prior to cleavage to amine **4**.


Scheme 2



In the case where $R_6 = \text{tert-butyloxycarbonyl}$, deprotection of the 7-aza group can be conveniently accomplished under acidic conditions in a suitable solvent such as methanol. After deprotection, the secondary amine may be functionalized with alkyl and substituted alkyl via reductive amination or alkylative procedures.

It will be apparent to those skilled in the art that the requisite carboxylic acids can be obtained through synthesis via literature procedures or through the slight modification thereof.

Preparation of *tert*-butyl (1*S*, 2*R*, 4*R*)-2-amino-7-azabicyclo[2.2.1]heptane-7-carboxylate:



Methyl propiolate (52 ml, 0.583 mol) is combined with recrystallized *N*-bromo-succinimide (120 g, 0.674 mol) in 1,700 ml acetone under nitrogen. The solution is treated with silver nitrate (9.9 g, 0.0583 mol) neat in a single lot and the

reaction is stirred 6 h at RT. The acetone is removed under reduced pressure (25°C, bath temperature) to provide a gray slurry. The slurry is washed with 2 x 200 ml hexane, the gray solid is removed by filtration, and the filtrate is concentrated *in vacuo* to provide 95 g of a pale yellow oily residue. The crude material is distilled via short path under reduced pressure (65°C, about 25 mm Hg) into a dry ice/acetone cooled receiver to give 83.7 g (88%) of methyl-3-bromo-propiolate as a pale yellow oil. Anal. calc'd for C₄H₃BrO₂: C, 29.48; H, 1.86. Found: C, 29.09; H, 1.97.

Methyl-3-bromo-propiolate (83.7 g, 0.513 mol) is added to *N*-*t*-butyloxy-pyrrole (430 ml, 2.57 mol) under nitrogen. The dark mixture is warmed in a 90 °C bath for 30 h, is cooled, and the bulk of the excess *N*-*t*-butyloxy-pyrrole is removed *in vacuo* using a dry ice/acetone condenser. The dark oily residue is chromatographed over 1 kg silica gel (230-400 mesh) eluting with 0-15% EtOAc/hexane. The appropriate fractions are combined and concentrated to afford 97 g (57%) of 7-*tert*-butyl 2-methyl 3-bromo-7-azabicyclo[2.2.1]hepta-2,5-diene-2,7-dicarboxylate as a dark yellow oil. HRMS (FAB) calc'd for C₁₃H₁₆BrNO₄+H: 330.0341, found 330.0335 (M+H)⁺.

7-*tert*-Butyl 2-methyl 3-bromo-7-azabicyclo[2.2.1]hepta-2,5-diene-2,7-dicarboxylate (97 g, 0.294 mol) is added to 10% Pd/C (6.8g) in 900 ml absolute EtOH in a PARR bottle. The suspension is diluted with a solution of NaHCO₃ (25 g, 0.301 mol) in 250 ml water and the mixture is hydrogenated at 50 PSI for 2.5 h. The catalyst is removed by filtration, is washed with fresh EtOH, and the filtrate is concentrated *in vacuo* to give a residue. The residue is partitioned between 1 x 200 ml saturated NaHCO₃ and CH₂Cl₂ (4 x 100 ml). The combined organic layer is dried over 1:1 K₂CO₃/MgSO₄ and concentrated *in vacuo* to afford 72.8 g (98%) of (+/-) *endo*-7-*tert*-butyl 2-methyl 7-azabicyclo[2.2.1]heptane-2,7-dicarboxylate. MS (EI) for C₁₄H₂₂O₄, *m/z*: 255 (M)⁺.

(+/-)-*Endo*-7-*tert*-butyl 2-methyl 7-azabicyclo[2.2.1]heptane-2,7-dicarboxylate (72.8 g, 0.285 mol) is dissolved in 1000 ml dry MeOH in a dried flask under nitrogen. The solution is treated with solid NaOMe (38.5 g, 0.713 mol) neat, in a single lot and the reaction is warmed to reflux for 4h. The mixture is cooled to 0°C, is treated with 400 ml water, and the reaction is stirred 1h as it warms to RT. The mixture is concentrated *in vacuo* to about 400 ml and the pH of the aqueous residue is adjusted to 4.5 with 12N HCl. The precipitate is collected and dried. The tan, slightly tacky

solid is washed with 2 x 100 ml 60% ether in hexane and is dried to provide 47 g (68%) of (+/-) *exo*-7-(*tert*-butoxycarbonyl)-7-azabicyclo[2.2.1]heptane-2-carboxylic acid as an off-white powder. HRMS (FAB) calc'd for $C_{12}H_{19}NO_4 + H$: 242.1392, found 242.1390 (M+H)⁺.

5 (+/-) *Exo*-7-(*tert*-butoxycarbonyl)-7-azabicyclo[2.2.1]heptane-2-carboxylic acid (103.9 g, 0.430 mol) is combined with TEA (60 ml, 0.430 mol) in 1200 ml dry toluene in a dry flask under nitrogen. The solution is treated drop-wise with diphenylphosphoryl azide (92.8 ml, 0.430 mol), and is allowed to stir for 20 min at RT. The mixture is treated with benzyl alcohol (47.9 ml, 0.463 mol), and the reaction
10 is stirred overnight at 55°C. The mixture is cooled, is extracted successively with 2 x 500 ml 5% citric acid, 2 x 500 ml water, 2 x 500 ml saturated sodium bicarbonate, and 500 ml brine. The organic layer is dried over $MgSO_4$ and concentrated *in vacuo* to an amber oil. The crude material is chromatographed over 900 g silica gel (230-400 mesh), eluting with 10-30% EtOAc/hexane. The appropriate fractions are combined
15 and concentrated to give 106 g (71%) of (+/-) *exo-tert*-butyl 2-[[*(benzyloxy)*carbonyl]amino]-7-azabicyclo[2.2.1]heptane-7-carboxylate as a pale oil. ¹H NMR ($CDCl_3$) δ 1.29-1.60, 1.44, 1.62-2.01, 3.76-3.88, 4.10, 4.24, 5.10, 7.36 ppm.

(+/-) *Exo-tert*-Butyl 2-[[*(benzyloxy)*carbonyl]amino]-7-azabicyclo[2.2.1]heptane-7-carboxylate (1.5 g, 4.33 mmol) is combined with 10%
20 Pd/C (150 mg) in 40 ml EtOH in a 250 ml Parr shaker bottle. The mixture is hydrogenated at 50 PSI for 1.5 h. The catalyst is removed by filtration and the filtrate is concentrated *in vacuo*. The crude material is chromatographed over 30 g silica gel (230-400 mesh), eluting with 7% MeOH/ CH_2Cl_2 + 1% conc. NH_4OH . The appropriate fractions are combined and concentrated to provide 606 mg (66%) of
25 (+/-) *exo-tert*-butyl 2-amino-7-azabicyclo[2.2.1]heptane-7-carboxylate. HRMS (FAB) calc'd for $C_{11}H_{20}N_2O_2 + H$: 213.1603, found 213.1580 (M+H)⁺. This racemic mixture will be referenced as (+/-)-7-aza-[2.2.1]-Amine.

Resolution of racemic carboxylate mixture:

The isolated (+/-) *exo-tert*-butyl 2-[[*(benzyloxy)*carbonyl]amino]-7-azabicyclo[2.2.1]heptane-7-carboxylate is resolved via preparative chiral HPLC
30 (50x500 mm Chiralcel OJ column, 30 deg. C, 70 mL/min. 10/90 (v/v) isopropanol/heptane). The resolution affords 40 g of *tert*-butyl (1*S*, 2*R*, 4*R*)-(+)-2[[*(benzyloxy)*carbonyl]amino]-7-azabicyclo[2.2.1]heptane-7-carboxylate and 42 g of

tert-butyl-(1*R*, 2*S*, 4*S*)-(-)-2-[[[(benzyloxy)carbonyl]amino]-7-azabicyclo[2.2.1]heptane-7-carboxylate.


The 2*R* enantiomer is triturated with 40 ml ether followed by 40 ml hexane (to remove lingering diastereo and enantiomeric impurities) and is dried to afford 30 g (56%) of purified *tert*-butyl (1*S*, 2*R*, 4*R*)-(+)-2-[[[(benzyloxy)carbonyl]amino]-7-azabicyclo[2.2.1]heptane-7-carboxylate with 99% enantiomeric excess. MS (EI) for C₁₉H₂₆N₂O₄, *m/z*: 346 (M)⁺. [α]²⁵_D = 22, (c 0.42, chloroform).

The 2*S* enantiomer is triturated with 40 ml ether followed by 40 ml hexane to give 35 g (66%) of purified *tert*-butyl (1*R*, 2*S*, 4*S*)-(-)-2-[[[(benzyloxy)carbonyl]amino]-7-azabicyclo[2.2.1]heptane-7-carboxylate with 99% enantiomeric excess. MS (EI) for C₁₉H₂₆N₂O₄, *m/z*: 346 (M)⁺. [α]²⁵_D = -23, (c 0.39, chloroform).

tert-Butyl (1*S*, 2*R*, 4*R*)-(+)-2-[[[(benzyloxy)carbonyl]amino]-7-azabicyclo[2.2.1]heptane-7-carboxylate (9.5 g, 27.4 mmol) is combined with 950 mg 10% Pd/C in 75 ml absolute EtOH in a 500 ml Parr bottle. The reaction mixture is hydrogenated at 50 PSI for 3h, the catalyst is removed by filtration, and the filter cake is washed with MeOH. The filtrate is concentrated *in vacuo* to give 6.4 g of a residue. The crude material is chromatographed over 200 g silica gel (230-400 mesh) eluting with 7% CH₃OH/CHCl₃ containing 1% conc. NH₄OH. The appropriate fractions are combined and concentrated to give 5.61 g (96%) of *tert*-butyl-(1*S*, 2*R*, 4*R*)-(+)-2-amino-7-azabicyclo[2.2.1]heptane-7-carboxylate as a pale oil. MS (EI) for C₁₁H₂₀N₂O₂, *m/z*: 212 (M)⁺. [α]²⁵_D = 9, (c 0.67, CHCl₃). This will be referenced as (2*R*)-7-aza-[2.2.1]-Amine.

The following examples are provided as examples and are not intended to limit the scope of this invention to only those provided examples and named compounds. Also, the salts made in the examples are only exemplary and are not intended to limit the invention. Any pharmaceutically acceptable salt can be made by one of ordinary skill in the art. The invention includes the following examples in pure stereoisomeric form or as racemic mixtures.

Example 1: N-[(1*S*, 2*R*, 4*R*)-7-azabicyclo[2.2.1]hept-2-yl]-3-methylfuro[2,3-c]pyridine-5-carboxamide dihydrochloride:



2-Chloro-6-(hydroxymethyl)-4-iodo-3-pyridinol (7.14 g, 25.0 mmol) is dissolved in DMF (50 mL) in a dried flask under nitrogen, is treated with sodium hydride (60% dispersion in mineral oil) (1.0 g, 25.0 mmol), and is stirred for 1 h at rt. Allyl bromide (2.38 ml, 27.5 mmol) is added to the reaction mixture and the resulting mixture is stirred 48 h at rt. The mixture is diluted with EtOAc (50 mL) and washed with a 50% saturated solution of 1:1 NaCl/ NaHCO₃ (4 X 25 mL). The organic layer is dried over MgSO₄ and is concentrated *in vacuo* to a white solid. The solid is washed with hexane and dried to afford 5.51 g (68%) of 3-(allyloxy)-2-chloro-6-(hydroxymethyl)-4-iodopyridine as a white solid. MS for C₉H₉ClINO₂, (EI) *m/z*: 325 (M)⁺.

3-(Allyloxy)-2-chloro-6-(hydroxymethyl)-4-iodopyridine (5.51 g, 16.9 mmol) is suspended in benzene (30 mL) in a dry flask under nitrogen. Azo(bis)isobutyryl nitrile (289 mg, 1.8 mmol) is added, the mixture rapidly heated to reflux, and tributyltin hydride (4.91 mL, 18.2 mmol) in benzene (10 mL) is added. The solution is refluxed for 1.5 h, cooled to rt and concentrated *in vacuo* to a residue. The resulting residue is chromatographed over 125 g slurry-packed silica gel, eluting with a gradient of EtOAc/hexane (20% - 60%). The appropriate fractions are combined and concentrated to a colorless oil that solidified upon standing to afford 3.0 g (89%) of (7-chloro-3-methyl-2,3-dihydrofuro[2,3-*c*]pyridin-5-yl)methanol as a white solid. MS for C₉H₁₀ClINO₂, (ESI): 200.1(MH)⁺.

(7-Chloro-3-methyl-2,3-dihydrofuro[2,3-*c*]pyridin-5-yl)methanol (3.00 g, 15.0 mmol) is combined with 20% Pd(OH)₂/C (800 mg) and 2N NaOH (9.2 mL, 18.2 mmol) in a PARR shaker bottle. The mixture is hydrogenated at 20 psi for 3 h, is filtered through celite and concentrated *in vacuo*. The resulting residue is partitioned between water (50 mL) and CH₂Cl₂ (4 X 30 mL). The combined organic layer is dried over MgSO₄ and concentrated to a colorless oil which solidified upon standing to afford 2.5 g of (3-methyl-2,3-dihydrofuro[2,3-*c*]pyridin-5-yl)methanol as a white crystalline solid. MS for C₉H₁₁NO₂, (EI) *m/z*: 165 (M)⁺.

(3-Methyl-2,3-dihydrofuro[2,3-c]pyridin-5-yl)methanol (2.48 g, 15.03 mmol) is dissolved in pyridine (15 mL), treated with Ac_2O (4.18 mL, 45.09 mmol) and is stirred for 16 h at rt under nitrogen. The mixture is concentrated *in vacuo*, the residue diluted with EtOAc (75 mL), washed with 50% saturated NaHCO_3 (4 X 30 mL) and dried over MgSO_4 . The organic layer is concentrated *in vacuo* to afford 2.85 g (92%) of (3-methyl-2,3-dihydrofuro[2,3-c]pyridin-5-yl)methyl acetate as a colorless oil. MS for $\text{C}_{11}\text{H}_{13}\text{NO}_3$ (EI) m/z : 207 (M^+).

(3-Methyl-2,3-dihydrofuro[2,3-c]pyridin-5-yl)methyl acetate (2.85 g, 13.8 mmol) is dissolved in dioxane (100 mL), is treated with 2,3,5,6-tertachlorobenzoquinone (3.72 g, 15.1 mmol) and is heated to reflux for 17 h. The mixture is concentrated *in vacuo*, the resulting brown solid washed with 1:1 EtOAc/ Et_2O (50 mL), and the insoluble material is filtered off. The filtrate is concentrated to a brown solid, dissolved in MeOH (50 mL), treated with 2 N NaOH (16 mL, 32 mmol), and stirred at rt for 1 h. The mixture is concentrated to dryness, dissolved in 1 N NaOH (75 mL), extracted with CH_2Cl_2 (4 X 50 mL), dried over K_2CO_3 and concentrated to a white solid (2.0 g). The crude material is adsorbed onto silica gel (4 g) and chromatographed over a standard 40 g Biotage column, eluting with 90% EtOAc/ hexane. The appropriate fractions are collected and concentrated to afford 1.88 g (84%) of (3-methylfuro[2,3-c]pyridin-5-yl)methanol as a white solid. MS $\text{C}_9\text{H}_9\text{NO}_2$ (EI) m/z : 163 (M^+).


Dimethylsulfoxide (18.8 mL, 26.5 mmol) is slowly added to a solution of oxalyl chloride (1.16 mL, 13.2 mmol) in CH_2Cl_2 (30 mL) in a dried flask, under nitrogen, in a dry ice/acetone bath. The solution is stirred for 20 min, then treated with (3-methylfuro[2,3-c]pyridin-5-yl)methanol (1.88 g, 11.5 mmol). The mixture is stirred for 1 h in a dry ice /acetone bath, then 30 min in an ice bath. The material is washed with saturated NaHCO_3 (75 mL), dried over K_2CO_3 and concentrated *in vacuo* to a yellow solid (3.23 g). The crude material is adsorbed onto silica gel (6 g) and chromatographed over a standard 40 g Biotage column, eluting with 25% EtOAc/ hexane. The appropriate fractions are concentrated to afford 1.33 g (72%) of 3-methylfuro[2,3-c]pyridine-5-carbaldehyde as a white solid. MS for $\text{C}_9\text{H}_7\text{NO}_2$, (EI) m/z : 161 (M^+).

3-Methylfuro[2,3-c]pyridine-5-carbaldehyde (1.33 g, 8.28 mmol) is dissolved in THF (50 mL), *tert*-butylalcohol (25 mL) and water (25 mL), under nitrogen, and

single portions of sodium chlorite (2.81 g, 24.84 mmol) and potassium dihydrogen phosphate (2.25 g, 16.56 mmol) are added. The reaction mixture is stirred overnight at rt, concentrated to dryness, dissolved in 50% saturated brine (60 mL) and extracted with ether (3 X). TLC of extracts indicated acid as well as residual aldehyde, so organics and aqueous layer combined and basified to pH 10 with conc. NH_4OH . The layers are separated and the residual aldehyde extracted with additional ether. The aqueous layer is acidified to pH 3 with 12M HCl, then extracted with CH_2Cl_2 (4 X). Large amounts of acid remained in the aqueous layer, so the aqueous layer is concentrated to dryness. Solid extractions with chloroform (4 X), followed by 10% MeOH/ CH_2Cl_2 (4X) sequestered much of the acid in the organic layer. The organic layer is dried over Na_2SO_4 and concentrated to a tan solid (1.69 g). The solid is diluted with CHCl_3 and refluxed for 3 h. The flask is removed from heat, allowed to cool slightly, then filtered. The filtrate is concentrated to a tan solid (1.02 g). The solid is triturated with ether, filtered and dried to afford 747 mg (51%) of 3-methylfuro[2,3-c]pyridine-5-carboxylic acid as a light tan solid. MS for $\text{C}_9\text{H}_7\text{NO}_3$, (CI) m/z : 178 (M)⁺.

3-Methyl-furo[2,3c]pyridine-5-carboxylic acid (213 mg, 1.2 mmol) is added to 10 ml CH_2Cl_2 in a dried flask under nitrogen. The solution is treated with TEA (153 μL , 1.1 mmol) followed by bis (2-oxo-3-oxazolidinyl) phosphinic chloride (280 mg, 1.1 mmol), and the reaction is stirred 1 h at rt. The mixture is treated with (2R)-7-aza-[2.2.1]-Amine (212 mg, 1.0 mmol) in 2 ml CH_2Cl_2 and the reaction is stirred 4 h at rt. The mixture is washed with 1 x 10 ml saturated NaHCO_3 , the organic layer is dried over K_2CO_3 , and is concentrated *in vacuo* to a residue. The crude material is chromatographed over 25 g silica gel (230-400 mesh) eluting with 35% EtOAc/hexane. The appropriate fractions are combined and concentrated to afford the intermediate *exo-tert*-butyl (1S, 2R, 4R)-2-{[3-methylfuro[2,3-c]pyridine-5-carbonyl]amino}-7-azabicyclo[2.2.1]heptane-7-carboxylate as a residue. The residue is combined with 5 ml 2N methanolic HCl acid in 5 ml MeOH under nitrogen. The reaction is warmed in a 60°C bath for 2 h, is cooled, and is concentrated *in vacuo* to a residue. The residue is dissolved in 1 ml IPA, is diluted with 2 ml diethyl ether, and is allowed to crystallize. The white solid is washed with ether and is dried to give 136 mg (62%) of Example 1 as a white solid. HRMS (FAB) calcd for $\text{C}_{15}\text{H}_{17}\text{N}_3\text{O}_2+\text{H}$: 272.1399, found 272.1400 (M+H)⁺.

Example 2: N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[2,3-c]pyridine-5-carboxamide dihydrochloride:



Glyoxylic acid monohydrate (20.3 g, 221 mmol) is combined with benzyl
 5 carbamate (30.6 g, 202 mmol) in ether (200 ml). The solution is allowed to stir for 24
 h at rt. The resulting thick precipitate is filtered, and the residue is washed with ether,
 affording 21.5 g (47%) of {[(benzyloxy)carbonyl]amino} (hydroxy)acetic acid as a
 white solid. MS for $C_{10}H_{11}NO_5$, (CI) m/z : 226 (M)⁺.

10 {[(Benzyloxy)carbonyl]amino} (hydroxy)acetic acid (11.6 g, 51.5 mmol) is
 dissolved in absolute MeOH (120 ml) and chilled to 0-5°C in an ice bath.
 Concentrated sulfuric acid (2.0 ml) is carefully added drop-wise. The ice bath is
 allowed to expire as the solution stirred for 2 days. The reaction is quenched by
 pouring the mixture onto 500 g ice with saturated $NaHCO_3$ solution (400 ml). The
 solution is extracted with EtOAc (3 x 300 ml), and the combined organic layer is dried
 15 over $MgSO_4$, filtered, and concentrated to a pale oil that crystallized upon standing,
 yielding 12.3 g (94%) of methyl {[(benzyloxy)carbonyl]amino} (methoxy)acetate as a
 white solid. Anal. Calcd for $C_{12}H_{15}NO_5$: C, 56.91; H, 5.97; N, 5.53; Found: C,
 56.99; H, 6.02; N, 5.60.

Methyl {[(benzyloxy)carbonyl]amino} (methoxy)acetate (11.76 g, 46.4 mmol)
 20 is dissolved in toluene (50 ml) under N_2 and placed in a 70°C bath. Phosphorous
 trichloride (23.2 ml, 46.4 mmol) is added drop-wise via syringe, and the solution is
 stirred for 18 h maintaining temperature. Trimethylphosphite (5.47 ml, 46.4 mmol) is
 then added dropwise, and stirring continued for an additional 2 h at elevated
 temperature. The mixture is concentrated *in vacuo* to an oil, and the crude material is
 25 dissolved in EtOAc (100 ml) and rinsed with saturated sodium bicarbonate (3 x 50
 ml). The organic layer is dried over Na_2SO_4 , filtered, and concentrated to a volume of
 30 ml. The residue is stirred vigorously while hexane is added until a precipitate
 forms. The slurry is filtered, affording 12.88 g (84%) of methyl
 {[(benzyloxy)carbonyl]amino} (dimethoxyphosphoryl)acetate as a white solid. MS for
 $C_{13}H_{18}NO_7P$, (EI) m/z : 331 (M)⁺.

Methyl {[[(benzyloxy)carbonyl]amino} (dimethoxyphosphoryl)acetate (12.65 g, 38.2 mmol) is combined with Ac₂O (9.02 ml, 95.5 mmol) in MeOH (100 ml) in a PARR flask. The solution is hydrogenated with 10% Pd/C catalyst (0.640 g) at 45 psi for 3h. The catalyst is filtered off, and the filtrate is concentrated *in vacuo* to a residue. The residue is placed under hi vacuum and began to solidify. The white residue is dissolved in a small amount of EtOAc and stirred vigorously while pentane is added until a precipitate began to form. The precipitate is collected to afford 7.9 g (87%) of methyl (acetylamino)(dimethoxyphosphoryl)acetate as a white powder. MS for C₇H₁₄NO₆P, (CI) m/z: 240 (M)⁺.


2,3-Thiophene dicarboxaldehyde (1.40 g, 9.99 mmol) is dissolved in CH₂Cl₂ (100 ml) and chilled to in an ice bath. Methyl (acetylamino)(dimethoxyphosphoryl)acetate (2.63 g, 11.0 mmol) is dissolved in CH₂Cl₂ (50 ml) and combined with DBU (1.65 ml, 11.0 mmol). This solution is added drop-wise to the chilled thiophene solution. The reaction mixture is stirred cold for 1 h and then over night at rt. The mixture is concentrated *in vacuo* and the crude material is chromatographed over 300 g slurry-packed silica eluting with 50% EtOAc/hexane to provide two separate pools of product. Methyl thieno[2,3-c]pyridine-5-carboxylate elutes first; the appropriate fractions are combined and concentrated to yield 780 mg (41%) of a white solid. Methyl thieno[3,2-c]pyridine-6-carboxylate elutes second; the appropriate fractions are combined and concentrated to afford 740 mg (38%) of a yellow solid. MS results for methyl thieno[2,3-c]pyridine-5-carboxylate: MS for C₉H₇NO₂S, (EI) m/z: 193 (M)⁺. MS results for of methyl thieno[3,2-c]pyridine-6-carboxylate: MS for C₉H₇NO₂S, (EI) m/z: 193 (M)⁺.

Methyl thieno[2,3-c]pyridine-5-carboxylate (736 mg, 3.8 mmol) is dissolved in MeOH (16 ml) with water (2 ml). 2M NaOH (2.0 ml, 4.0 mmol) is added drop-wise, and the solution is stirred at rt. After 2 days (complete disappearance of ester by TLC), the mixture is concentrated *in vacuo*. The residue is dissolved in water (12 ml) and the pH is adjusted to 3.5 with 10% HCl. The slurry is filtered, and the cake is rinsed with ether, yielding 394 mg (58%) of thieno[2,3-c]pyridine-5-carboxylic acid as a white solid. HRMS (FAB) calcd for C₈H₅NO₂S+H: 180.0119, found 180.0123 (M+H)⁺.

Thieno[2,3c]pyridine-5-carboxylic acid (158 mg, 0.88 mmol) is coupled with (2R)-7-aza-[2.2.1]-Amine (187 mg, 0.88 mmol) and deprotected as described in

Example 1 with non-critical variations to provide 140 mg (44%) of Example 2 as a white solid. HRMS (FAB) calcd for $C_{14}H_{15}N_3OS+H$: 274.1014, found 274.1011 ($M+H$)⁺.


- 5 **Example 3:** N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,2-c]pyridine-6-carboxamide dihydrochloride:



- Methyl thieno[3,2-c]pyridine-6-carboxylate (Example 2) (678 mg, 3.5 mmol) is dissolved in MeOH (16 ml) with water (2 ml). 2M NaOH (1.8 ml, 3.6 mmol) is added drop-wise, and the solution is stirred at rt. After 2 days (complete disappearance of ester by TLC), the mixture is concentrated *in vacuo*. The residue is dissolved in water (12 ml), and the pH is adjusted to 3.5 with 10% HCl. The slurry is filtered, and the cake is rinsed with ether, yielding 268 mg (43%) of thieno[3,2-c]pyridine-6-carboxylic acid as a white solid. HRMS (FAB) calcd for $C_8H_5NO_2S+H$: 180.0119, found 180.0123 ($M+H$)⁺.

- Thieno[3,2c]pyridine-5-carboxylic acid (77 mg, 0.43 mmol) is coupled with (2R)-7-aza-[2.2.1]-Amine (94 mg, 0.43 mmol) and deprotected as described in Example 1 with non-critical variations to provide give 55 mg (40%) of Example 3 as a white solid. HRMS (FAB) calcd for $C_{14}H_{15}N_3OS+H$: 274.1014, found 274.1017 ($M+H$)⁺.

Example 4: N-[(2R)-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-carboxamide dihydrochloride:



- 25 2-Chloro-3-pyridinol (20.0 g, 0.154 mole and $NaHCO_3$ (19.5g, 0.232 mole, 1.5 equ) are dissolved in 150 ml of water. The reaction mixture is placed in an oil bath at 90°C and after 5 min is treated with 37% aqueous formaldehyde (40.5 ml, 0.541 mole,

3.5 equ) which is added in six unequal doses; 12 ml initially, 3 x 8 ml followed by 1 x 2.2 ml all at 90 min intervals with the final 2.3 ml added after maintaining at 90°C overnight (15 h). After stirring in the 90°C bath for an additional 4 h, the flask is placed in ice bath, and the contents are treated with 100 ml of crushed ice, acidified with 39 ml of 6 N HCl to pH 1, and the precipitated material is stirred for 1.5 h in an ice bath. The undesired solid is removed by filtration, and the filtrate is extracted seven times with EtOAc. The combined organic extracts are concentrated at reduced pressure, treated with toluene, reconcentrated on rotary evaporator to azeotrope most of the water, suspended in CH₂Cl₂ and reconcentrated again at reduced pressure to obtain 19.9 g (81%) of 2-chloro-6-(hydroxymethyl)-3-pyridinol as a pale yellow solid sufficiently pure for subsequent reaction. MS for C₆H₆ClNO₂: *m/z*: 159 (M)⁺.

2-Chloro-6-(hydroxymethyl)-3-pyridinol (11.6 g, 72.7 mmol) and NaHCO₃ (18.3 g, 218 mmol) are dissolved in 200 ml water in a flask. The mixture is stirred until homogeneous, is cooled in an ice bath, is treated with iodine (19.4 g, 76.3 mmol), and is stirred over 60 h at rt as the cooling bath expired. The pH of the mixture is adjusted to 3 with 2N NaHSO₄, and the mixture is extracted with 4 x 50 ml EtOAc. The combined organic layer is dried over MgSO₄ and is concentrated *in vacuo* to a yellow solid. The crude solid is washed with EtOAc to provide 12.9 g (62%) of 2-chloro-6-(hydroxymethyl)-4-iodo-3-pyridinol as an off-white solid. The filtrate is concentrated to a small volume and is chromatographed over 250 g silica gel (230-400 mesh) eluting with EtOAc/CH₂Cl₂/hexane/acetic acid 2.5:4.5:4:0.1. The appropriate fractions are combined and concentrated to afford an additional 2.4 g (12%) of pure 2-chloro-6-(hydroxymethyl)-4-iodo-3-pyridinol. MS for C₆H₅ClINO₂, *m/z*: 285 (M)⁺.

To 2-chloro-6-(hydroxymethyl)-4-iodo-3-pyridinol (13.9 g, 48.6 mmol) in 80 ml CHCl₃/ 40 ml THF is added trimethylsilylacetylene (9.6 ml, 68 mmol), bis(triphenylphosphine) palladium dichloride (1.02 g, 1.46 mmol) and cuprous iodide (139 mg, 0.73 mmol) in a flask under nitrogen. The mixture is treated with Et₃N (21 ml, 151 mmol), is stirred 3 h at rt, and is diluted with 200 ml CHCl₃. The mixture is washed with 2 x 150 ml 5% HCl and the combined aqueous layers are extracted with 2 x 50 ml CHCl₃. The combined organic layer is washed with 1 x 100 ml 50% brine, is dried over MgSO₄, and is concentrated *in vacuo* to an amber oil. The crude material is chromatographed over 350 g silica gel (230-400 mesh), eluting with 35%

EtOAc/hexane. The appropriate fractions are combined and concentrated to afford 11.4 g (92%) of 2-chloro-6-(hydroxymethyl)-4-[(trimethylsilyl)ethynyl]-3-pyridinol as a golden solid. MS for $C_{11}H_{14}ClNO_2Si$, m/z : 255 (M)⁺.

2-Chloro-6-(hydroxymethyl)-4-[(trimethylsilyl)ethynyl]-3-pyridinol (7.9 g, 31.2 mmol) is combined with cuprous iodide (297 mg, 1.6 mmol) in 60 ml EtOH/60 ml Et₃N in a flask. The reaction is warmed in a 70°C oil bath for 3.5 h, is cooled, and concentrated *in vacuo*. The residue is partitioned between 1 x 100 ml 5% HCl and 4 x 50 ml CH₂Cl₂. The combined organic layer is dried over MgSO₄ and is concentrated *in vacuo* to give 6.5 g of a crude amber solid. The crude material is chromatographed over 300 g silica gel (230-400 mesh) eluting with 30-40 % EtOAc/hexane to give two pools of fractions. The early-eluting fractions are combined and concentrated to afford 3.7 g (46%) of [7-chloro-2-(trimethylsilyl)furo[2,3-c]pyridin-5-yl]methanol as a white solid. The later-eluting fractions are combined and concentrated to provide 1.56 g (27%) of (7-chlorofuro[2,3-c]pyridin-5-yl)methanol as a white solid. For [7-chloro-2-(trimethylsilyl)furo[2,3-c]pyridin-5-yl]methanol: MS, Calculated for $C_{11}H_{14}ClNO_2Si$: 255.0482. Found: 255.0481. For (7-chlorofuro[2,3-c]pyridin-5-yl)methanol: MS for $C_8H_6ClNO_2$, m/z : 183 (M)⁺.

[7-Chloro-2-(trimethylsilyl)furo[2,3-c]pyridin-5-yl]methanol (1.05 g, 4.1 mmol) is combined with 10% Pd/C (1.05 g) in 20 ml absolute EtOH in a flask. The suspension is treated with cyclohexene (4 ml, 40.1 mmol), and the mixture is refluxed for 2.5 h, and is filtered through celite. The solids are washed with 1:1 EtOH/CH₂Cl₂, and the filtrate is concentrated to a pale yellow solid. The residue is partitioned between 1 x 40 ml saturated sodium bicarbonate and CH₂Cl₂ (4 x 20 ml), and the combined organic layer is dried over MgSO₄. The organic layer is concentrated *in vacuo* to a residue (1.04 g) which is chromatographed over 50 g silica gel (230-400 mesh) eluting with 50-70% EtOAc/hexane. The appropriate fractions are combined and concentrated to afford 820 mg (90%) of [2-(trimethylsilyl)furo[2,3-c]pyridin-5-yl]methanol as a white solid. MS for $C_{11}H_{15}NO_2Si$, m/z : 221 (M)⁺.

5-Hydroxymethyl-2-trimethylsilyl-furo[2,3c]pyridine (770 mg, 3.48 mmol) is dissolved in 10 ml MeOH. 2N NaOH (3 ml, 6 mmol) is added, the reaction is stirred for 1.5 h at rt, and the mixture is concentrated *in vacuo*. The residue is partitioned between 1 x 20 ml water and CH₂Cl₂ (4 x 10 ml), and the combined organic layer is dried over K₂CO₃. The dried organic layer is concentrated *in vacuo* to afford 469 mg


(90%) of furo[2,3-c]pyridin-5-yl methanol as a white solid. Analysis: Calculated for $C_8H_7NO_2$: C, 64.42; H, 4.73; N, 9.39. Found: C, 64.60; H, 4.56; N, 9.44.

Oxalyl chloride (685 μ L, 7.8 mmol) is dissolved in 30 ml CH_2Cl_2 in a dried flask under nitrogen. The solution is cooled in a dry ice/acetone bath, is treated dropwise with DMSO (1.11 ml, 15.6 mmol) in 1 x 5 ml CH_2Cl_2 , and the mixture is stirred for 20 min. The mixture is treated with furo[2,3-c]pyridin-5-yl methanol (1.0 g, 6.7 mmol) in 1 x 10 ml CH_2Cl_2 , is stirred 30 min at in a dry ice/acetone bath, and is treated with Et_3N (4.7 ml, 33.5 mmol). The reaction is allowed to warm to rt, is stirred 1 h, and is washed with 1 x 25 ml saturated $NaHCO_3$. The organic layer is dried over K_2CO_3 and is concentrated *in vacuo* to an orange solid. The crude material is chromatographed over 50 g silica gel (230-400 mesh) eluting with 33% EtOAc/hexane. The appropriate fractions are combined and concentrated to provide 850 mg (86%) of furo[2,3-c]pyridine-5-carbaldehyde as a white solid. MS for $C_8H_5NO_2$, (EI) m/z : 147 (M)⁺.

Furo[2,3-c]pyridine-5-carbaldehyde (850 mg, 5.8 mmol) is dissolved in 10 ml DMSO. To this solution is added potassium dihydrogen phosphate (221 mg, 1.6 mmol) in 3 ml water followed by sodium chlorite (920 mg, 8.2 mmol) in 7 ml water. The resulting reaction mixture is stirred for 3h at rt. The reaction is diluted with 25 ml water, the pH is adjusted to 10 with 2N NaOH, and the mixture is extracted with 3 x 20 ml ether. The pH of the aqueous layer is adjusted to 3.5 with 10% aqueous HCl and is extracted with 13 x 10 ml 10% MeOH/ CH_2Cl_2 . The organic layer is dried over Na_2SO_4 and is concentrated *in vacuo* to a pale oil. The residual DMSO is removed under a stream of nitrogen to provide a white paste. The paste is dissolved in MeOH and is concentrated to dryness. The white solid is washed with ether and is dried to give 890 mg (94%) of crude furo[2,3-c]pyridine-5-carboxylic acid. MS for $C_8H_5NO_3$, (ESI): 162.8 ($M-H$)⁻.

Furo[2,3c]pyridine-5-carboxylic acid (186 mg, 1.12 mmol) is coupled with (2R)-7-aza-[2.2.1]-Amine (212 mg, 1.0 mmol) and deprotected as described in Example 1 with non-critical variations to provide 165mg (50%) of Example 4 as a white solid. HRMS (FAB) calcd for $C_{14}H_{15}N_3O_2+H$: 258.1242, found 258.1244 ($M+H$)⁺.


Example 5: N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethylfuro[2,3-c]pyridine-5-carboxamide dihydrochloride:



The synthesis of 3-ethylfuro[2,3-c]pyridine-5-carboxylic acid is carried out as outlined for the corresponding 3-methylfuro[2,3-c]pyridine-5-carboxylic acid described in Example 1 with non-critical changes by starting with 1-chloro-2-butene and 2-chloro-6-(hydroxymethyl)-4-iodo-3-pyridinol. HRMS (FAB) calcd for $C_{10}H_9NO_3 + H$: 192.0661, found 192.0659 ($M+H$)⁺.

3-Ethyl furo[2,3c]pyridine-5-carboxylic acid (213 mg, 1.1 mmol) is coupled with (2R)-7-aza-[2.2.1]-Amine (212 mg, 1.0 mmol) and deprotected as described in Example 1 with non-critical variations to provide 208 mg (58%) of Example 5 as a white solid. HRMS (FAB) calcd for $C_{16}H_{19}N_3O_2 + H$: 286.1555, found 286.1549 ($M+H$)⁺.


Example 6: N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-isopropyl-furo[2,3-c]pyridine-5-carboxamide dihydrochloride:



The synthesis of 3-isopropylfuro[2,3-c]pyridine-5-carboxylic acid is carried out as outlined for the corresponding 3-methylfuro[2,3-c]pyridine-5-carboxylic acid described in Example 1 with non-critical changes by starting with 1-chloro-3-methyl-2-butene and 2-chloro-6-(hydroxymethyl)-4-iodo-3-pyridinol. MS for $C_{11}H_{11}NO_3$, (EI) m/z : 205 (M)⁺.

3-Isopropyl furo[2,3c]pyridine-5-carboxylic acid (226 mg, 1.1 mmol) is coupled with (2R)-7-aza-[2.2.1]-Amine (212 mg, 1.0 mmol) and deprotected as described in Example 1 with non-critical variations to provide 258 mg (69%) of Example 6 as a white solid. MS for $C_{17}H_{21}N_3O_2$, (EI) m/z : 299 (M)⁺.

Example 7: N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1H-pyrrolo[2,3-c]pyridine-5-carboxamide dihydrochloride:



2,4-Lutidine (51.4 ml, 0.445 mole) is added drop-wise to 250 ml fuming sulfuric acid under nitrogen in a flask in an ice bath. The solution is treated portion-wise with potassium nitrate (89.9 g, 0.889 mole) over a 15 min period. The reaction is stirred 1h in an ice bath, 2 h at rt, is gradually warmed in a 100°C oil bath for 5 h, and then in a 130°C oil bath for 4 h. The mixture is cooled, is poured into 1000 ml ice, and the mixture is neutralized with NaHCO_3 (1,100g, 13.1 mole). The precipitated Na_2SO_4 is removed by filtration, the solid is washed with 500 ml water, and the filtrate is extracted with 4 x 500 ml ether. The combined organic layer is dried over MgSO_4 and is concentrated *in vacuo* to a yellow oil (50 g). The crude oil is distilled under vacuum to provide three fractions: 16 g recovered 2,4-lutidine (85°C), 16 g 2,4-dimethyl-3-nitro-pyridine contaminated with 25% 2,4-dimethyl-5-nitro-pyridine (135-145°C), and 16 g 2,4-dimethyl-5-nitro-pyridine contaminated with 2,4-dimethyl-3-nitropyridine (145-153°C). 2,4-Dimethyl-3-nitropyridine: ^1H NMR (CDCl_3) δ 2.33, 2.54, 7.10, 8.43 ppm. 2,4-Dimethyl-5-nitropyridine: ^1H NMR (CDCl_3) δ 2.61, 2.62, 7.16, 9.05 ppm.

2,4-Dimethyl-5-nitropyridine/2,4-dimethyl-3-nitropyridine (75:25) (5.64 g, 37 mmol) is combined with benzeneselenic anhydride (8.2 g, 22.8 mmol) in 300 ml dioxane in a flask under nitrogen. The reaction is warmed to reflux for 10 h, is cooled, and is concentrated to a dark yellow oil. The oil is chromatographed over 250 g silica gel (230-400 mesh) eluting with 15% EtOAc/hexane. The appropriate fractions are concentrated to give 2.5 g (66%) of 2-formyl-4-methyl-5-nitropyridine. HRMS (EI) calcd for $\text{C}_7\text{H}_6\text{N}_2\text{O}_3$: 166.0378, found 166.0383 ($\text{M}+\text{H}$) $^+$.

2-Formyl-4-methyl-5-nitropyridine (1.15 g, 6.9 mmol) is combined with p-toluene sulfonic acid (41 mg, 0.22 mmol) and ethylene glycol (1.41 ml, 25 mmol) in 25 ml toluene in a flask equipped with a Dean-Starke trap. The reaction is warmed to reflux for 2 h, is cooled to rt, and is concentrated *in vacuo* to an oily residue. The crude oil is chromatographed over 40 g silica gel (Biotage), eluting with 20%

EtOAc/hexane. The appropriate fractions are combined and concentrated to give 1.31 g (90%) of 2-(1,3-dioxolan-2-yl)-4-methyl-5-nitropyridine. MS for $C_9H_{10}N_2O_4$, (EI) m/z : 210 (M)⁺.


2-(1,3-Dioxolan-2-yl)-4-methyl-5-nitropyridine (1.3 g, 6.2 mmol) is combined with DMF dimethyl acetal (1.12 ml, 8.4 mmol) in 15 ml DMF in a flask under nitrogen. The reaction is warmed to 90°C for 3 h, is cooled, and the volatiles are removed *in vacuo* (hi vacuum). The residue is combined with 1.25 g 5% Pd/BaSO₄ in 20 ml EtOH in a 250 ml PARR shaker bottle, and the mixture is hydrogenated at ambient pressure until uptake ceased. The catalyst is removed by filtration, and the filtrate is combined with 500 mg 10% Pd/C in a 250 ml PARR shaker bottle. The mixture is hydrogenated at ambient pressure for 1 h. No additional hydrogen uptake is observed. The catalyst is removed by filtration, and the filtrate is concentrated *in vacuo* to a tan solid. The crude material is chromatographed over 50 g silica gel (230-400 mesh), eluting with 7% MeOH/CH₂Cl₂. The appropriate fractions are combined and concentrated to give 819 mg (69%) of 5-(1,3-dioxolan-2-yl)-1H-pyrrolo[2,3-c]pyridine. MS for $C_{10}H_{10}N_2O_2$, (EI) m/z : 190 (M)⁺.

5-(1,3-Dioxolan-2-yl)-1H-pyrrolo[2,3-c]pyridine (800 mg, 4.21 mmol) is dissolved in 44 ml 10% aqueous acetonitrile in a flask. The solution is treated with p-toluene sulfonic acid (630 mg, 3.3 mmol), and the mixture is heated to reflux for 5 h. The mixture is cooled to rt, is concentrated *in vacuo*, and the resultant residue is diluted with 15 ml saturated NaHCO₃. The pale yellow solid is collected, washed with water, and is dried to give 500 mg (81%) of 1H-pyrrolo[2,3-c]pyridine-5-carbaldehyde. HRMS (FAB) calcd for $C_8H_6N_2O+H$: 147.0558, found 147.0564 (M+H)⁺.

1H-Pyrrolo[2,3-c]pyridine-5-carbaldehyde (500 mg, 3.42 mmol) is dissolved in 1.5 ml formic acid. The solution is cooled in an ice bath, is treated drop-wise with 30% aqueous hydrogen peroxide (722 μ L, 6.8 mmol), is stirred 1 h in an ice bath, and allow to stand overnight at 5°C. The mixture is diluted with water, the solid is collected, washed with water and is dried to give 522 mg of an off-white solid. The formate salt is combined with 7 ml water, is diluted with 3 ml 2N NaOH, and the pH is adjusted to 3 with 5% aqueous HCl. The precipitate is collected and is dried to give 370 mg (67%) of 1H-pyrrolo[2,3-c]pyridine-5-carboxylic acid. HRMS (FAB) calcd for $C_8H_6N_2O_2+H$: 163.0508, found 163.0507 (M+H)⁺.


1H-Pyrrolo[2,3-c]pyridine-5-carboxylic acid (186 mg, 1.12 mmol) is coupled with (2R)-7-aza-[2.2.1]-Amine (212 mg, 1.0 mmol) and deprotected as described in Example 1 with non-critical variations to provide 133 mg (40%) of Example 7 as an off-white solid. HRMS(FAB) calc'd for $C_{14}H_{16}N_4O+H$: 257.1402. Found: 257.1391 (M+H)⁺.

Example 8: N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1,3-benzodioxole-5-carboxamide hydrochloride:



Piperonylic acid (91 mg, 0.55 mmol) is combined with TEA (0.076 ml, 0.55 mmol) and bis(2-oxo-3-oxazolidinyl)-phosphinic chloride (140 mg, 0.55 mmol) in CH_2Cl_2 (3 ml) and stirred at rt for 30 min. (2R)-7-Aza-[2.2.1]-Amine (106 mg, 0.5 mmol) is dissolved in CH_2Cl_2 (2 ml) and added drop-wise to the previous solution, stirring for 3 h. The reaction is washed with saturated $NaHCO_3$ solution (1x10ml), and the organic is dried over K_2CO_3 , filtered, and concentrated to an oil. The crude material is chromatographed over 20 g slurry-packed silica, eluting with 35% EtOAc/hexane. The appropriate fractions are collected and concentrated to a glass. This material is dissolved in 1M HCl in MeOH (10 ml) and stirred overnight. Volatiles are removed *in vacuo*, and the residue is treated with IPA (2 ml) and ether (1 ml). The resulting precipitate is isolated via filtration, affording 50 mg (35%) of Example 8 as a white solid. MS for $C_{14}H_{16}N_2O_3$, MS (ESI): m/z 261 (M+H)⁺.


Example 9: N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]isoquinoline-3-carboxamide dihydrochloride:



Isoquinoline-3-carboxylic acid hydrate is coupled with (2R)-7-aza-[2.2.1]-Amine (212 mg, 1.0 mmol) and deprotected as described in Example 1 with non-critical variations

to provide 136 mg (47%) of Example 9 as a white solid. HRMS (FAB) calcd for $C_{16}H_{17}N_3O + H$: 268.1450, found 268.1452 ($M+H$)⁺.

Example 10: N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1H-pyrrolo[2,3-c]pyridine-2-carboxamide dihydrochloride:



Potassium methoxide (2.8 g, 39.8 mmol) is combined with methyl oxalate (4.7 g, 39.8 mmol) in 80 ml Et_2O in a dry flask under nitrogen. The suspension is diluted with 12 ml CH_3OH , is treated dropwise with 4-methyl-3-nitropyridine (5 g, 36.2 mmol) in 25 ml Et_2O , and the black suspension is stirred 24 h at RT. The black solid is collected, washed with fresh Et_2O , and is dried to give 8.15 g (86%) of potassium-3-methoxy-1-(3-nitropyridin-4-yl)-3-oxoprop-1-en-2-olate. HRMS (FAB) calcd for $C_9H_8N_2O_5 + H$: 225.0511, found 225.0515 ($M+H$)⁺.


Potassium-3-methoxy-1-(3-nitropyridin-4-yl)-3-oxoprop-1-en-2-olate (4.19 g, 16 mmol) is combined with 10% Pd/C (400 mg) and 25 ml glacial acetic acid in a 250 ml PARR shaker flask. The mixture is hydrogenated at 40 PSI for 2 h. The catalyst is removed by filtration and the bulk of the volatiles are removed *in vacuo*. The residue is suspended in H_2O and the pH is adjusted to 7 with solid $NaHCO_3$. The solid is collected, washed with H_2O , and is dried to 1.98 g of a tan solid. The solid is triturated with hot $EtOAc$, is cooled, and is filtered to give 1.8 g (64%) of methyl 1H-pyrrolo[2,3-c]pyridine-2-carboxylate as a tan solid. HRMS (FAB) calcd for $C_9H_8N_2O_2 + H$: 177.0664, found 177.0671 ($M+H$)⁺.

Methyl 1H-pyrrolo[2,3-c]pyridine-2-carboxylate (1.0 g, 5.68 mmol) is suspended in 18 ml CH_3OH . The mixture is treated with 2N NaOH (6.24 ml, 12.5 mmol) and the mixture is stirred overnight at RT. The volatiles are removed *in vacuo*, the residue is dissolved in 10 ml H_2O , and the pH is adjusted to 4.3 with 5% aqueous HCl. The tan precipitate is collected, washed with H_2O , and is dried to 516 mg (56%) of 1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid as a tan solid. HRMS (FAB) calcd for $C_8H_6N_2O_2 + H$: 163.0508, found 163.0498 ($M+H$)⁺.

1H-Pyrrolo[2,3-c]pyridine-2-carboxylic acid (122 mg, 0.75 mmol) is dissolved in DMF (5 ml) with DIEA (0.39 ml, 2.25 mmol) and (2R)-7-aza-[2.2.1]-Amine (175


mg, 0.83 mmol) and cooled to 0°C. HATU (285 mg, 0.75 mmol) is added portionwise, and the reaction is stirred overnight at RT, allowing the ice bath to expire. Volatiles are removed *in vacuo*, and the crude material is chromatographed over 25 g slurry-packed silica, eluting with 5% CH₃OH/CHCl₃. The appropriate fractions are collected and concentrated to a yellow oil. The oil is dissolved in 1M HCl in CH₃OH (10 ml) and stirred 2 days. Volatiles are again removed *in vacuo*, and the residue is treated with Et₂O (2 ml). The resulting precipitate is isolated via filtration, rinsed with Et₂O, and dried to afford 111 mg (45%) of Example 10 as a tan solid. HRMS (FAB) calcd for C₁₄H₁₆N₄O+H: 257.1402, found 257.1409 (M+H)⁺.

Example 11: N-[(1S, 2R, 4R)-7-methyl-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-carboxamide:




N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-carboxamide dihydrochloride (495 mg, 1.5 mmol) is combined with NaHCO₃ (252 mg, 3.0 mmol) in 12 ml water. The solution is treated with glacial acetic acid (2.2 ml), 37% aqueous formaldehyde (3 ml), and NaCNBH₃ (94 mg, 1.5 mmol), and the reaction is stirred 4 h at RT. The reaction is added dropwise to a mixture of 6 g NaHCO₃ in 50 ml water, the mixture is diluted with 10 ml conc. NH₄OH, and is extracted with 4 x 20 ml CHCl₃. The combined organic layer is dried over K₂CO₃ and is concentrated *in vacuo* to a pale paste. The crude material is chromatographed over 30 g silica gel (230-400 mesh), eluting with 3.5% CH₃OH/CHCl₃ + 1% NH₄OH. The appropriate fractions are combined and concentrated to give 270 mg of a pale foam. The foam is crystallized from Et₂O to provide 125 mg (31%) of Example 11 as a fine white solid. MS (EI) *m/z*: 271 (M)⁺.

Example 12: N-[(1S, 2R, 4R)-7-methyl-7-azabicyclo[2.2.1]hept-2-yl]-1-benzofuran-5-carboxamide:



Example 12 is obtained as described in Example 11 with non-critical variations by starting with N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1-benzofuran-5-carboxamide (384 mg, 1.5 mmol) to give 280 mg (69%) of Example 12 as a fine white solid. MS (EI) m/z : 270 (M)⁺.

Example 13: N-[(1S, 2R, 4R)-7-Azabicyclo[2.2.1]hept-2-yl]-1-benzofuran-6-carboxamide hydrochloride:



3-Hydroxybenzoic acid (13.8 g, 100 mmol) is dissolved in concentrated NH₄OH (200 mL) using an overhead stirrer and is treated slowly dropwise with a solution of iodine (23.4 g, 92 mmol) and KI (18.26 g, 110 mmol) in water (100 mL). The solution is stirred for 1 h at RT and then treated rapidly dropwise with concentrated HCl (180 mL). The white solid is collected via filtration, rinsed with water and dried overnight by pulling air through the solid to afford 13.05 g (54%) of 3-hydroxy-4-iodobenzoic acid as a tan solid.

3-Hydroxy-4-iodobenzoic acid (12.55 g, 47.5 mmol) is dissolved in CH₃OH (200 mL), treated slowly dropwise with thionyl chloride (32.3 mL, 442.9 mmol) at RT, then heated to reflux for 20 h. The mixture is concentrated to dryness and partitioned between CH₂Cl₂ (100 mL) and saturated NaHCO₃ (50 mL). Not all of the residue is solubilized, so the mixture is filtered and the solid is washed with a small amount of CH₂Cl₂ and CH₃OH. The original filtrate and the organic washes are combined, concentrated to dryness, dissolved in 10% CH₃OH / CH₂Cl₂ (200 mL), diluted with water (50 mL) and the layers separated. The organics are washed with saturated NaHCO₃ (2 x 50 mL), then water (50 mL), dried over Na₂SO₄ and concentrated to a tan solid. This solid is triturated with CH₂Cl₂ (50 mL) and filtered. The two solids are combined to afford 9.4 g (70%) of methyl 3-hydroxy-4-

iodobenzoate as a beige solid. HRMS (FAB) calcd for $C_8H_7IO_3 + H$: 278.9520, found 278.9521 ($M+H$)⁺.

Methyl 3-hydroxy-4-iodobenzoate (5.22 g, 18.8 mmol) is combined with trimethylsilylacetylene (3.71 mL, 26.3 mmol), bis(triphenylphosphine)palladium dichloride (386 mg, 0.55 mmol) and cuprous iodide (54 mg, 0.28 mmol) in THF (20 mL) / $CHCl_3$ (40 mL) in a dry flask under nitrogen. TEA (8.14 mL, 58.4 mmol) is added and the mixture is heated to 50°C for 4 h. The mixture is diluted with $CHCl_3$ (60 mL), washed with 5% HCl (2 x 40 mL), dried over $MgSO_4$ and concentrated to a brown oily-solid (8.31 g). The crude material is chromatographed over a standard 90 g Biotage column, eluting with 10% EtOAc/hexane (1 L) followed by 15 % EtOAc/hexane (1 L). The appropriate fractions are combined and concentrated to afford 4.22 g (91%) of methyl 3-hydroxy-4-[(trimethylsilyl)ethynyl]benzoate as a yellow solid. HRMS (FAB) calcd for $C_{13}H_{16}O_3Si + H$: 249.0947, found 249.0947 ($M+H$)⁺.


Methyl 3-hydroxy-4-[(trimethylsilyl)ethynyl]benzoate (3.0 g, 12.1 mmol) is dissolved in 30 ml 1:1 EtOH/ Et_3N , is treated with cuprous iodide (114 mg, 0.6 mmol), and the reaction is warmed to 75°C for 3 h. The mixture is treated with DARCO and 15 ml MeOH and is heated to reflux for 1 h. The reaction is filtered through a fine fritted glass funnel, the filtrate is treated with 3N NaOH (24.2 ml, 72.5 mmol), and the mixture is stirred overnight at RT. The mixture is concentrated to dryness, the residue is dissolved in 20 ml water, and the pH of the mixture is adjusted to 2 with 12N HCl. The resulting yellow precipitate is collected, washed with water, and is dried to give 1.83 g (93%) of benzofuran-6-carboxylic acid as a tan solid. HRMS (FAB) calcd for $C_9H_6O_3 + H$: 163.0395, found 163.0389 ($M+H$)⁺.

1-Benzofuran-6-carboxylic acid (162 mg, 1.0 mmol) is coupled with (2R)-7-aza-[2.2.1]-Amine (212 mg, 1.0 mmol) and deprotected as described in Example 10 with non-critical variations (carbamate eluted with 40% EtOAc/hexane) to provide 233 mg (76%) of Example 13 as a white solid. HRMS (FAB) calcd for $C_{15}H_{16}N_2O_2 + H$: 257.1290, found 257.1299 ($M+H$)⁺.

30

Example 14: N-[(1S, 2R, 4R)-7-Azabicyclo[2.2.1]hept-2-yl]-1-benzofuran-5-carboxamide hydrochloride:

HCl



4-Hydroxy-3-iodobenzoic acid, see Edgar, K., Falling, S.N., *J. Org. Chem.*, **55** (18), 5287-5291, 1990, (59.6 g, 226 mmol) is combined with 3 N methanolic HCl (276 mL, 678 mmol) and heated to 65°C for 24 h, then concentrated to dryness. The residue is diluted with water, neutralized to pH 7 with 3 N NaOH and the resulting solid collected via filtration. The crude material is adsorbed onto silica gel and chromatographed over 1 kg of silica gel. Solubility problems necessitated flushing the column with 50% EtOAc/hexane. All fractions containing product are combined and concentrated to a solid (47.2 g). The material is recrystallized with EtOAc to afford methyl 4-hydroxy-3-iodobenzoate (16.6 g). A second recrystallization of the filtrate from EtOAc resulted in a second solid of comparable purity (6.2 g). The remaining solid (24.5 g) is carried on without further purification. Recrystallized total: 22.8 g (36%) as a white solid. HRMS (FAB) calcd for $C_8H_7IO_3 + H$: 278.9520, found 278.9534 ($M+H$)⁺.


Methyl 4-hydroxy-3-iodobenzoate (5.56 g, 20 mmol) is combined with trimethylsilylacetylene (3.96 mL, 28 mmol), bis(triphenylphosphine)palladium dichloride (414 mg, 0.6 mmol) and cuprous iodide (57 mg, 0.3 mmol) in THF (20 mL)/CHCl₃ (40 mL) in a dry flask under nitrogen. TEA (8.7 mL, 62.3 mmol) is added and the mixture heated to 50°C for 4 h. The mixture is diluted with CHCl₃ (60 mL), washed with 5% HCl (2 x 40 mL), dried over MgSO₄ and concentrated to a brown solid. The crude material is adsorbed onto silica gel and chromatographed over 200 g silica gel, eluting with 15% EtOAc/hexane (2 L) followed by 20% EtOAc/hexane (1 L). The appropriate fractions are combined and concentrated to afford 2.50 g (50%) of methyl 4-hydroxy-3-[(trimethylsilyl)ethynyl]benzoate as a yellow solid. Given poor recovery, the column is flushed with 25-30% EtOAc/hexane and fractions with the desired compound are combined to afford 2.73 g (55%) of the benzoate as an orange solid. HRMS (FAB) calcd for $C_{13}H_{16}O_3Si + H$: 249.0947, found 249.0955 ($M+H$)⁺.

Methyl 4-hydroxy-3-[(trimethylsilyl)ethynyl]benzoate (11 g, 44.5 mmol) is combined with cuprous iodide (423 mg, 2.2 mmol) and diisopropylamine (7.1 mL, 50

mmol) in 110 ml CH₃OH in a flask under nitrogen. The reaction is warmed to 60°C for 6 h, the volatiles are removed *in vacuo*, and the brown-green residue is chromatographed over 500 g silica gel (230-400 mesh) eluting with 20% EtOAc/hexane. Two separate groups of fractions are combined to provide 3.43 g (31%) of the early eluting methyl 2-trimethylsilylbenzofuran-5-carboxylate and 2.63 g (33%) of the later eluting methyl benzofuran-5-carboxylate. The pools are combined in 130 ml CH₃OH in a 500 ml. The solution is treated with 2N NaOH (46.8 ml, 93.6 mmol), is warmed to 50°C, and is stirred 2 h. The mixture is cooled, the volatiles are removed *in vacuo*, and the residue is dissolved in 50 ml H₂O. The pH of the mixture is adjusted to 2 with 12 N HCl, is diluted with 40 ml H₂O, and the mixture is cooled to 0°C. The off-white solid is collected, washed with water, and is dried to give 6.0 g. The solid is dried *in vacuo* over P₂O₅ for 18 h to give 4.6 g (99%) of benzofuran-5-carboxylic acid as an off-white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ 7.08, 7.69, 7.91, 8.11, 8.30, 12.91 ppm.

Example 14 is obtained in 41% yield by coupling 1-benzofuran-5-carboxylic acid with (2R)-7-aza-[2.2.1]-Amine (elution of the carbamate with 40% EtOAc/hexane), deprotecting, and making the salt according to the procedures provided for Example 10, making non-critical changes. Example 14 is a hygroscopic, amorphous yellow solid. HRMS (FAB) calcd for C₁₅H₁₆N₂O₂ +H: 257.1290, found 257.1304 (M+H)⁺.

Example 15: N-[(1S, 2R, 4R)-7-Azabicyclo[2.2.1]hept-2-yl]-3-bromofuro[2,3-c]pyridine-5-carboxamide dihydrochloride:



Furo[2,3-c]pyridin-5-ylmethyl acetate (5.17 g, 27.05 mmol) is dissolved in CH₂Cl₂ (130 mL), layered with saturated NaHCO₃ (220 mL), treated with Br₂ (8.36 mL, 162.3 mmol) and stirred very slowly for 4.5 h at RT. The mixture is stirred vigorously for 30 min, is diluted with CH₂Cl₂ (100 mL) and the layers are separated. The aqueous layer is extracted with CH₂Cl₂ (2 x 100 mL) and the combined organics are concentrated to a small volume under a stream of nitrogen. The solution is diluted

with EtOH (200 mL), treated with K_2CO_3 (22.13 g, 160.1 mmol) and stirred for 2.5 days at RT. The mixture is concentrated to dryness, partitioned between 50% brine (200 mL) and CH_2Cl_2 (5 x 200 mL), dried over Na_2SO_4 and concentrated *in vacuo* to a yellow solid (6.07 g). The crude material is adsorbed onto silica gel (12 g) and chromatographed over 250 g slurry-packed silica gel, eluting with a gradient of 50% EtOAc/hexane to 100% EtOAc. The appropriate fractions are combined and concentrated *in vacuo* to afford 5.02 g (81%) of (3-bromofuro[2,3-c]pyridin-5-yl)methanol as a white solid. MS (EI) m/z : 227 (M^+).


Oxalyl chloride (1.77 mL, 20.1 mmol) is combined with CH_2Cl_2 (60 mL) in a dry flask under nitrogen, cooled to $-78^\circ C$, treated dropwise with DMSO (2.86 mL, 40.25 mmol) and stirred for 20 min. The cooled solution is treated dropwise with a solution of (3-bromofuro[2,3-c]pyridin-5-yl)methanol (4.0 mg, 17.5 mmol) in THF (50 mL), stirred for 1 h, then treated dropwise with Et_3N (12.2 mL, 87.5 mmol). The mixture is stirred for 30 min at $-78^\circ C$, then 30 min at $0^\circ C$. The mixture is washed with saturated $NaHCO_3$ (120 mL) and the organics dried over K_2CO_3 and concentrated *in vacuo* to a dark yellow solid (3.91 g). The crude material is chromatographed over 150 g slurry-packed silica gel, eluting with 30% EtOAc/hexane. The appropriate fractions are combined and concentrated *in vacuo* to afford 3.93 g (99%) of 3-bromofuro[2,3-c]pyridine-5-carbaldehyde as a white solid. MS (EI) m/z : 225 (M^+).

3-Bromofuro[2,3-c]pyridine-5-carbaldehyde (3.26 g, 14.42 mmol) is dissolved in THF (100 mL)/t-BuOH (50 mL)/ H_2O (50 mL), treated with a single portion of $NaOCl_2$ (4.89 g, 43.3 mmol) and KH_2PO_4 (3.92 g, 28.8 mmol) and stirred at RT for 18 h. The white solid is collected via filtration (lot A) and the filtrate is concentrated *in vacuo* to dryness. The residue is suspended in water (25 mL), acidified to pH 2 with concentrated HCl and the resulting solid collected via filtration (lot B). Both lots are dried in a vacuum oven at $50^\circ C$ for 18 h and combined to afford 3.52 g (99%) of 3-bromofuro[2,3-c]pyridine-5-carboxylic acid as a white solid. MS (EI) m/z : 241 (M^+).

3-Bromofuro[2,3-c]pyridine-5-carboxylic acid (242 mg, 1.0 mmol) is coupled with (2R)-7-aza-[2.2.1]-Amine (233 mg, 1.1 mmol) (elution of the carbamate with 40% EtOAc/hexane) and deprotected as described in Example 10 with non-critical variations (elution of the carbamate with 30% EtOAc/hexane) to provide 167 mg


(41%) of Example 15 as a white solid. HRMS (FAB) calcd for $C_{14}H_{14}BrN_3O_2 + H$: 336.0348, found 336.0346 ($M+H$)⁺.

Example 16: N-[(1S, 2R, 4R)-7-Azabicyclo[2.2.1]hept-2-yl]-1-benzofuran-2-carboxamide hydrochloride:



1-Benzofuran-2-carboxylic acid (162 mg, 1.0 mmol) is coupled with (2R)-7-aza-[2.2.1]-Amine (212 mg, 1.0 mmol) and deprotected as described in Example 10 with non-critical variations (elution of the carbamate with 30% EtOAc/hexane) to provide 150 mg (51%) of Example 16 as a white solid. HRMS (FAB) calcd for $C_{15}H_{16}N_2O_2 + H$: 257.1290, found 257.1279 ($M+H$)⁺.

Example 17: N-[(1S, 2R, 4R)-7-Azabicyclo[2.2.1]hept-2-yl]furo[3,2-c]pyridine-6-carboxamide dihydrochloride:



3-Bromofuran (8.99 mL, 100.0 mmol) is dissolved in DMF (8.5 mL), cooled to 0°C, treated dropwise with $POCl_3$ (9.79 mL, 105.0 mmol), stirred for 1 h at RT and then heated to 80°C for 2 h. The mixture is cooled to RT, poured over ice (1 kg) and neutralized to pH 9 with solid K_2CO_3 . The mixture is stirred for 1 h, extracted with Et_2O (3 X 500 mL), dried over K_2CO_3 and concentrated to a dark brown oil. The crude material is chromatographed over 600 g slurry-packed silica gel, eluting with 6% EtOAc/hexane (4L), 8% EtOAc/hexane (2L), 10% EtOAc/hexane (1L), and finally 20% EtOAc/hexane. The appropriate fractions are combined and concentrated *in vacuo* to afford 14.22 g (81%) of 3-bromo-2-furaldehyde as a yellow oil. MS (EI) m/z : 174 (M^+).


3-Bromo-2-furaldehyde (14.22 g, 81.3 mmol) is combined with ethylene glycol (6.55 mL, 117.4 mmol) and *para*-toluene sulfonic acid monohydrate (772 mg,

- 4.06 mmol) in benzene (200 mL) and heated to reflux with a Dean-Stark trap for 5 h. Additional ethylene glycol (1.64 mL, 29.41 mmol) and benzene (150 mL) are added and the solution is heated for an additional 2 h. The mixture is cooled to RT, treated with saturated NaHCO_3 and stirred for 0.5 h. The layers are separated and the organics are dried over Na_2SO_4 and concentrated to a brown oil (18.8 g). The crude material is chromatographed over 700 g slurry-packed silica gel, eluting with 15% EtOAc/hexane. The appropriate fractions are combined and concentrated *in vacuo* to afford 16.45 g (92%) of 2-(3-bromo-2-furyl)-1,3-dioxolane as a yellow-orange oil. MS (EI) m/z : 218 (M^+).
- 2-(3-Bromo-2-furyl)-1,3-dioxolane (438 mg, 2.0 mmol) is dissolved in Et_2O (5 mL) in a dry flask under nitrogen, cooled to -78°C , treated dropwise with *tert*-butyllithium (2.59 mL, 4.4 mmol) and stirred for 1 h. DMF (178 μL , 2.3 mmol) in Et_2O (2 mL) is added dropwise, the mixture stirred for 4 h at -78°C , then treated with oxalic acid dihydrate (504 mg, 4.0 mmol) followed by water (2 mL). The cooling bath is removed and the mixture allowed to warm to RT over 1 h. The mixture is diluted with water (20 mL) and EtOAc (20 mL), the layers are separated and the aqueous layer extracted with EtOAc (1 X 20 mL). The organics are dried over Na_2SO_4 and concentrated to a yellow oil. The crude material is chromatographed over 12 g slurry-packed silica gel, eluting with 15% EtOAc/hexane. The appropriate fractions are combined and concentrated *in vacuo* to afford 228 mg (68%) of 2-(1,3-dioxolan-2-yl)-3-furaldehyde as a pale yellow oil. MS (EI) m/z : 168 (M^+).
- 2-(1,3-Dioxolan-2-yl)-3-furaldehyde (2.91 g, 17.31 mmol) is combined with formic acid (17 mL, 451 mmol) and water (4.25 mL) and stirred at RT for 18 h. The mixture is slowly transferred into a solution of NaHCO_3 (45 g, 541 mmol) in water (600 mL), then stirred for 0.5 h. EtOAc (200 mL) is added, the layers separated and the aqueous layer extracted with EtOAc (2 X 200 mL). The combined organics are dried over Na_2SO_4 and concentrated to a yellow oil (3.28 g). The crude material is chromatographed over 90 g slurry-packed silica gel, eluting with 20% EtOAc/hexane. The appropriate fractions are combined and concentrated to afford 2.45 g of furan-2,3-dicarbalddehyde slightly contaminated with ethylene glycol diformate as a yellow oil. ^1H NMR (CDCl_3): δ 7.00 (d, $J = 2$ Hz, 1 H), 7.67 (d, $J = 2$ Hz, 1 H), 10.07 (s, 1 H), 10.49 (s, 1 H) ppm.

- Methyl (acetylamino)(dimethoxyphosphoryl)acetate (2.34 g, 9.8 mmol) is dissolved in CHCl_3 (40 mL), treated with DBU (1.46 mL, 9.8 mmol), stirred for 5 min then added dropwise to a 0°C solution of furan-2,3-dicarbaldehyde (1.65 g, 8.9 mmol) in CHCl_3 (80 mL). The mixture is stirred for 2.5 h as the cooling bath expires then 5.5 h at RT and finally 24 h at 50°C . The mixture is concentrated *in vacuo* to a yellow oily-solid (6.66 g). The crude material is chromatographed over a standard 100g slurry-packed silica gel, eluting with 65% EtOAc/hexane. The appropriate fractions are combined and concentrated *in vacuo* to afford 1.30 g (82%) of methyl furo[3,2-c]pyridine-6-carboxylate as a yellow solid. MS (EI) m/z : 177 (M^+).
- Methyl furo[3,2-c]pyridine-6-carboxylate (1.55 g, 8.74 mmol) is dissolved in MeOH (30 mL) and H_2O (15 mL), treated with 3 N NaOH (6.4 mL) and stirred at RT for 7 h. The mixture is concentrated to dryness, dissolved in H_2O (10 mL) and acidified to pH 2 with concentrated HCl. The solution is concentrated to dryness, suspended in a smaller amount of water (7 mL) and the resulting solid collected via filtration (lot A). The filtrate is concentrated, triturated with water (3 mL) and the resulting solid collected via filtration (lot B). The filtrate from lot B is concentrated and carried on without further purification as an acid/salt mixture (lot C). Both lots A and B are dried in a vacuum oven at 50°C for 18 h to afford 690 mg (48%) for lot A and 591 mg (42%) for lot B of furo[3,2-c]pyridine-6-carboxylic acid as yellow solids.
- MS (CI) m/z : 164 ($\text{M} + \text{H}^+$).

- Furo[3,2-c]pyridine-6-carboxylic acid (199 mg, 1.0 mmol) is coupled with (2R)-7-aza-[2.2.1]-Amine (233 mg, 1.1 mmol) and deprotected as described in Example 10 with non-critical variations (elution of the carbamate with 45% EtOAc/hexane) to provide 257 mg (78%) of Example 17 as a white solid. HRMS (FAB) calcd for $\text{C}_{14}\text{H}_{15}\text{N}_3\text{O}_2 + \text{H}$: 258.1242, found 258.1253 ($\text{M} + \text{H}^+$).

Example 18: N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-chlorofuro[2,3-c]pyridine-5-carboxamide dihydrochloride:



Furo[2,3-c]pyridin-5-ylmethanol (7.70 g, 51.63 mmol) is dissolved in pyridine (45 mL), treated with acetic anhydride (14.36 mL, 154.9 mmol) and stirred for 18 h at RT. The pyridine is removed under high vacuum, and the resulting residue is dissolved in EtOAc (200 mL), washed with 50% saturated sodium bicarbonate (4 x 90 mL), dried over MgSO₄ and concentrated *in vacuo* to afford 9.32 g (94%) of furo[2,3-c]pyridin-5-ylmethyl acetate as a yellow oil. MS (EI) *m/z*: 191 (M⁺), 277, 148, 119, 118, 86, 84, 77, 63, 51, 50. .

Furo[2,3-c]pyridin-5-ylmethyl acetate (956 mg, 5 mmol) is dissolved in CH₂Cl₂ (40 mL) and cooled to 0°C. Chlorine gas is bubbled through the solution for 15 min, the cooling bath is immediately removed and the mixture stirred for 2 h. The mixture is re-cooled to 0°C, saturated with chlorine gas, the cooling bath removed and the solution warmed to RT. The solution is layered with saturated NaHCO₃ (20 mL), stirred gently for 2 h then stirred vigorously for 15 min. The mixture is diluted with saturated NaHCO₃ (50 mL), extracted with CH₂Cl₂ (1 x 40 mL then 1 x 20 mL), dried over K₂CO₃ and concentrated to a volume of 20 mL under a stream of nitrogen. The solution is diluted with EtOH (35 mL), treated with K₂CO₃ (4.09 g, 29.6 mmol) and stirred for 18 h at RT. Water (7 mL) is added and the mixture is stirred for 2 days. The mixture is concentrated to dryness, partitioned between 50% brine (50 mL) and CH₂Cl₂ (4 x 50 mL), dried over K₂CO₃ and concentrated *in vacuo* to a brown solid (833 mg). The crude material is chromatographed over a standard 40 g Biotage column, eluting with 50% EtOAc/hexane. The appropriate fractions are combined and concentrated to afford 624 mg (68%) of (3-chlorofuro[2,3-c]pyridin-5-yl)methanol as a yellow oil. ¹H NMR (DMSO-*d*₆): δ 4.69 (d, *J* = 6 Hz, 2 H), 5.56 (t, *J* = 6 Hz, 1 H), 7.69 (s, 1 H), 8.55 (s, 1 H), 8.93 (s, 1 H) ppm.


Oxalyl chloride (231 μL, 2.6 mmol) is combined with CH₂Cl₂ (10 mL), cooled to -78°C, treated dropwise with DMSO (373 μL, 5.3 mmol) and stirred for 20 min. The cooled solution is treated dropwise with a solution of (3-chlorofuro[2,3-c]pyridin-5-yl)methanol (420 mg, 2.3 mmol) in THF (5 mL)/CH₂Cl₂ (5 mL), stirred for 1 h, then treated dropwise with Et₃N (1.59 mL, 11.45 mmol). The mixture is stirred for 30 min at -78°C, then 30 min at 0°C. The mixture is washed with saturated NaHCO₃ (20 mL) and the organics dried over K₂CO₃ and concentrated *in vacuo* to a yellow solid (410 mg). The crude material is chromatographed over 20 g slurry-packed silica gel, eluting with 15% EtOAc/hexane. The appropriate fractions are combined and

concentrated *in vacuo* to afford 322 mg (77%) of 3-chlorofuro[2,3-c]pyridine-5-carbaldehyde as a white solid. ^1H NMR (CDCl_3): δ 7.89 (s, 1 H), 8.33 (s, 1 H), 9.02 (s, 1 H), 10.18 (s, 1 H) ppm.

3-Chlorofuro[2,3-c]pyridine-5-carbaldehyde (317 mg, 1.74 mmol) is dissolved in THF (10 mL)/*t*-BuOH (5 mL)/ H_2O (5 mL), treated with a single portion of sodium chlorite (592 mg, 5.24 mmol) and KH_2PO_4 (473 mg, 3.48 mmol) and stirred at RT for 18 h. The reaction mixture is concentrated *in vacuo* to dryness, suspended in water (10 mL), acidified to pH 3.5 with concentrated HCl and stirred at RT for 2 h. The resulting solid is filtered, washed with water and dried in a vacuum oven at 40°C for 18 h to afford 364 mg of 3-chlorofuro[2,3-c]pyridine-5-carboxylic acid as a white solid. MS (EI) m/z : 197 (M^+).

3-Chlorofuro[2,3-c]pyridine-5-carboxylic acid (147 mg, 0.75 mmol) is coupled with (2R)-7-aza-[2.2.1]-Amine (175 mg, 0.83 mmol) and deprotected as described in Example 10 with non-critical variations (elution of the carbamate with 40% EtOAc/hexane) to provide 157 mg (58%) of Example 18 as a pale yellow solid. HRMS (FAB) calcd for $\text{C}_{14}\text{H}_{14}\text{ClN}_3\text{O}_2 + \text{H}$: 292.0853, found 292.0843 ($\text{M} + \text{H}$) $^+$.

Example 19: N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,4-c]pyridine-6-carboxamide dihydrochloride:



3,4-Dibromothiophene (12.5 ml, 113 mmol) is combined with CuCN (30.4 g, 339 mmol) in DMF (40 ml) in a dry flask under nitrogen utilizing an over-head stirrer. The reaction is allowed to reflux at 180°C for 5 h. The dark mixture is then poured into a solution of FeCl_3 (113.6 g, 700 mmol) in 1.7M HCl (200 ml) and heated at 65°C for 0.5 h, again using the over-head stirrer. The reaction is cooled to rt and extracted with CH_2Cl_2 (7 x 300 ml). Each extract is washed individually with 200 ml each 6M HCl (2X), water, saturated NaHCO_3 , and water. The organics are then combined, dried over MgSO_4 , filtered, and concentrated, affording 10.49 g (69%) of 3,4-dicyanothiophene as a fluffy tan solid. HRMS (EI) calcd for $\text{C}_6\text{H}_2\text{N}_2\text{S}$: 133.9939, found 133.9929 (M^+).

3,4-Dicyanothiophene (5.0 g, 37.2 mmol) is suspended in benzene (150 ml) in a dry flask under nitrogen utilizing an over-head stirrer. Diisobutyl aluminum hydride (1.0M in toluene) (82.0 ml, 82.0 mmol) is added dropwise, and the reaction stirred at rt for 2 h. The reaction is then carefully quenched with MeOH (5 ml) and poured onto 30% H₂SO₄ (60 ml) with ice (200 g). The slurry is stirred until all lumps are dissolved, and the layers are allowed to separate. The aqueous layer is extracted with Et₂O (4 x 200 ml), and the combined organics are dried over MgSO₄, filtered, and adsorbed onto silica. The crude material is chromatographed over 225 g slurry-packed silica, eluting with 40% EtOAc/hexane. The appropriate fractions are combined and concentrated to afford 1.88 g (36%) of 3,4-thiophene dicarboxaldehyde as a pale yellow solid. MS (EI) *m/z*: 140 (M⁺).


3,4-Thiophene dicarboxaldehyde (1.0 g, 7.13 mmol) is dissolved in CH₂Cl₂ (40 ml) and chilled to 0°C. Methyl (acetylamino)(dimethoxyphosphoryl)acetate (1.88 g, 7.85 mmol) is dissolved in CH₂Cl₂ (30 ml) and combined with DBU (1.1 ml, 7.85 mmol). This solution is added dropwise to the chilled thiophene solution after stirring for 5 min. The reaction mixture is stirred at 0°C for 1 h and then overnight at rt. The volatiles are removed *in vacuo* and the crude material is chromatographed over 68 g slurry-packed silica eluting with 70% EtOAc/hexane. The appropriate fractions are combined and concentrated to yield 2.09 g of the carbinol intermediate as a white foam. The intermediate is dissolved in CHCl₃ (50 ml) and treated with DBU (1.32 ml, 8.8 mmol) and trifluoroacetic anhydride (1.24 ml, 8.8 mmol) in a drop-wise fashion. The reaction is stirred overnight at rt and is then quenched with saturated NaHCO₃ solution (50ml). The layers are separated, and the aqueous layer is extracted with CHCl₃ (2 x 50 ml). The combined organics are dried over MgSO₄, filtered, and concentrated to a yellow oil. This oil is chromatographed over 50 g slurry-packed silica, eluting with 90% EtOAc/hexane. The appropriate fractions are combined and concentrated to afford 1.2 g (88%) of methyl thieno[3,4-c]pyridine-6-carboxylate as a yellow solid. MS (EI) *m/z*: 193 (M⁺).

Methyl thieno[3,4-c]pyridine-6-carboxylate (250 mg, 1.3 mmol) is dissolved in MeOH (7 ml) and water (1 ml). 2M NaOH (0.72 ml, 1.43 mmol) is added drop-wise. The reaction is stirred overnight at rt and is monitored by TLC. The volatiles are removed *in vacuo* and the residue is dissolved in water (2 ml). 10% HCl is used to adjust the pH to 3, and the reaction again stirred overnight at rt. The aqueous solution

is extracted repeatedly with EtOAc (20 x 10 ml). The combined organics are dried over MgSO_4 , filtered, and concentrated to a yellow solid. The amount of isolated product via extraction is minimal (67 mg), so the aqueous layer is concentrated and found to contain the majority of product. Extraction of the solid aqueous residue with EtOAc provided 225 mg (97%) of thieno[3,4-c]pyridine-6-carboxylic acid as a yellow solid. MS (EI) m/z : 179 (M^+).

Thieno[3,4-c]pyridine-6-carboxylic acid (97 mg, 0.54 mmol) is coupled with (2R)-7-aza-[2.2.1]-Amine (126 mg, 0.6 mmol) and deprotected as described in Example 10 with non-critical variations (elution of the carbamate with 35% EtOAc/hexane) to provide 15 mg (15%) of Example 19 as a dark yellow solid. HRMS (FAB) calcd for $\text{C}_{14}\text{H}_{15}\text{N}_3\text{OS}+\text{H}$: 274.1014, found 274.1004 ($\text{M}+\text{H}$) $^+$.

Example 20: N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]dibenzo[b,d]thiophene-2-carboxamide hydrochloride:




15

Dibenzo[b,d]thiophene-2-carboxylic acid (171 mg, 0.75 mmol) is coupled with (2R)-7-aza-[2.2.1]-Amine (175 mg, 0.83 mmol) and deprotected as described in Example 10 with non-critical variations (elution of the carbamate with 35% EtOAc/hexane) to provide 183 mg (68%) of Example 20 as a tan solid. HRMS (FAB) calcd for $\text{C}_{19}\text{H}_{18}\text{N}_2\text{OS}+\text{H}$: 323.1218, found 323.1217 ($\text{M}+\text{H}$) $^+$.

20

Example 21: N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothieno[2,3-c]pyridine-3-carboxamide dihydrochloride:



25

N-Butyl lithium (150.6 ml, 241 mmol) is added dropwise to Et_2O (100 ml) at -20°C under N_2 . 3-Bromothianaphthene (10.5 ml, 80.3 mmol) is dissolved in ether (50 ml) and also added dropwise to the chilled solution, stirring cold for 0.5 h. DMF (16.3 ml, 210 mmol) is suspended in Et_2O (75 ml) and added in a similar manner, and

the solution stirred an additional 15 h at -20°C . The reaction is quenched on ice (300 g) and 10% sulfuric acid (200 ml) and is stirred until both layers turned yellow in color. The resulting slurry is filtered and the cake is allowed to dry in the air stream, affording 8.69 g (60%) of 1-benzothiophene-2,3-dicarbaldehyde as a yellow solid.

5 MS (EI) m/z : 190 (M^+).

1-Benzothiophene-2,3-dicarbaldehyde (1.91 g, 10.0 mmol) is dissolved in CH_2Cl_2 (100 ml) and chilled to 0°C . Methyl (acetylamino)(dimethoxyphosphoryl) acetate (2.63 g, 11.0 mmol) is dissolved in CH_2Cl_2 (50 ml) and combined with DBU (1.65 ml, 11.0 mmol), stirring for 5 min. This solution is added dropwise to the
10 chilled thiophene solution. The reaction mixture is stirred cold for 1 h and then over night at RT. The volatiles are removed *in vacuo* and the crude material is chromatographed over 500 g slurry-packed silica eluting with 50% EtOAc/hexane. Two sets of fractions are collected:


The appropriate earlier-eluting fractions are combined and concentrated to give 300
15 mg (12%) methyl benzothieno[2,3-c]pyridine-3-carboxylate: ^1H NMR (CDCl_3) δ 4.12, 7.62, 7.69, 7.99, 8.37, 8.92, 9.30 ppm.

The appropriate later-eluting fractions are combined and concentrated to yield 1.75 g (73%) of methyl benzothieno[3,2-c]pyridine-3-carboxylate as a white solid: ^1H NMR (CDCl_3) δ 4.10, 7.63, 7.96, 8.37, 8.72, 9.51 ppm. MS (EI) m/z : 243 (M^+).

20 Methyl benzothieno[2,3-c]pyridine-3-carboxylate (200 mg, 0.82 mmol) is dissolved in MeOH (4 ml) with water (0.5 ml). 2M NaOH (0.45 ml, 0.9 mmol) is added dropwise and the solution stirred at RT. When the reaction is complete by TLC, the volatiles are removed *in vacuo*, and the residue is dissolved in water (10 ml). The pH is adjusted to 3.5 with concentrated HCl, and the solution is allowed to stir
25 over night. The slurry is then filtered and the cake is dried in an air stream, yielding 162 mg (86%) of benzothieno[2,3-c]pyridine-3-carboxylic acid as a tan solid. ^1H NMR ($\text{DMSO}-d_6$) δ 7.62, 7.73, 8.21, 8.70, 9.05, 9.42 ppm.


Benzothieno[2,3-c]pyridine-3-carboxylic acid (75 mg, 0.33 mmol) is coupled with (2R)-7-aza-[2.2.1]-Amine (77 mg, 0.36 mmol) and deprotected as described in
30 Example 10 with non-critical variations (elution of the carbamate with 45% EtOAc/hexane) to provide 115 mg (89%) of Example 21 as a white solid. HRMS (FAB) calcd for $\text{C}_{18}\text{H}_{17}\text{N}_3\text{O}_3\text{S}+\text{H}$: 324.1170, found 324.1177 ($M+\text{H}$) $^+$.

Example 22: N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothieno[3,2-c]pyridine-3-carboxamide dihydrochloride:




Example 22 is prepared using the method outlined in Example 21 making non-critical changes by coupling the acid derived from the saponification of methyl benzothieno[3,2-c]pyridine-3-carboxylate with (2R)-7-aza-[2.2.1]-Amine to provide Example 22 as a white fluffy solid. HRMS (FAB) calcd for $C_{18}H_{17}N_3OS+H$: 324.1170, found 324.1180 ($M+H$)⁺.

Example 23: N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]dibenzo[b,d]furan-2-carboxamide dihydrochloride:



Dibenzo[b,d]furan-2-carboxylic acid (159 mg, 0.75 mmol) is coupled with (2R)-7-aza-[2.2.1]-Amine (176 mg, 0.83 mmol) and deprotected as described in Example 10 with non-critical variations (elution of the carbamate with 40% EtOAc/hexane) to provide 225 mg (89%) of Example 23 as a white solid. HRMS (FAB) calcd for $C_{19}H_{18}N_2O_2+H$: 307.1446, found 307.1449 ($M+H$)⁺.


Example 24: N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-5-carboxamide hydrochloride:



1-Benzothiophene-5-carboxylic acid (Badger, G.M.; Clark, D.J.; Davies, W.; Ferrer, K.T.; Kefford, N.P. Thionaphthencarboxylic Acids. *J. Am. Chem. Soc.* 1957, 79, 2624-2630. Amin, H.B.; Awad, A.A.; Archer, W.J.; Taylor, R. Electrophilic Aromatic Substitution. Part 33. Partial Rate Factors for Protiodetratiation of

Benzo[*b*]thiophen; the Resonance-dependent Reactivity of the Ring Positions. *J. Chem. Soc., Perkin Trans. II* **1982**, 1489-1492.) (134 mg, 0.75 mmol) is coupled with (2R)-7-aza-[2.2.1]-Amine (175 mg, 0.83 mmol) and deprotected as described in Example 10 with non-critical variations (elution of the carbamate with 50% EtOAc/hexane) to provide 112 mg (48%) of Example 24 as an ivory solid. HRMS (FAB) calcd for C₁₅H₁₆N₂OS+H: 273.1061, found 273.1054.

Example 25: N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-methyl-1-benzofuran-6-carboxamide hydrochloride:




Methyl 3-hydroxy-4-iodobenzoate (2.0 g, 7.2 mmol) is dissolved in DMF (15 ml) with propargyl trimethylsilane (1.19 ml, 7.98 mmol), bis(triphenylphosphine)palladium dichloride (71 mg, 0.10 mmol), copper iodide (55 mg, 0.29 mmol), and piperidine (1.14 ml, 11.5 mmol) in a dry flask under nitrogen. The reaction is heated at 45°C for 7 h and then stirred at RT overnight. The reaction mixture is diluted with EtOAc (75 ml) and washed with 50% 1:1 NaCl/NaHCO₃ (4 x 25 ml). The organic is dried over Na₂SO₄ and concentrated to an amber oil. The crude material is chromatographed over 100 g slurry-packed silica gel, eluting with 20% EtOAc/hexane. The appropriate fractions are collected and concentrated to afford 1.5 g of a mixture of esters, neither of which could be isolated independently from one another. The mixture of esters is dissolved in MeOH (15 ml) and water (1 ml) and treated with 2N NaOH (3.15 ml, 6.3 mmol). After 2 days, the volatiles are removed *in vacuo* and the residue dissolved in water (5 ml). TLC indicates the presence of 2 spots, so the solution is washed with Et₂O (3 x 10 ml) to remove the undesired reaction component. The pH is then adjusted to 3 with concentrated HCl and the resulting slurry is filtered. The isolated cake is dried overnight to yield 789 mg (85%) of 2-methyl-1-benzofuran-6-carboxylic acid as a pale yellow solid. MS (EI) *m/z* 176 (M)⁺.

2-Methyl-1-benzofuran-6-carboxylic acid (176 mg, 1.0 mmol) is coupled with (2R)-7-aza-[2.2.1]-Amine (233 mg, 1.1 mmol) and deprotected as described in Example 10 with non-critical variations (elution of the carbamate with 40%

EtOAc/hexane) to provide 102 mg (33%) of Example 25 as a white solid. HRMS (FAB) calcd for $C_{16}H_{18}N_2O_2 + H$: 271.1446, found 271.1454 ($M+H$)⁺.

Example 26: N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-methyl-1-benzofuran-6-carboxamide hydrochloride:



Methyl 3-hydroxy-4-iodobenzoate (2.0 g, 7.2 mmol) is dissolved in DMF (25 ml) in a dry flask under nitrogen. Allyl bromide (0.65 ml, 7.55 mmol) is added dropwise, followed by the careful addition of sodium hydride (303 mg, 7.55 mmol).

The reaction is stirred over night at RT and is quenched onto water (30 ml). The mixture is extracted with EtOAc (3 x 30 ml), and the combined organics are washed with 50% saturated brine (4 x 25 ml), dried over $MgSO_4$, filtered, and concentrated under high-vacuum to an oil that solidified upon standing to obtain 2.28 g (100%) of methyl 3-(allyloxy)-4-iodobenzoate as a tan solid. HRMS (FAB) calcd for $C_{11}H_{11}IO_3 + H$: 318.9833, found 318.9831 ($M+H$)⁺.

Methyl 3-(allyloxy)-4-iodobenzoate (2.0 g, 6.28 mmol) is dissolved in DMF (15 ml) and treated with palladium acetate (71 mg, 0.31 mmol), Na_2CO_3 (1.67 g, 15.7 mmol), sodium formate (427 mg, 6.28 mmol), and $(n-Bu)_4N^+Cl^-$ hydrate (1.92 g, 6.92 mmol). The reaction is stirred at 80°C for 2 days. The mixture is then filtered, and the liquor is diluted with EtOAc (75 ml). The solution is washed with 50% saturated brine (4 x 25 ml) followed by 5% HCl (1 x 25 ml). The organic is dried over Na_2SO_4 , filtered, and concentrated to a brown oil. The crude material is chromatographed over 50 g slurry-packed silica gel, eluting with 20% EtOAc/hexane. The appropriate fractions are combined and concentrated to afford 797 mg (67%) of methyl 3-methyl-1-benzofuran-6-carboxylate as a pale oil. HRMS (FAB) calcd for $C_{11}H_{10}O_3 + H$: 191.0708, found 191.0714 ($M+H$)⁺.


Methyl 3-methyl-1-benzofuran-6-carboxylate (720 mg, 3.78 mmol) is dissolved in MeOH (10 ml) and treated with 2N NaOH (2.27 ml, 4.5 mmol). Following overnight stirring, the volatiles are removed *in vacuo*. The residue is dissolved in water (5 ml) and concentrated HCl is used to adjust the pH to 3. The resulting slurry is filtered after overnight stirring to afford 545 mg (82%) of 3-methyl-

1-benzofuran-6-carboxylic acid as a white solid. HRMS (FAB) calcd for $C_{10}H_8O_3 + H$: 177.0552, found 177.0551 ($M+H$)⁺.

3-Methyl-1-benzofuran-6-carboxylic acid (176 mg, 1.0 mmol) is coupled with (2R)-7-aza-[2.2.1]-Amine (233 mg, 1.1 mmol) and deprotected as described in

- 5 Example 10 with non-critical variations (elution of the carbamate with 40% EtOAc/hexane) to provide 225 mg (74%) of Example 26 as a white solid. HRMS (FAB) calcd for $C_{16}H_{18}N_2O_2 + H$: 271.1446, found 271.1437 ($M+H$)⁺.

- Example 27:** N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuro[3,2-c]pyridine-3-carboxamide dihydrochloride:



- Benzofuran (11.02 ml, 100 mmol) and potassium acetate (1.96g, 200 mmol) are dissolved in $CHCl_3$ (50 ml). Bromine (10.3 ml, 200 mmol) is dissolved in $CHCl_3$ (20 ml) and added dropwise. Following addition, the reaction is heated at 50°C for 5
- 15 h. The mixture is cooled to RT and quenched onto 5% sodium bisulfite solution (100 ml). The layers are allowed to separate, and the organic is washed with 5% $NaHCO_3$ (1 x 100 ml), dried over Na_2SO_4 , filtered, and concentrated to a green oil. The crude material is chromatographed over 1 kg slurry-packed silica eluting with 100% pentane. The appropriate fractions are combined and concentrated to give 15.86 g
- 20 (57%) of 2,3-dibromobenzofuran as a pale oil. HRMS (EI) calcd for $C_8H_4Br_2O$: 273.8630, found 273.8624 (M)⁺.

- 2,3-Dibromobenzofuran (1.37 g, 5.0 mmol) is dissolved in Et_2O (20 ml) in a dry flask under nitrogen and cooled to -78°C. *tert*-Butyllithium (6.47 ml, 11.0 mmol) is added dropwise, and the chilled solution is stirred 1 h. DMF (0.45 ml, 5.75 mmol)
- 25 is dissolved in Et_2O (5 ml) and also added dropwise, and the mixture is stirred at -78°C for another 4 h. The reaction is warmed to RT, and then oxalic acid dihydrate (1.26 g, 10.0 mmol) and water (5 ml) are added. The reaction continues stirring at RT for 2 days and is then diluted with water (25 ml) and EtOAc (35 ml). The layers are allowed to separate, and the aqueous is extracted with EtOAc (1 x 35 ml). The
- 30 organics are combined, dried over Na_2SO_4 , filtered, and concentrated to an orange oil

that solidified upon standing. The crude material is chromatographed over 100 g slurry-packed silica, eluting with 20% EtOAc/hexane. The appropriate fractions are combined and concentrated to afford 628 mg (56%) of 3-bromo-1-benzofuran-2-carbaldehyde as a yellow crystalline solid. HRMS (FAB) calcd for $C_9H_5BrO_2+H$: 224.9552, found 224.9555 ($M+H$)⁺.

3-Bromo-1-benzofuran-2-carbaldehyde (5.49 g, 24.4 mmol) is combined with *para*-toluene sulfonic acid hydrate (232 mg, 1.2 mmol) and ethylene glycol (2.44 ml, 43.9 mmol) in benzene (75 ml). The reaction is refluxed with a Dean-Stark trap for 5 h. The mixture is cooled to RT and diluted with saturated $NaHCO_3$ solution (20 ml) and left to stir for an additional 12 h. The layers are allowed to separate, and the organic layer is dried over Na_2SO_4 , filtered, and concentrated to afford 6.6 g (100%) of 3-bromo-2-(1,3-dioxolan-2-yl)-1-benzofuran as a dark brown oil. HRMS (FAB) calcd for $C_{11}H_9BrO_3+H$: 268.9814, found 268.9821 ($M+H$)⁺.

3-Bromo-2-(1,3-dioxolan-2-yl)-1-benzofuran (6.6 g, 24.5 mmol) is dissolved in Et_2O (100 ml) in a dry flask under nitrogen and cooled to -78°C. *tert*-Butyllithium (31.7 ml, 53.9 mmol) is added dropwise, and the chilled solution is stirred 1 h. DMF (2.18 ml, 28.2 mmol) is dissolved in Et_2O (25 ml) and also added dropwise, and the mixture is stirred at -78°C for another 7 h. The reaction is warmed to RT, and then oxalic acid dihydrate (6.18 g, 49.0 mmol) and water (25 ml) are added. The reaction continues stirring at RT overnight and is then diluted with water (125 ml) and EtOAc (175 ml). The layers are allowed to separate, and the aqueous is extracted with EtOAc (1 x 100 ml). The organics are combined, dried over Na_2SO_4 , filtered, and concentrated to a brown oil. The crude material is chromatographed over 350 g slurry-packed silica, eluting with 30% EtOAc/hexane. The appropriate fractions are combined and concentrated to afford 3.84 g (72%) of 2-(1,3-dioxolan-2-yl)-1-benzofuran-3-carbaldehyde as a yellow/orange oil. MS (EI) m/z : 218 (M^+).


2-(1,3-Dioxolan-2-yl)-1-benzofuran-3-carbaldehyde (3.63 g, 16.6 mmol) is dissolved in formic acid (16.3 ml, 433 mmol) with water (4.1 ml). After 2 h, additional formic acid (10 ml) and water (2.5 ml) are added to alleviate the slurry. The reaction is stirred 12 h and is diluted with water (30 ml). The resulting slurry is filtered, dried in an air stream, affording 2.66 g (92%) of 1-benzofuran-2,3-dicarbaldehyde as an orange solid. MS (EI) m/z : 174 (M^+).

1-Benzofuran-2,3-dicarbaldehyde (174 mg, 1.0 mmol) is dissolved in CH_2Cl_2 (5 ml) and chilled to 0°C . Methyl (acetylamino)(dimethoxyphosphoryl) acetate (263 mg, 1.1 mmol) is dissolved in CH_2Cl_2 (5 ml) and combined with DBU (0.16 ml, 1.1 mmol), stirring for 5 min. This solution is added dropwise to the chilled benzofuran solution. The reaction mixture is stirred 0°C for 1 h, 4 days at RT, and 2 days at 45°C . The volatiles are removed *in vacuo* and the crude material is chromatographed over 50 g slurry-packed silica eluting with 40% EtOAc/hexane. The appropriate fractions are combined and concentrated to give 180 mg (79%) of methyl benzofuro[3,2-c]pyridine-3-carboxylate as a yellow solid. HRMS (FAB) calcd for $\text{C}_{13}\text{H}_9\text{NO}_3+\text{H}$: 228.0661, found 228.0654 ($\text{M}+\text{H}$)⁺.

Methyl benzofuro[3,2-c]pyridine-3-carboxylate (2.02 g, 8.89 mmol) is dissolved in MeOH (50 ml) and water (10 ml). 2M NaOH (5.3 ml, 10.67 mmol) is added dropwise, and the reaction is stirred overnight at RT. When the reaction is complete by TLC, the volatiles are removed *in vacuo*. The solid residue is suspended in water (40 ml) and the pH is adjusted to 3 with concentrated HCl. The white slurry is filtered, and the cake is dried first in a stream of air and then in a vacuum oven overnight, affording 1.84 g (97%) of benzofuro[3,2-c]pyridine-3-carboxylic acid as a pale yellow solid. ^1H NMR ($\text{DMSO}-d_6$) δ 7.56, 7.68, 7.88, 8.38, 9.51 ppm.

Benzofuro[3,2-c]pyridine-3-carboxylic acid (213 mg, 1.0 mmol) is coupled with (2R)-7-aza-[2.2.1]-Amine (233 mg, 1.1 mmol) and deprotected as described in Example 10 with non-critical variations (elution of the carbamate with 40% EtOAc/hexane) to provide 297 mg (78%) of Example 27 as a white solid. HRMS (FAB) calcd for $\text{C}_{18}\text{H}_{17}\text{N}_3\text{O}_2+\text{H}$: 308.1399, found 308.1401 ($\text{M}+\text{H}$)⁺.

Example 28: N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuro[2,3-c]pyridine-3-carboxamide dihydrochloride:



2-(1,3-Dioxolan-2-yl)-1-benzofuran-3-carbaldehyde (1.4 g, 6.4 mmol) is dissolved in CH_2Cl_2 (50 ml) and chilled to 0°C . Methyl (acetylamino)(dimethoxyphosphoryl) acetate (1.69 g, 7.06 mmol) is dissolved in


CH₂Cl₂ (20 ml) and combined with DBU (1.05 ml, 7.06 mmol), stirring for 5 min. This solution is added dropwise to 1-benzofuran-2,3-dicarbaldehyde. The reaction mixture is stirred 2 days, allowing the ice bath to expire. The volatiles are removed *in vacuo* and the crude material is chromatographed over 100 g slurry-packed silica eluting with 50% EtOAc/hexane. The appropriate fractions are combined and concentrated, yielding 1.97 g (93%) of methyl (2Z)-2-(acetylamino)-3-[2-(1,3-dioxolan-2-yl)-1-benzofuran-3-yl] prop-2-enoate as a yellow oil. ¹H NMR (CDCl₃) δ 1.99, 3.91, 4.13, 4.26, 6.10, 7.29, 7.35, 7.49 ppm.

Methyl (2Z)-2-(acetylamino)-3-[2-(1,3-dioxolan-2-yl)-1-benzofuran-3-yl] prop-2-enoate (1.97 g, 5.94 mmol) is dissolved in formic acid (6 ml, 160 mmol) with water (2 ml). The reaction stirred 2 days at RT. The reaction is diluted with water (40 ml), and the resulting slurry is filtered and dried in an air stream to afford 1.02 g (75%) of methyl benzofuro[2,3-c]pyridine-3-carboxylate as tan solid. ¹H NMR (CDCl₃) δ 4.09, 7.51, 7.71, 8.12, 8.82, 9.19 ppm.

Methyl benzofuro[2,3-c]pyridine-3-carboxylate (681 mg, 3.0 mmol) is dissolved in MeOH (15 ml) and water (3.5 ml). 2M Sodium hydroxide (1.8ml, 3.6 mmol) is added dropwise, and the reaction is stirred overnight at RT. When the reaction is complete by TLC, the volatiles are removed *in vacuo*. The solid residue is suspended in water (25 ml) and the pH is adjusted to 3 with concentrated HCl. The solution is stirred overnight, and the resulting white slurry is filtered. The cake is dried first in a stream of air and then in a vacuum oven overnight, affording 583 mg (91%) of benzofuro[2,3-c]pyridine-3-carboxylic acid as an ivory solid. HRMS (FAB) calcd for C₁₂H₇NO₃+H: 214.0504, found 214.0493 (M+H)⁺.

Benzofuro[2,3-c]pyridine-3-carboxylic acid (213 mg, 1.0 mmol) is coupled with (2R)-7-aza-[2.2.1]-Amine (233 mg, 1.1 mmol) and deprotected as described in Example 10 with non-critical variations (elution of the carbamate with 50% EtOAc/hexane) to provide 293 mg (77%) of Example 28 as an ivory solid. HRMS (FAB) calcd for C₁₈H₁₇N₃O₂+H 308.1399, found 308.1389 (M+H)⁺.

Example 29: N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-isopropyl-1-benzofuran-5-carboxamide hydrochloride:




Methyl 4-hydroxy-3-iodobenzoate (6.0 g, 21.5 mmol) is dissolved in DMF (35 ml) in a dry flask under nitrogen and cooled to 0°C. 60% Sodium hydride (860 mg, 21.5 mmol) is added portionwise and the reaction is stirred 1 h, allowing the ice bath to expire. The mixture is then treated with 1-chloro-3-methyl-2-butene (2.67 ml, 23.7 mmol) and sodium iodide (323 mg, 2.15 mmol), and the reaction stirred 18 h at RT. The mixture is diluted with EtOAc (150 ml) and washed with 1:1 saturated NaCl/NaHCO₃ (1 x 100 ml). The organic layer is dried with MgSO₄ and concentrated to an oil. The crude material is chromatographed over 700 g slurry-packed silica gel, eluting with 15% EtOAc/hexane. The appropriate fractions are collected and concentrated to afford 5.13 g of a pale oil. The oil is then dissolved in DMF (40 ml) and treated successively with palladium acetate (165 mg, 0.74 mmol), sodium carbonate (3.9 g, 36.8 mmol), sodium formate (1.0 g, 14.7 mmol), and N-butyl tetraammonium chloride (4.5 g, 16.2 mmol). The mixture stirred 2 days at 80°C. The reaction is quenched onto EtOAc (200 ml) and washed with 50% saturated brine (3 x 75 ml) and 5% HCl (1 x 75 ml). The organic is dried over MgSO₄, filtered, and concentrated to a brown oil. The crude material is chromatographed over 250 g slurry-packed silica gel, eluting with 10% EtOAc/hexane. The appropriate fractions are collected and concentrated to afford 1.33 g (28% over 2 steps) of methyl 3-isopropyl-1-benzofuran-5-carboxylate as a mobile oil. HRMS (FAB) calcd for C₁₃H₁₄O₃+H: 219.1021, found 219.1021 (M+H)⁺.

Methyl 3-isopropyl-1-benzofuran-5-carboxylate 1.20 g, 5.51 mmol) is dissolved in MeOH (20 ml) and water (4 ml). 2N NaOH (3.3 ml, 6.6 mmol) is added dropwise and the reaction is stirred 2 days. Slight heating at 40°C is required for 4 h. Volatiles are removed *in vacuo*, and the residue is dissolved in water (10 ml). Concentrated HCl is used to adjust the pH to 3, and the resulting precipitate is isolated via filtration and dried overnight to afford 1.08 g (97%) of 3-isopropyl-1-benzofuran-5-carboxylic acid as a white solid. MS (ESI-) for C₁₂H₁₂O₃ m/z: 203.0 (M-H)⁻.

3-Isopropyl-1-benzofuran-5-carboxylic acid (204 mg, 1.0 mmol) is coupled with (2R)-7-aza-[2.2.1]-Amine (233 mg, 1.1 mmol) and deprotected as described in

Example 10 with non-critical variations (elution of the carbamate with 40% EtOAc/hexane) to provide 245 mg (73%) of Example 29 as a white solid. HRMS (FAB) calcd for $C_{18}H_{22}N_2O_2+H$: 299.1759, found 299.1754 ($M+H$)⁺.


- 5 **Example 30:** N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-methyl-1-benzofuran-5-carboxamide hydrochloride:



- 2-Methyl-1-benzofuran-5-carboxylic acid is obtained from methyl 4-hydroxy-3-iodobenzoate according to the procedures discussed in Example 25, making non-critical changes (eluting the intermediate ester with 15% EtOAc/hexane) in 80% overall yield as a gray solid. ¹H NMR (DMSO-*d*₆) δ 2.47, 6.70, 7.57, 7.85, 8.16, 12.81 ppm.

- 2-Methyl-1-benzofuran-5-carboxylic acid (176 mg, 1.0 mmol) is coupled with (2R)-7-aza-[2.2.1]-Amine (233 mg, 1.1 mmol) and deprotected as described in Example 10 with non-critical variations (elution of the carbamate with 40% EtOAc/hexane) to provide 244 mg (80%) of Example 30 as a light tan solid. HRMS (FAB) calcd for $C_{16}H_{18}N_2O_2+H$ 271.1446, found 271.1446 ($M+H$)⁺.

- 20 **Example 31:** N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-bromo-1-benzofuran-5-carboxamide hydrochloride:




- Methyl benzofuran-5-carboxylate (667 mg, 3.8 mmol) (described in Example 14) is dissolved in 20 ml CH_2Cl_2 under nitrogen. The solution is treated with bromine (1.2 ml, 22.8 mmol), is layered with 20 ml saturated $NaHCO_3$, and the reaction is stirred gently for 2 h at RT. The reaction is stirred vigorously for 30 min, the layers are separated, and the organic layer is concentrated *in vacuo* to an amber oil. The residue is dissolved in 30 ml EtOH, the solution is treated with anhydrous potassium carbonate (3.15 g, 22.8 mmol), and the reaction is stirred vigorously overnight. The

insoluble material is removed by filtration and the filtrate is diluted with 3 ml 3N NaOH and the mixture is stirred 3 h at RT. The mixture is concentrated *in vacuo*, the residue is dissolved in 10 ml water, and the pH of the solution is adjusted to 2 with 10% aqueous HCl. The precipitate is collected, washed with water, and is dried to afford 880 mg (96%) of 3-bromobenzofuran-5-carboxylic acid as an off-white solid. HRMS (FAB) calcd for $C_9H_5BrO_3 + H$: 240.9501, found 240.9505 (M+H)⁺.

3-Bromobenzofuran-5-carboxylic acid (241 mg, 1.0 mmol) is coupled with (2R)-7-aza-[2.2.1]-Amine (233 mg, 1.1 mmol) and deprotected as described in Example 10 with non-critical variations (elution of the carbamate with 32% EtOAc/hexane) to provide 310 mg (83%) of Example 31 as a white solid. HRMS (FAB) calcd for $C_{15}H_{15}BrN_2O_2 + H$: 335.0396, found 335.0379 (M+H)⁺.

Example 32: N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethynyl-1-benzofuran-5-carboxamide fumarate:



15

3-Bromobenzofuran-5-carboxylic acid (1.25 g, 5.2 mmol) is dissolved in DMF (10 ml) with DIEA (3.6 ml, 20.6 mmol) and (2R)-7-aza-[2.2.1]-Amine (1.1 g, 5.2 mmol). HATU (1.97 g, 5.2 mmol) is added portion-wise and the reaction is stirred overnight at RT. Volatiles are removed *in vacuo*, and the residue is dissolved in 50 ml $CHCl_3$, is washed with 1 x 50 ml 1:1 sat'd NaCl/conc. NH_4OH , and the aqueous layer is washed with 50 ml $CHCl_3$. The combined organic layer is dried over K_2CO_3 and is concentrated *in vacuo*. The residue is chromatographed over 50 g silica gel (230-400 mesh), eluting with 32% EtOAc/hexane. The appropriate fractions are collected and concentrated to give 1.64 g (73%) of *tert*-butyl (1S, 2R, 4R)-2-[(3-bromo-1-benzofuran-5-yl)carbonyl]amino}-7-azabicyclo[2.2.1]heptane-7-carboxylate as a pale oil.


25

tert-Butyl (1S, 2R, 4R)-2-[(3-bromo-1-benzofuran-5-yl)carbonyl]amino}-7-azabicyclo[2.2.1]heptane-7-carboxylate (436 mg, 1.0 mmol) is combined with bis(benzonitrile)palladium dichloride (57 mg, 0.15 mmol), cuprous iodide (19 mg,

0.10 mmol), tri-*t*-butylphosphine ((10% in hexane) 658 μ L, 0.325 mmol), and trimethylsilyl acetylene (170 μ L, 1.2 mmol) in 3 ml dry dioxane in a dry flask under nitrogen. The mixture is treated with diisopropylamine (168 μ L, 1.2 mmol) is stirred overnight at RT, and is diluted with 25 ml EtOAc. The reaction is washed with 4 x 25
5 ml 1:1:0.1 H₂O/brine/conc NH₄OH, the organic layer is dried over K₂CO₃, and the volatiles are removed *in vacuo*. The crude material is chromatographed over 30 g silica gel (230-400 mesh) eluting with 25% EtOAc/hexane. The appropriate fractions are combined and concentrated to give 385 mg (81%) of N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[(trimethylsilyl)ethynyl]-1-benzofuran-5-carboxamide
10 as an orange foam. HRMS (FAB) calcd for C₂₅H₃₂N₂O₄Si +H: 453.2209, found 453.2227 (M+H)⁺.

N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[(trimethylsilyl)ethynyl]-1-benzofuran-5-carboxamide is dissolved in 5 ml CH₃OH, and the solution is treated with 5 ml 3N methanolic HCl. The reaction is warmed to 50°C for 2 h, is carefully
15 quenched with 9 ml saturated NaHCO₃, and the reaction is stirred overnight at RT and then at 50°C for an additional 2 h. The volatiles are removed *in vacuo* and the residue is partitioned between 10 ml H₂O and 4 x 10 ml CHCl₃. The combined organic layer is dried over K₂CO₃ and is concentrated *in vacuo* to a dark oil. The crude material is chromatographed over 30 g silica gel (230-400 mesh) eluting with 8% CH₃OH/CHCl₃
20 + 1% NH₄OH. The appropriate fractions are combined and concentrated to afford 166 mg of a pale oil. The oil is combined with fumaric acid (69 mg, 0.59 mmol) in 1 ml CH₃OH and the solution is treated dropwise with 15 ml EtOAc. The mixture is stirred 1 h, the solid is collected, washed with EtOAc/Et₂O and is dried to give 208 mg (69%) of Example 32 as a white solid. HRMS (FAB) calcd for C₁₇H₁₆N₂O₂ +H: 281.1290,
25 found 281.1279 (M+H)⁺.

Example 33: N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-prop-1-ynyl-1-benzofuran-5-carboxamide fumarate:




Methyl-3-bromobenzofuran-5-carboxylate (750 mg, 2.94 mmol) is combined with bis(benzonitrile)palladium dichloride (169 mg, 0.44 mmol), cuprous iodide (19 mg, 0.10 mmol), tri-*t*-butylphosphine ((10% in hexane) 1.92 ml, 0.95 mmol), and propyne (2 ml, 35 mmol) in 7 ml dry dioxane in 15 ml screw cap pressure tube under nitrogen. The mixture is treated with diisopropylamine (494 μ L, 3.6 mmol), is stirred overnight at RT, and is diluted with 50 ml EtOAc. The reaction is washed with 4 x 25 ml 1:1:0.1 H₂O/brine/conc NH₄OH, the organic layer is dried over MgSO₄, and the volatiles are removed *in vacuo*. The crude material is chromatographed over 50 g silica gel (230-400 mesh) eluting with 12% EtOAc/hexane. The appropriate fractions are combined and concentrated to give 460 mg (73%) of methyl 3-prop-1-ynyl-1-benzofuran-5-carboxylate as a pale solid. MS (EI) *m/z*: 214 (M)⁺.

Methyl 3-prop-1-ynyl-1-benzofuran-5-carboxylate (388 mg, 1.81 mmol) is dissolved in 10 ml CH₃OH. The solution is treated with 2N NaOH (2.3 ml, 4.6 mmol) followed by 2 ml H₂O and the reaction is stirred overnight at RT. The reaction is concentrated to dryness, the residue is dissolved in 9 ml H₂O, and the pH is adjusted to 3 with 10% aqueous HCl. The precipitate is collected, washed with H₂O, and is dried to afford 356 mg (98%) of 3-prop-1-ynyl-1-benzofuran-5-carboxylic acid as an off-white solid. HRMS (EI) calcd for C₁₂H₈O₃: 200.0473, found 200.0476 (M⁺).

3-Prop-1-ynyl-1-benzofuran-5-carboxylic acid (208 mg, 1.1 mmol) is coupled with (2R)-7-aza-[2.2.1]-Amine (257 mg, 1.2 mmol) and deprotected as described in Example 10 with non-critical variations (elution of the carbamate with 30% EtOAc/hexane) and making the salt as described in Example 32 to provide 330 mg (80%) of Example 33 as a white solid. HRMS (FAB) calcd for C₁₈H₁₈N₂O₂ +H: 295.1446, found 295.1439 (M+H)⁺.

Example 34: N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-bromothieno[2,3-c]pyridine-5-carboxamide dihydrochloride:




Methyl-thieno[2,3-c]pyridine-5-carboxylate (630 mg, 3.3 mmol) is dissolved in 20 ml CH₂Cl₂. The solution is treated with Br₂ (1.1 ml, 20 mmol), is layered with 20 ml saturated NaHCO₃, and the two-phase mixture is agitated gently for 2 h. The

reaction is stirred vigorously for 30 min, the layers are separated, and the organic layer is dried over K_2CO_3 . The organic layer is concentrated to a dark tan solid. The solid is dissolved in 20 ml 10% MeOH/ CH_2Cl_2 , is adsorbed onto 2 g silica gel (230-400 mesh), and the plug is chromatographed over 25 g silica gel (230-400 mesh) eluting with 65% EtOAc/hexane. The appropriate fractions are combined and concentrated to afford 635 mg (71%) of methyl-3-bromothieno[2,3-c]pyridine-5-carboxylate as a tan solid. 1H NMR ($CDCl_3$) δ 4.09 (s, 3 H), 7.82 (s, 1 H), 8.59 (m, 1 H), 9.25 (s, 1 H) ppm.

Methyl-3-bromothieno[2,3-c]pyridine-5-carboxylate (635 mg, 2.33 mmol) is combined with 25 ml MeOH. The mixture is treated with 2N NaOH (3 ml, 6 mmol) and 3 ml H_2O and the reaction is stirred 4 h at RT. The volatiles are removed *in vacuo* and the residue is combined with 5 ml H_2O . The pH of the mixture is adjusted to 3.5 with 10% aqueous HCl. The tan precipitate is collected, washed with water, and is dried *in vacuo* at 50°C to afford 475 mg (79%) of 3-bromothieno[2,3-c]pyridine-5-carboxylic acid as a tan solid. MS (ESI): 257.9.


3-Bromo-thieno[2,3-c]pyridine-5-carboxylic acid (237 mg, 0.92 mmol) is coupled with (2R)-7-aza-[2.2.1]-Amine (212 mg, 1.0 mmol) and deprotected as described in Example 10 with non-critical variations (elution of the carbamate with 35% EtOAc/hexane) to provide 330 mg (84%) of Example 34 as a white solid. MS (EI) m/z : 365 (M) $^+$.

Example 35: N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1H-indole-2-carboxamide hydrochloride:




Indole-2-carboxylic acid (133 mg, 0.83 mmol) is coupled with (2R)-7-aza-[2.2.1]-Amine (160 mg, 0.75 mmol) and deprotected as described in Example 1 with non-critical variations to provide 140 mg (50%) of Example 35 as a pale yellow solid. HRMS (FAB) calcd for $C_{15}H_{17}N_3O + H$: 256.1450, found 256.1450 (M+H) $^+$.

Example 36: N-[(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl]-1-benzothiophene-2-carboxamide hydrochloride:



Benzo[b]thiophene-2-carboxylic acid (147 mg, 0.83 mmol) is coupled with
 5 (2R)-7-aza-[2.2.1]-Amine (160 mg, 0.75 mmol) and deprotected as described in
 Example 10 with non-critical variations (elution of the carbamate with 25%
 EtOAc/hexane) to provide 125 mg (32%) of Example 36 as a white solid. HRMS
 (FAB) calcd for $C_{15}H_{16}N_2OS + H$: 273.1061, found 273.1058 ($M+H$)⁺.

10 **Example 37:** N-[(1S, 2R, 4R)-7-Azabicyclo[2.2.1]hept-2-yl]-3-methyl-1-benzofuran-5-carboxamide hydrochloride:



Methyl 4-hydroxy-3-iodobenzoate (1.85 g, 6.65 mmol) is dissolved in
 anhydrous DMF (15 mL) in a dry flask under nitrogen, treated with sodium hydride
 15 (60% dispersion in oil, 265 mg, 6.65 mmol) and stirred for 1 h at RT. Allyl bromide
 (633 μ L, 7.32 mmol) is added and the mixture is stirred for 16 h. The mixture is
 concentrated and the residue is partitioned between EtOAc (25 mL) and water (25
 mL). The organic layer is washed with a 50% saturated mixture of 1:1 NaCl /
 NaHCO₃ (2 x 10 mL), dried over magnesium sulfate and concentrated to a yellow oil
 20 which solidified to a white solid upon standing (2.12 g). The crude material is
 chromatographed over 100 g slurry-packed silica gel, eluting with 10%
 EtOAc/hexane. The appropriate fractions are combined and concentrated to afford
 1.94 g (90%) of methyl 4-(allyloxy)-3-iodobenzoate. MS (EI) m/z : 318 (M)⁺.

Methyl 4-(allyloxy)-3-iodobenzoate (587 mg, 1.84 mmol) is combined with
 25 palladium acetate (5%, 20 mg, 0.1 mmol), Na₂CO₃ (487 mg, 4.6 mmol), sodium
 formate (125 mg, 1.8 mmol) and (nBu)₄N⁺Cl⁻ (561 mg, 2.0 mmol) in DMF (5 mL)
 and heated to 80°C for 2 d. The mixture is concentrated under high vacuum and
 partitioned between 50% brine (10 mL) and CH₂Cl₂ (4 x 10 mL). The combined

organics are washed with 5% HCl (10 mL), dried over Na₂SO₄ and concentrated to a brown oil. The crude material is chromatographed over 15 g slurry-packed silica gel, eluting with 15% EtOAc/hexane. The appropriate fractions are combined and concentrated to afford 153 mg (44%) of methyl 3-methyl-1-benzofuran-5-carboxylate as a white solid. HRMS (FAB) calcd for C₁₁H₁₀O₃ +H: 191.0708, found: 191.0705 (M+H)⁺.

Methyl 3-methyl-1-benzofuran-5-carboxylate (365 mg, 1.9 mmol) is dissolved in MeOH (7 mL), diluted with water (3.5 mL) and treated with 3N NaOH (1.41 mL, 4.2 mmol). The mixture is diluted with MeOH (3.5 mL) to homogeneity, stirred at RT for 2.5 days then concentrated to dryness. The residue is dissolved in water (5 mL) and acidified to pH 2 with concentrated HCl. The resulting solid is filtered and dried in a vacuum oven at 40°C for 18 h to afford 321 mg (95%) of 3-methyl-1-benzofuran-5-carboxylic acid as a white solid. HRMS (FAB) calcd for C₁₀H₈O₃ +H: 177.0552, found: 177.0553 (M+H)⁺.

3-Methyl-1-benzofuran-5-carboxylic acid (156 mg, 0.9 mmol) is coupled with (2R)-7-aza-[2.2.1]-Amine (212 mg, 1.0 mmol) and deprotected as described in Example 10 with non-critical variations (elution of the carbamate with 45% EtOAc/hexane) to provide 213 mg (79%) of Example 37 as a white solid. HRMS (FAB) calcd for C₁₆H₁₈N₂O₂ +H: 271.1446, found: 271.1452 (M+H)⁺.

Materials and Methods for Determining $\alpha 7$ nAChR Agonist Activity

Cell-based Assay for Measuring the EC₅₀ of $\alpha 7$ nAChR Agonists

Construction and expression of the $\alpha 7$ -5HT₃ receptor:

The cDNA encoding the N-terminal 201 amino acids from the human $\alpha 7$ nAChR that contain the ligand binding domain of the ion channel was fused to the cDNA encoding the pore forming region of the mouse 5HT₃ receptor as described by Eisele JL, et al., Chimaeric nicotinic-serotonergic receptor combines distinct ligand binding and channel specificities, Nature (1993), Dec. 2;366(6454):479-83, and modified by Groppi, et al., WO 00/73431. The chimeric $\alpha 7$ -5HT₃ ion channel was inserted into pGS175 and pGS179 which contain the resistance genes for G-418 and hygromycin B, respectively. Both plasmids were simultaneously transfected into SH-

EP1 cells and cell lines were selected that were resistant to both G-418 and hygromycin B. Cell lines expressing the chimeric ion channel were identified by their ability to bind fluorescent α -bungarotoxin on their cell surface. The cells with the highest amount of fluorescent α -bungarotoxin binding were isolated using a
5 Fluorescent Activated Cell Sorter (FACS). Cell lines that stably expressed the chimeric $\alpha 7$ -5HT₃ were identified by measuring fluorescent α -bungarotoxin binding after growing the cells in minimal essential medium containing nonessential amino acids supplemented with 10% fetal bovine serum, L-glutamine, 100 units/ml penicillin/streptomycin, 250 ng/mg fungizone, 400 μ g/ml hygromycin B, and 400
10 μ g/ml G-418 at 37° C with 6% CO₂ in a standard mammalian cell incubator for at least 4 weeks in continuous culture.

Assay of the activity of the chimeric $\alpha 7$ -5HT₃ receptor

To assay the activity of the $\alpha 7$ -5HT₃ ion channel, cells expressing the channel
15 were plated into each well of either a 96 or 384 well dish (Corning #3614) and grown to confluence prior to assay. On the day of the assay, the cells were loaded with a 1:1 mixture of 2 mM Calcium Green 1, AM (Molecular Probes) dissolved in anhydrous DMSO and 20% pluronic F-127 (Molecular Probes). This solution was added directly to the growth media of each well to achieve a final concentration 2 μ M. The cells
20 were incubated with the dye for 60 min at 37° C and then washed with a modified version of Earle's balanced salt solution (MMEBSS) as described in WO 00/73431. The ion conditions of the MMEBSS was adjusted to maximize the flux of calcium ion through the chimeric $\alpha 7$ -5HT₃ ion channel as described in WO 00/73431. The activity of compounds on the chimeric $\alpha 7$ -5HT₃ ion channel was analyzed on FLIPR.
25 The instrument was set up with an excitation wavelength of 488 nanometers using 500 milliwatts of power. Fluorescent emission was measured above 525 nanometers with an appropriate F-stop to maintain a maximal signal to noise ratio. Agonist activity of each compound was measured by directly adding the compound to cells expressing the chimeric $\alpha 7$ -5HT₃ ion channel and measuring the resulting increase in intracellular
30 calcium that is caused by the agonist-induced activation of the chimeric ion channel. The assay is quantitative such that concentration-dependent increase in intracellular calcium is measured as concentration-dependent change in Calcium Green fluorescence. The effective concentration needed for a compound to cause a 50%

maximal increase in intracellular calcium is termed the EC_{50} . The examples of the present invention have EC_{50} values ranging from 45-18,000 nM.

Binding Constants:

5 Another way for measuring $\alpha 7$ nAChR agonist activity is to determine binding constants of a potential agonist in a competition binding assay. For $\alpha 7$ nAChR agonists, there is good correlation between functional EC_{50} values using the chimeric $\alpha 7$ -5HT₃ ion channel as a drug target and binding affinity of compounds to the endogenous $\alpha 7$ nAChR.

10

Membrane Preparation.

Male Sprague-Dawley rats (300-350g) are sacrificed by decapitation and the brains (whole brain minus cerebellum) are dissected quickly, weighed and homogenized in 9 volumes/g wet weight of ice-cold 0.32 M sucrose using a rotating
15 pestle on setting 50 (10 up and down strokes). The homogenate is centrifuged at 1,000 x g for 10 minutes at 4 °C. The supernatant is collected and centrifuged at 20,000 x g for 20 minutes at 4 °C. The resulting pellet is resuspended to a protein concentration of 1 - 8 mg/mL. Aliquots of 5 mL homogenate are frozen at -80 °C until needed for the assay. On the day of the assay, aliquots are thawed at rt and
20 diluted with Kreb's - 20 mM Hepes buffer pH 7.0 (at rt) containing 4.16 mM NaHCO₃, 0.44 mM KH₂PO₄, 127 mM NaCl, 5.36 mM KCl, 1.26 mM CaCl₂, and 0.98 mM MgCl₂, so that 25 - 150 µg protein are added per test tube. Proteins are determined by the Bradford method (Bradford, M.M., *Anal. Biochem.*, 72, 248-254, 1976) using bovine serum albumin as the standard.

25

Binding Assay.

For saturation studies, 0.4 mL homogenate are added to test tubes containing buffer and various concentrations of radioligand, and are incubated in a final volume of 0.5 mL for 1 hour at 25 °C. Nonspecific binding was determined in tissues
30 incubated in parallel in the presence of 0.05 mls MLA for a final concentration of 1 µM, added before the radioligand. In competition studies, drugs are added in increasing concentrations to the test tubes before addition of 0.05 mls [³H]-MLA for a final concentration 3.0 to 4.0 nM. The incubations are terminated by rapid vacuum

filtration through Whatman GF/B glass filter paper mounted on a 48 well Brandel cell harvester. Filters are pre-soaked in 50 mM Tris HCl pH 7.0 - 0.05 % polyethylenimine. The filters are rapidly washed two times with 5 mL aliquots of cold 0.9% saline and then counted for radioactivity by liquid scintillation spectrometry.


5 Data Analysis.

In competition binding studies, the inhibition constant (K_i) was calculated from the concentration dependent inhibition of [^3H]-MLA binding obtained from non-linear regression fitting program according to the Cheng-Prusoff equation (Cheng, Y.C. and Prusoff, W.H., *Biochem. Pharmacol.*, 22, p. 3099-3108, 1973). Hill

10 coefficients were obtained using non-linear regression (GraphPad Prism sigmoidal dose-response with variable slope).

What is claimed:

1. A compound of Formula I:




Formula I

- 5 wherein the stereochemistry of the of the 7-azabicyclo[2.2.1]heptane ring is 1*S*, 4*R* and the nitrogen substituent at the C-2 carbon has the *exo* orientation and is 2*R*;

X is O or S;

W is



- 10 A₁ is N;

Each E₁, E₂, G₁, G₂, and T is independently selected from CR₃ and N, provided that no more than two of E₁, E₂, G₁, G₂, and T are N, and further provided that when E₁ is N, G₁ and E₂ must be CR₃, and further provided that when E₂ is N, E₁ and G₂ must be CR₃;

- 15 Each V, V₈, V₉, and V₁₀ is independently selected from O, S, NA₅, and C(R₃)₂, provided that when V₈ is C(R₃)₂ the R₃ substituents on the carbon atoms adjacent to V₈ are moieties other than H;

- Each V₁, V₂, V₃, V₄, V₅, V₆, and V₇ is independently selected from O, S, N, C(R₃), C(R₃)₂, or NA₅, provided that V₁ and V₂, V₂ and V₃, V₄ and V₅, V₅ and V₆, and V₆ and V₇ are not simultaneously O or S, or combinations of O and S, and further provided that at least one of V₁, V₂, and V₃, at least one of V₄, V₅, and V₆, and at least one of V₅, V₆, and V₇ is C(R₃) or C(R₃)₂;

Each J, J₁, J₂, L, L₁, L₂, M, M₁, M₂, Q, Q₁, and Q₂ is independently selected from CR₃ and N, provided that no more than two of J, L, M, and Q, or no more than two of J₁, L₁, M₁, and Q₁, or no more than two of J₂, L₂, M₂, and Q₂ are N, and provided that at least one of J, L, M, and Q is N when V₁, V₂, and V₃ are
 5 independently selected from C(R₃)₂ and C(R₃), when V₄, V₅, V₆, and V₇ are independently selected from C(R₃)₂ and C(R₃), and when V₈ is C(R₃)₂, and further provided that at least one of J₁, L₁, M₁, and Q₁ or at least one of J₂, L₂, M₂, and Q₂ is N when V is C(R₃)₂ and when V₉ and V₁₀ are C(R₃)₂;

Each A₅ is independently H, alkyl, alkenyl, alkynyl, cycloalkyl,
 10 heterocycloalkyl, halogenated alkyl, halogenated alkenyl, halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, R₇, R₉, -C(O)R₈, -C(S)R₈, -C(O)NR₈R₈, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, phenyl optionally substituted with 1-4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅, naphthyl optionally
 15 substituted with 1-4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅, or

A₅ forms a bond to the carbon of the amide or thio amide group bound to the C-2 carbon of the 7-azabicyclo[2.2.1]heptane ring provided that only one of R₃ or A₅ forms a bond to the carbon of the amide or thio amide group;

20 R₁ is H, alkyl, cycloalkyl, halogenated alkyl, or aryl;

R₂ is H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl;


Each R₃ is independently H, F, Cl, Br, I, -CN, -NO₂, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated alkenyl, halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl,
 25 substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, -OR₈, -SR₈, -S(O)₂R₈, -S(O)R₈, -OS(O)₂R₈, -NR₈R₈, -C(O)R₈, -C(S)R₈, -C(O)OR₈, -C(O)NR₈R₈, -NR₈C(O)R₈, -NR₈C(O)NR₈R₈, -S(O)₂NR₈R₈, -NR₈S(O)₂R₈, R₇, R₉, phenyl optionally substituted with 1-4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅, naphthyl optionally substituted
 30 with 1-4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅, or
 two R₃ groups bound to the same atom together form =O or =S where valency allows, or

R_3 forms a bond to the carbon of the amide or thio amide group bound to the C-2 carbon of the 7-azabicyclo[2.2.1]heptane ring provided that only one of R_3 or A_5 forms a bond to the carbon of the amide or thio amide group;


Each R_4 is independently H, alkyl, and substituted alkyl;

5 R_6 is H, alkyl, an amino protecting group, or an alkyl group having 1-3 substituents selected from F, Cl, Br, I, -OH, -CN, -NH₂, -NH(alkyl), and -N(alkyl)₂;


R_7 is 5-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms independently selected from the group consisting of =N-,
10 -N(R_{18})-, -O-, and -S-, and having 0-1 substituent selected from R_{17} and further having 0-3 substituents independently selected from F, Cl, Br, or I, or R_7 is 9-membered fused-ring moieties having a 6-membered ring fused to a 5-membered ring including the formula



15 wherein Z_1 is O, S or NR_{18} ,



wherein Z is $C(R_{14})$ or N, and Z_2 and Z_3 are independently selected from $C(R_{14})_2$, $C(R_{14})$, O, S, N, and $N(R_{18})$, provided that both Z_2 and Z_3 are not simultaneously O, simultaneously S, or simultaneously O and S, or



20

wherein Z is $C(R_{14})$ or N, and Z_2 and Z_3 are independently selected from $C(R_{14})_2$, $C(R_{14})$, O, S, N, and $N(R_{18})$, and Z is CR_{14} or N, each 9-membered bicyclic ring having 0-1 substituent selected from R_{17} and 0-3 substituents independently selected from F, Cl, Br, or I,

25 wherein the R_7 moiety attaches to other substituents as defined in Formula I at any position on either ring as valency allows;

Each R_8 is independently H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl,

halogenated heterocycloalkyl, substituted heterocycloalkyl, R₇, R₉, phenyl optionally substituted with 1-4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅, or naphthyl optionally substituted with 1-4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅;

- 5 R₉ is 6-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms selected from =N- and having 0-1 substituent selected from R₁₅ and 0-3 substituent(s) independently selected from F, Cl, Br, or I, or R₉ is 10-membered heteroaromatic bi-cyclic moieties containing within one or both rings 1-3 heteroatoms selected from =N-, including, but not limited to, quinolinyl or isoquinolinyl, each 10-membered fused-ring moiety having 0-1 substituent selected from R₁₇ and 0-3 substituent(s) independently selected from F, Cl, Br, or I, wherein the R₉ moiety attaches to other substituents as defined in formula I at any position on either ring as valency allows;

- Each R₁₀ is independently H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from R₁₃, cycloalkyl substituted with 1 substituent selected from R₁₃, heterocycloalkyl substituted with 1 substituent selected from R₁₃, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, or phenyl optionally substituted with 1-4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅;

- 20 Each R₁₁ is independently H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, or halogenated heterocycloalkyl;

- R₁₂ is alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -OR₁₁, -SR₁₁, -S(O)₂R₁₁, -S(O)R₁₁, -OS(O)₂R₁₁, -NR₁₁R₁₁, -C(O)R₁₁, -C(S)R₁₁, -NO₂, -C(O)NR₁₁R₁₁, -CN, -NR₁₁C(O)R₁₁, -NR₁₁C(O)NR₁₁R₁₁, -S(O)₂NR₁₁R₁₁, or -NR₁₁S(O)₂R₁₁;

- R₁₃ is -OR₁₁, -SR₁₁, -NR₁₁R₁₁, -C(O)R₁₁, -C(S)R₁₁, -C(O)NR₁₁R₁₁, -CN, -CF₃, -NR₁₁C(O)R₁₁, -NR₁₁C(O)NR₁₁R₁₁, -S(O)₂NR₁₁R₁₁, -NR₁₁S(O)₂R₁₁, or -NO₂;

- R₁₄ is H or a substituent selected from alkyl, cycloalkyl, phenyl, or naphthyl, each optionally substituted with 1-4 substituents independently selected from F, Cl, Br, I, -OR₁₆, -SR₁₆, -S(O)₂R₁₆, -S(O)R₁₆, -OS(O)₂R₁₆, -NR₁₆R₁₆, -C(O)R₁₆, -C(S)R₁₆, -NO₂, -C(O)NR₁₆R₁₆, -CN, -NR₁₆C(O)R₁₆, -NR₁₆C(O)NR₁₆R₁₆, -S(O)₂NR₁₆R₁₆, and

-NR₁₆S(O)₂R₁₆, and the cycloalkyl also being further optionally substituted with =O or =S;

R₁₅ is alkyl, cycloalkyl, heterocycloalkyl, heteroaryl, phenyl, or naphthyl, each optionally substituted with 1-4 substituents independently selected from F, Cl, Br, I, -CN, -NO₂, -OR₁₆, -SR₁₆, -S(O)₂R₁₆, -S(O)R₁₆, -OS(O)₂R₁₆, -NR₁₆R₁₆, -C(O)R₁₆, -C(S)R₁₆, -C(O)NR₁₆R₁₆, -NR₁₆C(O)R₁₆, -NR₁₆C(O)NR₁₆R₁₆, -S(O)₂NR₁₆R₁₆, and -NR₁₆S(O)₂R₁₆, and the cycloalkyl and heterocycloalkyl also being further optionally substituted with =O or =S;

Each R₁₆ is independently H, alkyl, cycloalkyl, halogenated alkyl, or halogenated cycloalkyl;

Each R₁₇ is independently H, F, Cl, Br, I, R₇, R₉, -CN, -NO₂, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated alkenyl, halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, -OR₈, -SR₈, -S(O)₂R₈, -S(O)R₈, -OS(O)₂R₈, -NR₈R₈, -C(O)R₈, -C(S)R₈, -C(O)NR₈R₈, -NR₈C(O)R₈, -NR₈C(O)NR₈R₈, -S(O)₂NR₈R₈, -NR₈S(O)₂R₈, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, phenyl optionally substituted with 1-4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅, and naphthyl optionally substituted with 1-4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅;

R₁₈ is H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, phenyl, -SO₂R₈, or phenyl having 1 substituent selected from R₁₂ and further having 0-3 substituents independently selected from F, Cl, Br, or I; and pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein X is O.
3. The compound of claim 2, wherein R₁ is H, alkyl, or cycloalkyl, and wherein R₂ is H, alkyl, substituted alkyl, cycloalkyl, halogenated alkyl, or aryl.
4. The compound of claim 3, wherein W is (b).
5. The compound of claim 4, wherein (b) is thieno[2,3-b]pyridin-2-yl, thieno[2,3-b]pyridin-5-yl, thieno[2,3-b]pyridin-6-yl, thieno[2,3-c]pyridin-2-yl, furo[3,2-c]pyridin-2-yl, thieno[3,2-b]pyridin-2-yl, furo[2,3-b]pyridin-2-yl, thieno[3,2-b]pyridin-5-yl, thieno[3,2-b]pyridin-6-yl, furo[2,3-c]pyridin-5-yl, thieno[3,2-c]pyridin-2-yl, 2,3-dihydrofuro[2,3-c]pyridin-5-yl, thieno[2,3-c]pyridin-5-yl, furo[2,3-

- c]pyridin-2-yl, thieno[3,2-c]pyridin-6-yl, 1H-pyrrolo[2,3-c]pyridin-5-yl, furo[3,2-c]pyridin-6-yl, 1-benzofuran-5-yl, 1-benzofuran-6-yl, 1-benzofuran-2-yl, 1-benzothiophene-5-yl, 1-benzothiophen-6-yl, 1-benzothiophen-2-yl, indol-5-yl, indol-6-yl, indol-2-yl, 1,3-benzothiazole-6-yl, 1,3-benzothiazole-5-yl, 1,3-benzoxazole-6-yl, 1,3-benzoxazole-5-yl, benzimidazole-6-yl, benzimidazole-5-yl, 1,3-benzodioxole-5-yl, 1H-indazole-5-yl, 1H-indazole-6-yl, 1,2-benzisothiazole-6-yl, 1,2-benzisothiazole-6-yl, 1,3-benzothiazole-5-yl, 1,3-benzothiazole-6-yl, 1,3-benzodioxole-5-yl, 1,3-benzodioxole-6-yl, 2H-isindole-5-yl, 2H-isindole-6-yl, 1H-benzimidazole-5-yl, 1H-benzimidazole-6-yl, [1,3]thiazolo[5,4-c]pyridine-6-yl, [1,3]thiazolo[4,5-c]pyridine-6-yl, [1,3]dioxolo[4,5-c]pyridine-6-yl, or [1,3]oxazolo[4,5-c]pyridine-6-yl any of which is optionally substituted with up to 4 substituents independently selected from F, Cl, Br, -CN, -NO₂, alkyl, substituted alkyl, halogenated alkyl, alkenyl, substituted alkenyl, halogenated alkenyl, alkynyl, substituted alkynyl, halogenated alkynyl, heterocycloalkyl, substituted heterocycloalkyl, halogenated heterocycloalkyl, -OR₈, -SR₈, -NR₈R₈, -NR₈C(O)R₈, or phenyl optionally substituted with up to 4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅.

6. The compound of claim 5, wherein each R₄ is independently H, lower alkyl, or substituted lower alkyl.

7. The compound according to claim 6, wherein R₆ is an amino protecting group.

8. The compound according to claim 6, wherein R₆ is H, or lower alkyl optionally substituted with up to 3 substituents independently selected from F, Cl, Br, I, -OH, -CN, -NH₂, -NH(alkyl), or -N(alkyl)₂.

9. The compound of claim 8, wherein R₁ is H or lower alkyl, and wherein R₂ is H or lower alkyl.

10. The compound of claim 9, wherein at least one R₄ is H and one R₄ is H or lower alkyl optionally substituted with 1 substituent selected from -OR₁₀, -SR₁₀, -S(O)R₁₀, -S(O)₂R₁₀, -OS(O)₂R₁₀, -NR₁₀R₁₀, -C(O)R₁₀, -C(O)OR₁₀, -C(S)R₁₀,

- C(O)NR₁₀R₁₀, -CN, -NR₁₀C(O)R₁₀, -NR₁₀C(O)NR₁₀R₁₀, -S(O)₂NR₁₀R₁₀,
 -NR₁₀S(O)₂R₁₀, -NO₂, or phenyl optionally substituted with up to 4 substituents
 independently selected from F, Cl, Br, I, R₁₃, and R₁₅, provided that when said lower
 alkyl is optionally substituted, said lower alkyl can be further optionally substituted
 5 with up to 3 substituents independently selected from F, Cl, Br, and I,
 wherein R₁₀ is H, lower alkyl, or halogenated lower alkyl.

11. The compound according to claim 10, wherein R₁, R₂, and each R₄ are H.
- 10 12. The compound according to claim 11, wherein the compound is
 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-methylfuro[2,3-c]pyridine-5-
 carboxamide;
 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[2,3-c]pyridine-5-carboxamide;
 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,2-c]pyridine-6-carboxamide;
 15 N-[(2R)-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-carboxamide;
 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethylfuro[2,3-c]pyridine-5-
 carboxamide;
 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-isopropyl-furo[2,3-c]pyridine-5-
 carboxamide;
 20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1H-pyrrolo[2,3-c]pyridine-5-
 carboxamide;
 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1,3-benzodioxole-5-carboxamide;
 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1H-pyrrolo[2,3-c]pyridine-2-
 carboxamide;
 25 N-[(1S, 2R, 4R)-7-methyl-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-
 carboxamide;
 N-[(1S, 2R, 4R)-7-methyl-7-azabicyclo[2.2.1]hept-2-yl]-1-benzofuran-5-
 carboxamide;
 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1-benzofuran-6-carboxamide;
 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1-benzofuran-5-carboxamide;
 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-bromofuro[2,3-c]pyridine-5-
 carboxamide;
 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1-benzofuran-2-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[3,2-c]pyridine-6-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-chlorofuro[2,3-c]pyridine-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-5-carboxamide;
5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-methyl-1-benzofuran-6-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-methyl-1-benzofuran-6-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-isopropyl-1-benzofuran-5-carboxamide;
10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-methyl-1-benzofuran-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-bromo-1-benzofuran-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethynyl-1-benzofuran-5-carboxamide;
15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-prop-1-ynyl-1-benzofuran-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-bromothieno[2,3-c]pyridine-5-carboxamide;
20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1H-indole-2-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1-benzothiophene-2-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-methyl-1-benzofuran-5-carboxamide; or a pharmaceutically acceptable salt thereof.
- 25 13. The compound according to claim 12, wherein the compound is
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-methylfuro[2,3-c]pyridine-5-carboxamide;
N-[(2R)-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethylfuro[2,3-c]pyridine-5-carboxamide;
30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-isopropyl-furo[2,3-c]pyridine-5-carboxamide;

- N-[(1S, 2R, 4R)-7-methyl-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-bromofuro[2,3-c]pyridine-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-chlorofuro[2,3-c]pyridine-5-carboxamide; or a pharmaceutically acceptable salt thereof.

14. The compound according to claim 12, wherein the compound is
- 10 N-[(1S, 2R, 4R)-7-methyl-7-azabicyclo[2.2.1]hept-2-yl]-1-benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1-benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-methyl-1-benzofuran-6-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-isopropyl-1-benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-methyl-1-benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-bromo-1-benzofuran-5-carboxamide;
- 20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethynyl-1-benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-prop-1-ynyl-1-benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-methyl-1-benzofuran-5-
- 25 carboxamide; or a pharmaceutically acceptable salt thereof.

15. The compound according to claim 12, wherein the compound is
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,2-c]pyridine-6-carboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-bromothieno[2,3-c]pyridine-5-carboxamide; or a pharmaceutically acceptable salt thereof.

16. The compound according to claim 12, wherein the compound is

N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-5-carboxamide; or a pharmaceutically acceptable salt thereof.

17. The compound according to claim 11, wherein (b) is 1-benzofuran-6-yl, 1-benzofuran-5-yl, or 1-benzofuran-2-yl, any of which is optionally substituted with up to 4 substituents independently selected from F, Cl, Br, -CN, -NO₂, alkyl, substituted alkyl, halogenated alkyl, alkenyl, substituted alkenyl, halogenated alkenyl, alkynyl, substituted alkynyl, halogenated alkynyl, heterocycloalkyl, substituted heterocycloalkyl, halogenated heterocycloalkyl, -OR₈, -SR₈, -NR₈R₈, -NR₈C(O)R₈, or phenyl optionally substituted with up to 4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅.
18. The compound according to claim 17, wherein the compound is selected from
- 7-methyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-5-carboxamide;
 - 7-methylthio-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-5-carboxamide;
 - 7-methoxy-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-5-carboxamide;
 - 7-chloro-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-5-carboxamide;
 - N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-vinylbenzofuran-5-carboxamide;
 - N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-ethynylbenzofuran-5-carboxamide;
 - N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-prop-1-ynylbenzofuran-5-carboxamide;
 - N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-hydroxyprop-1-ynyl)benzofuran-5-carboxamide;
 - methyl 3-(5-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl) benzofuran-2-yl)prop-2-ynoate;
 - 2-(5-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl) benzofuran-2-yl)prop-2-ynoic acid;
 - 2-(3-amino-3-oxoprop-1-ynyl)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-5-carboxamide;
 - N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-cyanobenzofuran-5-carboxamide;
 - N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-chlorobenzofuran-5-carboxamide;
 - N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-fluorobenzofuran-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-iodobenzofuran-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-trifluoromethylbenzofuran-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-mercaptobenzofuran-5-carboxamide;
5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylthio)benzofuran-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylamino)benzofuran-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(formylamino)benzofuran-5-carboxamide;
10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[formyl(methyl)amino]benzofuran-5-carboxamide;
2-(acetylamino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-5-carboxamide;
15 2-(acetyl(methyl)amino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(trifluoroacetyl)amino]benzofuran-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(benzoylamino)benzofuran-5-carboxamide;
20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(diethylamino)benzofuran-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(diisopropylamino)benzofuran-5-carboxamide;
25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(pyrrolidin-1-yl)benzofuran-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopyrrolidin-1-yl)benzofuran-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperidin-1-yl)benzofuran-5-carboxamide;
30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopiperidin-1-yl)benzofuran-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(morpholin-4-yl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxomorpholin-4yl)benzofuran-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(thiomorpholin-4yl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxothiomorpholin-4yl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperazin-1-yl)benzofuran-5-
- 10 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopiperazin-1yl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methylpiperazin-1-yl)benzofuran-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methyl-2-oxopiperazin-1yl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxopiperazin-1yl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methyl-3-oxopiperazin-
- 20 1yl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(cyclopropylamino)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[dimethylamino]benzofuran-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-pyrrole-1yl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-imidazol-1-yl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-1,2,4-triazol-1-yl)benzofuran-5-
- 30 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-1,2,3-triazol-1-yl)benzofuran-5-carboxamide;
- N-5-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-2,5-dicarboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(pyrrolidin-1-ylcarbonyl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperidin-1-ylcarbonyl)benzofuran-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperazin-1-ylcarbonyl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(4-methylpiperazin-1-yl)carbonyl]benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(morpholin-4-ylcarbonyl)benzofuran-5-carboxamide;
- 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(thiomorpholin-4-ylcarbonyl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(aziridin-1-ylcarbonyl)benzofuran-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(azetidin-1-ylcarbonyl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-formylbenzofuran-5-carboxamide;
- 2-acetyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(trifluoroacetyl)benzofuran-5-carboxamide;
- 20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(phenyl)sulfonyl]benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylsulfonyl)benzofuran-5-carboxamide;
- 25 5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl} benzofuran -2-carboxylic acid;
- methyl 5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl} benzofuran-2-carboxylate;
- isopropyl 5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl} benzofuran-2-carboxylate;
- 30 2,2,2-trifluoroethyl 5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl} benzofuran-2-carboxylate;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-vinylbenzofuran-6-carboxamide;
 4-methyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-6-carboxamide;
 4-methylthio-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-6-
 carboxamide;
- 5 4-methoxy-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-6-carboxamide;
 4-chloro-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-6-carboxamide;
 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-ethynylbenzofuran-6-carboxamide;
 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-prop-1-ynylbenzofuran-6-
 carboxamide;
- 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-hydroxyprop-1-ynyl)benzofuran-
 6-carboxamide;
 methyl 3-(6-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl) benzofuran-
 2-yl)prop-2-ynoate;
 2-(6-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl) benzofuran-2-
 15 yl)prop-2-ynoic acid;
 2-(3-amino-3-oxoprop-1-ynyl)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-
 yl]benzofuran-6-carboxamide;
 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-cyanobenzofuran-6-carboxamide;
 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-chlorobenzofuran-6-carboxamide;
- 20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-fluorobenzofuran-6-carboxamide;
 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-iodobenzofuran-6-carboxamide;
 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-trifluoromethylbenzofuran-6-
 carboxamide;
 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-mercaptobenzofuran-6-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylthio)benzofuran-6-
 carboxamide;
 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylamino)benzofuran-6-
 carboxamide;
 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(formylamino)benzofuran-6-
 30 carboxamide;
 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[formyl(methyl)amino]benzofuran-6-
 carboxamide;

- 2-(acetylamino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-6-carboxamide;
- 2-(acetyl(methyl)amino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-6-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(trifluoroacetyl)amino]benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(benzoylamino)benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(diethylamino)benzofuran-6-carboxamide;
- 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(diisopropylamino)benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(pyrrolidin-1-yl)benzofuran-6-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopyrrolidin-1-yl)benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperidin-1-yl)benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopiperidin-1-yl)benzofuran-6-carboxamide;
- 20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(morpholin-4-yl)benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxomorpholin-4-yl)benzofuran-6-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(thiomorpholin-4-yl)benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxothiomorpholin-4-yl)benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperazin-1-yl)benzofuran-6-carboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopiperazin-1-yl)benzofuran-6-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methylpiperazin-1-yl)benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methyl-2-oxopiperazin-1-yl)benzofuran-6-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxopiperazin-1-yl)benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methyl-3-oxopiperazin-1-yl)benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(cyclopropylamino)benzofuran-6-
- 10 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[dimethylamino]benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-pyrrole-1-yl)benzofuran-6-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-imidazol-1-yl)benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-1,2,4-triazol-1-yl)benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-1,2,3-triazol-1-yl)benzofuran-6-
- 20 carboxamide;
- N-6-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-2,6-dicarboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(pyrrolidin-1-ylcarbonyl)benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperidin-1-ylcarbonyl)benzofuran-
- 25 6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperazin-1-ylcarbonyl)benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(4-methylpiperazin-1-yl)carbonyl]benzofuran-6-carboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(morpholin-4-ylcarbonyl)benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(thiomorpholin-4-ylcarbonyl)benzofuran-6-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(aziridin-1-ylcarbonyl)benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(azetidin-1-ylcarbonyl)benzofuran-6-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-formylbenzofuran-6-carboxamide;
2-acetyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-6-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(trifluoroacetyl)benzofuran-6-carboxamide;
- 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(phenyl)sulfonyl]benzofuran-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylsulfonyl)benzofuran-6-carboxamide;
- 6-[[[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl] benzofuran-2-carboxylic acid;
- 15 methyl 6-[[[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl] benzofuran-2-carboxylate;
- isopropyl 6-[[[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl] benzofuran-2-carboxylate;
- 2,2,2-trifluoroethyl 6-[[[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl] benzofuran-2-carboxylate;
- 20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-vinylbenzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethynylbenzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-prop-1-ynylbenzofuran-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(3-hydroxyprop-1-ynyl)benzofuran-5-carboxamide;
- methyl 3-(5-[[[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl] benzofuran-3-yl)prop-2-ynoate;
- 30 3-(5-[[[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl] benzofuran-3-yl)prop-2-ynoic acid;
- 3-(3-amino-3-oxoprop-1-ynyl)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-cyanobenzofuran-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-chlorobenzofuran-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-fluorobenzofuran-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-iodobenzofuran-5-carboxamide;
5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-trifluoromethylbenzofuran-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-mercaptobenzofuran-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(methylthio)benzofuran-5-carboxamide;
10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(methylamino)benzofuran-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(formylamino)benzofuran-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[formyl(methyl)amino]benzofuran-5-
15 carboxamide;
3-(acetylamino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-5-carboxamide;
3-(acetyl(methyl)amino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-5-carboxamide;
20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[(trifluoroacetyl)amino]benzofuran-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(benzoylamino)benzofuran-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(diethylamino)benzofuran-5-
25 carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(diisopropylamino)benzofuran-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(pyrrolidin-1-yl)benzofuran-5-carboxamide;
30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(2-oxopyrrolidin-1-yl)benzofuran-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(piperidin-1-yl)benzofuran-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(2-oxopiperidin-1-yl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(morpholin-4-yl)benzofuran-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(3-oxomorpholin-4-yl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(thiomorpholin-4-yl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(3-oxothiomorpholin-4-yl)benzofuran-5-carboxamide;
- 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(piperazin-1-yl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(2-oxopiperazin-1-yl)benzofuran-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(4-methylpiperazin-1-yl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(4-methyl-2-oxopiperazin-1-yl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(3-oxopiperazin-1-yl)benzofuran-5-carboxamide;
- 20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(4-methyl-3-oxopiperazin-1-yl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(cyclopropylamino)benzofuran-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[dimethylamino]benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(1H-pyrrole-1-yl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(1H-imidazol-1-yl)benzofuran-5-carboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(1H-1,2,4-triazol-1-yl)benzofuran-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(1H-1,2,3-triazol-1-yl)benzofuran-5-carboxamide;
- N-5-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-3,5-dicarboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(pyrrolidin-1-ylcarbonyl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(piperidin-1-ylcarbonyl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(piperazin-1-ylcarbonyl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[(4-methylpiperazin-1-yl)carbonyl]benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(morpholin-4-ylcarbonyl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(thiomorpholin-4-ylcarbonyl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(aziridin-1-ylcarbonyl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(azetidin-1-ylcarbonyl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-formylbenzofuran-5-carboxamide;
- 3-acetyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(trifluoroacetyl)benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[(phenyl)sulfonyl]benzofuran-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(methylsulfonyl)benzofuran-5-carboxamide;
- 5-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl) benzofuran -3-carboxylic acid;
- methyl 5-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl) benzofuran-3-carboxylate;
- isopropyl 5-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl) benzofuran-3-carboxylate;

2,2,2-trifluoroethyl 5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}benzofuran-3-carboxylate; and a pharmaceutically acceptable salt thereof.

19. The compound according to claim 11, wherein (b) is 1-benzothiophen-6-yl, 1-benzothiophene-5-yl, or 1-benzothiophen-2-yl, any of which is optionally substituted with up to 4 substituents independently selected from F, Cl, Br, -CN, -NO₂, alkyl, substituted alkyl, halogenated alkyl, alkenyl, substituted alkenyl, halogenated alkenyl, alkynyl, substituted alkynyl, halogenated alkynyl, heterocycloalkyl, substituted heterocycloalkyl, halogenated heterocycloalkyl, -OR₈, -SR₈, -NR₈R₈, -NR₈C(O)R₈, or phenyl optionally substituted with up to 4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅.
20. The compound according to claim 19, wherein the compound is selected from
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-vinylbenzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-ethynylbenzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-prop-1-ynylbenzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-hydroxyprop-1-ynyl)benzothiophene-5-carboxamide;
- methyl 3-(5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}benzothiophen-2-yl)prop-2-ynoate;
- 3-(5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}benzothiophen-2-yl)prop-2-ynoic acid;
- 2-(3-amino-3-oxoprop-1-ynyl)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-cyanobenzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-chlorobenzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-fluorobenzothiophene-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-iodobenzothiophene-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-trifluoromethylbenzothiophene-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-mercaptobenzothiophene-5-carboxamide;
5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylthio)benzothiophene-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylamino)benzothiophene-5-carboxamide;
10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(formylamino)benzothiophene-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[formyl(methyl)amino]benzothiophene-5-carboxamide;
2-(acetylamino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-5-carboxamide;
15 2-(acetyl(methyl)amino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(trifluoroacetyl)amino]benzothiophene-5-carboxamide;
20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(benzoylamino)benzothiophene-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(diethylamino)benzothiophene-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(diisopropylamino)benzothiophene-5-carboxamide;
25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(pyrrolidin-1-yl)benzothiophene-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopyrrolidin-1-yl)benzothiophene-5-carboxamide;
30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperidin-1-yl)benzothiophene-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopiperidin-1-yl)benzothiophene-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(morpholin-4-yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxomorpholin-4-yl)benzothiophene-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(thiomorpholin-4-yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxothiomorpholin-4-yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperazin-1-yl)benzothiophene-5-carboxamide;
- 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopiperazin-1-yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methylpiperazin-1-yl)benzothiophene-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methyl-2-oxopiperazin-1-yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxopiperazin-1-yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methyl-3-oxopiperazin-1-yl)benzothiophene-5-carboxamide;
- 20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(cyclopropylamino)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[dimethylamino]benzothiophene-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-pyrrole-1-yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-imidazol-1-yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-1,2,4-triazol-1-yl)benzothiophene-5-carboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-1,2,3-triazol-1-yl)benzothiophene-5-carboxamide;
- N-5-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-2,5-dicarboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(pyrrolidin-1-ylcarbonyl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperidin-1-ylcarbonyl)benzothiophene-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperazin-1-ylcarbonyl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(4-methylpiperazin-1-yl)carbonyl]benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(morpholin-4-ylcarbonyl)benzothiophene-5-carboxamide;
- 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(thiomorpholin-4-ylcarbonyl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(aziridin-1-ylcarbonyl)benzothiophene-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(azetidin-1-ylcarbonyl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-formylbenzothiophene-5-carboxamide;
- 2-acetyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-5-
- 20 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(trifluoroacetyl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(phenyl)sulfonyl]benzothiophene-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylsulfonyl)benzothiophene-5-carboxamide;
- 5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl} benzothiophene-2-carboxylic acid;
- methyl 5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-
- 30 ylamino]carbonyl} benzothiophene-2-carboxylate;
- isopropyl 5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl} benzothiophene-2-carboxylate;

- 2,2,2-trifluoroethyl 5-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl} benzothiophene-2-carboxylate;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-vinylbenzothiophene-6-carboxamide;
- 5 4-methyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-6-carboxamide;
- 4-methylthio-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-6-carboxamide;
- 4-methoxy-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-6-
- 10 carboxamide;
- 4-chloro-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-ethynylbenzothiophene-6-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-prop-1-ynylbenzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-hydroxyprop-1-ynyl)benzothiophene-6-carboxamide;
- methyl 3-(6-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl} benzothiophene-2-yl)prop-2-ynoate;
- 20 2-(6-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl} benzothiophen-2-yl)prop-2-ynoic acid;
- 2-(3-amino-3-oxoprop-1-ynyl)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-6-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-cyanobenzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-chlorobenzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-fluorobenzothiophene-6-
- 30 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-iodobenzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-trifluoromethylbenzothiophene-6-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-mercaptobenzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylthio)benzothiophene-6-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylamino)benzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(formylamino)benzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-
- 10 [formyl(methyl)amino]benzothiophene-6-carboxamide;
- 2-(acetylamino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-6-carboxamide;
- 2-(acetyl(methyl)amino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-6-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-
- [(trifluoroacetyl)amino]benzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(benzoylamino)benzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(diethylamino)benzothiophene-6-
- 20 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(diisopropylamino)benzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(pyrrolidin-1-yl)benzothiophene-6-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopyrrolidin-1-yl)benzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperidin-1-yl)benzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopiperidin-1-yl)benzothiophene-
- 30 6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(morpholin-4-yl)benzothiophene-6-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxomorpholin-4yl)benzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(thiomorpholin-4yl)benzothiophene-6-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxothiomorpholin-4yl)benzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperazin-1-yl)benzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopiperazin-1-yl)benzothiophene-6-carboxamide;
- 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methylpiperazin-1-yl)benzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methyl-2-oxopiperazin-1-yl)benzothiophene-6-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxopiperazin-1-yl)benzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methyl-3-oxopiperazin-1-yl)benzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(cyclopropylamino)benzothiophene-6-carboxamide;
- 20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[dimethylamino]benzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-pyrrole-1-yl)benzothiophene-6-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-imidazol-1-yl)benzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-1,2,4-triazol-1-yl)benzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-1,2,3-triazol-1-yl)benzothiophene-6-carboxamide;
- 30 N-6-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-2,6-dicarboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(pyrrolidin-1-ylcarbonyl)benzothiophene-6-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperidin-1-ylcarbonyl)benzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperazin-1-ylcarbonyl)benzothiophene-6-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(4-methylpiperazin-1-yl)carbonyl]benzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(morpholin-4-ylcarbonyl)benzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(thiomorpholin-4-ylcarbonyl)benzothiophene-6-carboxamide;
- 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(aziridin-1-ylcarbonyl)benzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(azetidin-1-ylcarbonyl)benzothiophene-6-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-formylbenzothiophene-6-carboxamide;
- 2-acetyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(trifluoroacetyl)benzothiophene-6-
- 20 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(phenyl)sulfonyl]benzothiophene-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylsulfonyl)benzothiophene-6-carboxamide;
- 25 6-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl} benzothiophene-2-carboxylic acid;
- methyl 6-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl} benzothiophene-2-carboxylate;
- isopropyl 6-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl} benzothiophene-2-carboxylate;
- 30 2,2,2-trifluoroethyl 6-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl} benzothiophene-2-carboxylate;

- 7-methyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-5-carboxamide;
- 7-methylthio-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-5-carboxamide;
- 5 7-methoxy-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-5-carboxamide;
- 7-chloro-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-vinylbenzothiophene-5-carboxamide;
- 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethynylbenzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-prop-1-ynylbenzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(3-hydroxyprop-1-ynyl)benzothiophene-5-carboxamide;
- 15 methyl 3-(5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl} benzothiophen-3-yl)prop-2-ynoate;
- 3-(5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl} benzothiophen-3-yl)prop-2-ynoic acid;
- 20 3-(3-amino-3-oxoprop-1-ynyl)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-cyanobenzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-chlorobenzothiophene-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-fluorobenzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-iodobenzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-trifluoromethylbenzothiophene-5-carboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-mercaptobenzothiophene-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(methylthio)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(methylamino)benzothiophene-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(formylamino)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[formyl(methyl)amino]benzothiophene-5-carboxamide;
- 3-(acetylamino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-5-
- 10 carboxamide;
- 3-(acetyl(methyl)amino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[(trifluoroacetyl)amino]benzothiophene-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(benzoylamino)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(diethylamino)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(diisopropylamino)benzothiophene-
- 20 5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(pyrrolidin-1-yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(2-oxopyrrolidin-1-yl)benzothiophene-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(piperidin-1-yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(2-oxopiperidin-1-yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(morpholin-4-yl)benzothiophene-5-
- 30 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(3-oxomorpholin-4-yl)benzothiophene-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(thiomorpholin-4yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(3-oxothiomorpholin-4yl)benzothiophene-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(piperazin-1-yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(2-oxopiperazin-1-yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(4-methylpiperazin-1-yl)benzothiophene-5-carboxamide;
- 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(4-methyl-2-oxopiperazin-1-yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(3-oxopiperazin-1-yl)benzothiophene-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(4-methyl-3-oxopiperazin-1-yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(cyclopropylamino)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[dimethylamino]benzothiophene-5-carboxamide;
- 20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(1H-pyrrole-1-yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(1H-imidazol-1-yl)benzothiophene-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(1H-1,2,4-triazol-1-yl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(1H-1,2,3-triazol-1-yl)benzothiophene-5-carboxamide;
- N-5-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-3,5-dicarboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(pyrrolidin-1-ylcarbonyl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(piperidin-1-ylcarbonyl)benzothiophene-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(piperazin-1-ylcarbonyl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[(4-methylpiperazin-1-yl)carbonyl]benzothiophene-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(morpholin-4-ylcarbonyl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(thiomorpholin-4-ylcarbonyl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(aziridin-1-ylcarbonyl)benzothiophene-5-carboxamide;
- 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(azetidin-1-ylcarbonyl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-formylbenzothiophene-5-carboxamide;
- 15 3-acetyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(trifluoroacetyl)benzothiophene-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[(phenyl)sulfonyl]benzothiophene-
- 20 5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(methylsulfonyl)benzothiophene-5-carboxamide;
- 5-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl} benzothiophene -3-carboxylic acid;
- 25 methyl 5-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl} benzothiophene-3-carboxylate;
- isopropyl 5-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl} benzothiophene-3-carboxylate;
- 2,2,2-trifluoroethyl 5-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-
- 30 ylamino]carbonyl} benzothiophene-3-carboxylate; and a pharmaceutically acceptable salt thereof.

21. The compound according to claim 11, wherein (b) is furo[3,2-c]pyridin-2-yl, furo[2,3-b]pyridin-2-yl, furo[2,3-c]pyridin-5-yl, 2,3-dihydrofuro[2,3-c]pyridin-5-yl, furo[2,3-c]pyridin-2-yl, or furo[3,2-c]pyridin-6-yl, any of which is optionally substituted with up to 4 substituents independently selected from F, Cl, Br, -CN, -NO₂, alkyl, substituted alkyl, halogenated alkyl, alkenyl, substituted alkenyl, halogenated alkenyl, alkynyl, substituted alkynyl, halogenated alkynyl, heterocycloalkyl, substituted heterocycloalkyl, halogenated heterocycloalkyl, -OR₈, -SR₈, -NR₈R₈, -NR₈C(O)R₈, or phenyl optionally substituted with up to 4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅.
22. The compound according to claim 21, wherein the compound is selected from
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-vinylfuro[2,3-c]pyridine-5-carboxamide;
- 7-methyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-carboxamide;
- 7-methylthio-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-carboxamide;
- 7-chloro-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-carboxamide;
- 7-methoxy-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethynylfuro[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-prop-1-ynylfuro[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(3-hydroxyprop-1-ynyl)furo[2,3-c]pyridine-5-carboxamide;
- methyl 3-(5-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl)furo[2,3-c]pyridin-3-yl)prop-2-ynoate;
- 3-(5-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl)furo[2,3-c]pyridin-3-yl)prop-2-ynoic acid;
- 3-(3-amino-3-oxoprop-1-ynyl)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-cyanofuro[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-fluorofuro[2,3-c]pyridine-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-iodofuro[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-trifluoromethylfuro[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-mercaptofuro[2,3-c]pyridine-5-
- 10 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(methylthio)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(methylamino)furo[2,3-c]pyridine-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(formylamino)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[formyl(methyl)amino]furo[2,3-c]pyridine-5-carboxamide;
- 3-(acetylamino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-
- 20 carboxamide;
- 3-(acetyl(methyl)amino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[(trifluoroacetyl)amino]furo[2,3-c]pyridine-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(benzoylamino)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(diethylamino)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(diisopropylamino)furo[2,3-
- 30 c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(pyrrolidin-1-yl)furo[2,3-c]pyridine-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(2-oxopyrrolidin-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(piperidin-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(2-oxopiperidin-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(morpholin-4-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(3-oxomorpholin-4-yl)furo[2,3-c]pyridine-5-carboxamide;
- 10 c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(thiomorpholin-4-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(3-oxothiomorpholin-4-yl)furo[2,3-c]pyridine-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(piperazin-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(2-oxopiperazin-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(4-methylpiperazin-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- 20 c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(4-methyl-2-oxopiperazin-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(3-oxopiperazin-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(4-methyl-3-oxopiperazin-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(cyclopropylamino)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[dimethylamino]furo[2,3-c]pyridine-5-carboxamide;
- 30 5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(1H-pyrrole-1-yl)furo[2,3-c]pyridine-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(1H-imidazol-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(1H-1,2,4-triazol-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(1H-1,2,3-triazol-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-5-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-3,5-dicarboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(pyrrolidin-1-ylcarbonyl)furo[2,3-c]pyridine-5-carboxamide;
- 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(piperidin-1-ylcarbonyl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(piperazin-1-ylcarbonyl)furo[2,3-c]pyridine-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[(4-methylpiperazin-1-yl)carbonyl]furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(morpholin-4-ylcarbonyl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(thiomorpholin-4-ylcarbonyl)furo[2,3-c]pyridine-5-carboxamide;
- 20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(aziridin-1-ylcarbonyl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(azetidin-1-ylcarbonyl)furo[2,3-c]pyridine-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-formylfuro[2,3-c]pyridine-5-carboxamide;
- 3-acetyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(trifluoroacetyl)furo[2,3-c]pyridine-
- 30 5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[(phenyl)sulfonyl]furo[2,3-c]pyridine-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(methylsulfonyl)furo[2,3-c]pyridine-5-carboxamide;
- 5-{{{(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino}carbonyl}furo[2,3-c]pyridine-3-carboxylic acid;
- 5 methyl 5-{{{(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino}carbonyl}furo[2,3-c]pyridine-3-carboxylate;
- isopropyl 5-{{{(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino}carbonyl}furo[2,3-c]pyridine-3-carboxylate;
- 2,2,2-trifluoroethyl 5-{{{(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino}carbonyl}furo[2,3-c]pyridine-3-carboxylate;
- 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-vinylfuro[3,2-c]pyridine-6-carboxamide;
- 4-methyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[3,2-c]pyridine-6-carboxamide;
- 15 4-methylthio-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[3,2-c]pyridine-6-carboxamide;
- 4-methoxy-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[3,2-c]pyridine-6-carboxamide;
- 20 4-chloro-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-ethynylfuro[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-prop-1-ynylfuro[3,2-c]pyridine-6-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-hydroxyprop-1-ynyl)furo[3,2-c]pyridine-6-carboxamide;
- methyl 3-(6-{{{(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino}carbonyl}furo[3,2-c]pyridin-2-yl)prop-2-ynoate;
- 30 2-(6-{{{(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino}carbonyl}furo[3,2-c]pyridin-2-yl)prop-2-ynoic acid;
- 2-(3-amino-3-oxoprop-1-ynyl)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[3,2-c]pyridine-6-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-cyanofuro[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-chlorofuro[3,2-c]pyridine-6-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-fluorofuro[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-iodofuro[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-trifluoromethylfuro[3,2-c]pyridine-6-
- 10 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-mercaptofuro[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylthio)furo[3,2-c]pyridine-6-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylamino)furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(formylamino)furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[formyl(methyl)amino]furo[3,2-
- 20 c]pyridine-6-carboxamide;
- 2-(acetyl(amino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[3,2-c]pyridine-6-carboxamide;
- 2-(acetyl(methyl)amino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[3,2-c]pyridine-6-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(trifluoroacetyl)amino]furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(benzoylamino)furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(diethylamino)furo[3,2-c]pyridine-6-
- 30 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(diisopropylamino)furo[3,2-c]pyridine-6-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(pyrrolidin-1-yl)furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopyrrolidin-1-yl)furo[3,2-c]pyridine-6-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperidin-1-yl)furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopiperidin-1-yl)furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(morpholin-4-yl)furo[3,2-c]pyridine-10 6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxomorpholin-4-yl)furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(thiomorpholin-4-yl)furo[3,2-c]pyridine-6-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxothiomorpholin-4-yl)furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperazin-1-yl)furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopiperazin-1-yl)furo[3,2-20 c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methylpiperazin-1-yl)furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methyl-2-oxopiperazin-1-yl)furo[3,2-c]pyridine-6-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxopiperazin-1-yl)furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methyl-3-oxopiperazin-1-yl)furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(cyclopropylamino)furo[3,2-30 c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[dimethylamino]furo[3,2-c]pyridine-6-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-pyrrole-1-yl)furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-imidazol-1-yl)furo[3,2-c]pyridine-6-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-1,2,4-triazol-1-yl)furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-1,2,3-triazol-1-yl)furo[3,2-c]pyridine-6-carboxamide;
- N-6-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[3,2-c]pyridine-2,6-
- 10 dicarboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(pyrrolidin-1-ylcarbonyl)furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperidin-1-ylcarbonyl)furo[3,2-c]pyridine-6-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperazin-1-ylcarbonyl)furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(4-methylpiperazin-1-yl)carbonyl]furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(morpholin-4-ylcarbonyl)furo[3,2-
- 20 c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(thiomorpholin-4-ylcarbonyl)furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(aziridin-1-ylcarbonyl)furo[3,2-c]pyridine-6-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(azetidin-1-ylcarbonyl)furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-formylfuro[3,2-c]pyridine-6-carboxamide;
- 2-acetyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[3,2-c]pyridine-6-
- 30 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(trifluoroacetyl)furo[3,2-c]pyridine-6-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(phenyl)sulfonyl]furo[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylsulfonyl)furo[3,2-c]pyridine-6-carboxamide;
- 5 6-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl} furo[3,2-c]pyridine-2-carboxylic acid;
- methyl 6-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl} furo[3,2-c]pyridine-2-carboxylate;
- isopropyl 6-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl} furo[3,2-c]pyridine-2-carboxylate;
- 10 2,2,2-trifluoroethyl 6-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl} furo[3,2-c]pyridine-2-carboxylate;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-vinylfuro[2,3-c]pyridine-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-ethynylfuro[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-prop-1-ynylfuro[2,3-c]pyridine-5-carboxamide;
- 20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-hydroxyprop-1-ynyl)furo[2,3-c]pyridine-5-carboxamide;
- methyl 3-(5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl} furo[2,3-c]pyridin-2-yl)prop-2-ynoate;
- 2-(5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl} furo[2,3-c]pyridin-2-yl)prop-2-ynoic acid;
- 25 2-(3-amino-3-oxoprop-1-ynyl)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-cyanofuro[2,3-c]pyridine-5-carboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-chlorofuro[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-fluorofuro[2,3-c]pyridine-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-iodofuro[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-trifluoromethylfuro[2,3-c]pyridine-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-mercaptofuro[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylthio)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylamino)furo[2,3-c]pyridine-5-
- 10 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(formylamino)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[formyl(methyl)amino]furo[2,3-c]pyridine-5-carboxamide;
- 15 2-(acetylamino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-carboxamide;
- 2-(acetyl(methyl)amino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(trifluoroacetyl)amino]furo[2,3-
- 20 c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(benzoylamino)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(diethylamino)furo[2,3-c]pyridine-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(diisopropylamino)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(pyrrolidin-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopyrrolidin-1-yl)furo[2,3-
- 30 c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperidin-1-yl)furo[2,3-c]pyridine-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopiperidin-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(morpholin-4-yl)furo[2,3-c]pyridine-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxomorpholin-4-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(thiomorpholin-4-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxothiomorpholin-4-yl)furo[2,3-c]pyridine-5-carboxamide;
- 10 c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperazin-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopiperazin-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methylpiperazin-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methyl-2-oxopiperazin-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxopiperazin-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- 20 c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methyl-3-oxopiperazin-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(cyclopropylamino)furo[2,3-c]pyridine-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[dimethylamino]furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-pyrrole-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-imidazol-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- 30 c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-1,2,4-triazol-1-yl)furo[2,3-c]pyridine-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-1,2,3-triazol-1-yl)furo[2,3-c]pyridine-5-carboxamide;
- N-5-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[3,2-c]pyridine-2,5-dicarboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(pyrrolidin-1-ylcarbonyl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperidin-1-ylcarbonyl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperazin-1-ylcarbonyl)furo[2,3-c]pyridine-5-carboxamide;
- 10 c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(4-methylpiperazin-1-yl)carbonyl]furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(morpholin-4-ylcarbonyl)furo[2,3-c]pyridine-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(thiomorpholin-4-ylcarbonyl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(aziridin-1-ylcarbonyl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(azetidin-1-ylcarbonyl)furo[2,3-c]pyridine-5-carboxamide;
- 20 c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-formylfuro[2,3-c]pyridine-5-carboxamide;
- 2-acetyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[2,3-c]pyridine-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(trifluoroacetyl)furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(phenyl)sulfonyl]furo[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylsulfonyl)furo[2,3-c]pyridine-5-carboxamide;
- 30 5-5-[[[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl]furo[2,3-c]pyridine-2-carboxylic acid;

- methyl 5-[[[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl]furo[2,3-c]pyridine-2-carboxylate;
- isopropyl 5-[[[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl]furo[3,2-c]pyridine-2-carboxylate;
- 5 2,2,2-trifluoroethyl 5-[[[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl]furo[2,3-c]pyridine-2-carboxylate; and a pharmaceutically acceptable salt thereof.

23. The compound according to claim 11, wherein (b) is thieno[2,3-b]pyridin-2-yl, thieno[2,3-b]pyridin-5-yl, thieno[2,3-b]pyridin-6-yl, thieno[2,3-c]pyridin-2-yl, thieno[3,2-b]pyridin-2-yl, thieno[3,2-b]pyridin-5-yl, thieno[3,2-b]pyridin-6-yl, thieno[3,2-c]pyridin-2-yl, thieno[2,3-c]pyridin-5-yl, or thieno[3,2-c]pyridin-6-yl, any of which is optionally substituted with up to 4 substituents independently selected from F, Cl, Br, -CN, -NO₂, alkyl, substituted alkyl, halogenated alkyl, alkenyl, substituted alkenyl, halogenated alkenyl, alkynyl, substituted alkynyl, halogenated alkynyl, heterocycloalkyl, substituted heterocycloalkyl, halogenated heterocycloalkyl, -OR₈, -SR₈, -NR₈R₈, -NR₈C(O)R₈, or phenyl optionally substituted with up to 4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅.

24. The compound according to claim 23, wherein the compound is selected from 7-methyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[2,3-c]pyridine-5-carboxamide;
- 7-methylthio-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[2,3-c]pyridine-5-carboxamide;
- 25 7-methoxy-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[2,3-c]pyridine-5-carboxamide;
- 7-chloro-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-vinylthieno[2,3-c]pyridine-5-carboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethynylthieno[2,3-c]pyridine-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-prop-1-ynylthieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(3-hydroxyprop-1-ynyl)thieno[2,3-c]pyridine-5-carboxamide;
- 5 methyl 3-(5-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl)thieno[2,3-c]pyridin-3-yl)prop-2-ynoate;
- 3-(5-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl)thieno[2,3-c]pyridin-3-yl)prop-2-ynoic acid;
- 3-(3-amino-3-oxoprop-1-ynyl)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[2,3-c]pyridine-5-carboxamide;
- 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-cyanothieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-chlorothieno[2,3-c]pyridine-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-fluorothieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-iodothieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-trifluoromethylthieno[2,3-c]pyridine-5-carboxamide;
- 20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-mercaptothieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(methylthio)thieno[2,3-c]pyridine-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(methylamino)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(formylamino)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[formyl(methyl)amino]thieno[2,3-c]pyridine-5-carboxamide;
- 30 3-(acetylamino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[2,3-c]pyridine-5-carboxamide;

- 3-(acetyl(methyl)amino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[(trifluoroacetyl)amino]thieno[2,3-c]pyridine-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(benzoylamino)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(diethylamino)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(diisopropylamino)thieno[2,3-c]pyridine-5-carboxamide;
- 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(pyrrolidin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(2-oxopyrrolidin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(piperidin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(2-oxopiperidin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(morpholin-4-yl)thieno[2,3-c]pyridine-5-carboxamide;
- 20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(3-oxomorpholin-4-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(thiomorpholin-4-yl)thieno[2,3-c]pyridine-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(3-oxothiomorpholin-4-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(piperazin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(2-oxopiperazin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(4-methylpiperazin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(4-methyl-2-oxopiperazin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(3-oxopiperazin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(4-methyl-3-oxopiperazin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(cyclopropylamino)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[dimethylamino]thieno[2,3-c]pyridine-5-carboxamide;
- 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(1H-pyrrole-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(1H-imidazol-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(1H-1,2,4-triazol-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(1H-1,2,3-triazol-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-5-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[2,3-c]pyridine-3,5-dicarboxamide;
- 20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(pyrrolidin-1-ylcarbonyl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(piperidin-1-ylcarbonyl)thieno[2,3-c]pyridine-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(piperazin-1-ylcarbonyl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[(4-methylpiperazin-1-yl)carbonyl]thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(morpholin-4-ylcarbonyl)thieno[2,3-c]pyridine-5-carboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(thiomorpholin-4-ylcarbonyl)thieno[2,3-c]pyridine-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(aziridin-1-ylcarbonyl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(azetidin-1-ylcarbonyl)thieno[2,3-c]pyridine-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-formylthieno[2,3-c]pyridine-5-carboxamide;
- 3-acetyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(trifluoroacetyl)thieno[2,3-c]pyridine-5-carboxamide;
- 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-[(phenyl)sulfonyl]thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-(methylsulfonyl)thieno[2,3-c]pyridine-5-carboxamide;
- 15 5-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl)thieno[2,3-c]pyridine-3-carboxylic acid;
- methyl 5-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl)thieno[2,3-c]pyridine-3-carboxylate;
- isopropyl 5-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl)thieno[2,3-c]pyridine-3-carboxylate;
- 20 2,2,2-trifluoroethyl 5-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl)thieno[2,3-c]pyridine-3-carboxylate;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-vinylthieno[2,3-c]pyridine-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-ethynylthieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-prop-1-ynylthieno[2,3-c]pyridine-5-carboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-hydroxyprop-1-ynyl)thieno[2,3-c]pyridine-5-carboxamide;
- methyl 3-(5-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl)thieno[2,3-c]pyridin-2-yl)prop-2-ynoate;

- 2-(5-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl)thieno[2,3-c]pyridin-2-yl)prop-2-ynoic acid;
- 2-(3-amino-3-oxoprop-1-ynyl)-N-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[2,3-c]pyridine-5-carboxamide;
- 5 N-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-cyanothieno[2,3-c]pyridine-5-carboxamide;
- N-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-chlorothieno[2,3-c]pyridine-5-carboxamide;
- N-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-fluorothieno[2,3-c]pyridine-5-
- 10 carboxamide;
- N-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-iodothieno[2,3-c]pyridine-5-carboxamide;
- N-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-trifluoromethylthieno[2,3-c]pyridine-5-carboxamide;
- 15 N-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-mercaptothieno[2,3-c]pyridine-5-carboxamide;
- N-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylthio)thieno[2,3-c]pyridine-5-carboxamide;
- N-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylamino)thieno[2,3-c]pyridine-
- 20 5-carboxamide;
- N-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(formylamino)thieno[2,3-c]pyridine-5-carboxamide;
- N-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[formyl(methyl)amino]thieno[2,3-c]pyridine-5-carboxamide;
- 25 2-(acetylamino)-N-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[2,3-c]pyridine-5-carboxamide;
- 2-(acetyl(methyl)amino)-N-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[2,3-c]pyridine-5-carboxamide;
- N-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(trifluoroacetyl)amino]thieno[2,3-
- 30 c]pyridine-5-carboxamide;
- N-([(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(benzoylamino)thieno[2,3-c]pyridine-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(diethylamino)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(diisopropylamino)thieno[2,3-c]pyridine-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(pyrrolidin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopyrrolidin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperidin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- 10 c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopiperidin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(morpholin-4-yl)thieno[2,3-c]pyridine-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxomorpholin-4-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(thiomorpholin-4-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxothiomorpholin-4-yl)thieno[2,3-c]pyridine-5-carboxamide;
- 20 c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperazin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopiperazin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methylpiperazin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methyl-2-oxopiperazin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxopiperazin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- 30 c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methyl-3-oxopiperazin-1-yl)thieno[2,3-c]pyridine-5-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(cyclopropylamino)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[dimethylamino]thieno[2,3-c]pyridine-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-pyrrole-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-imidazol-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-1,2,4-triazol-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-1,2,3-triazol-1-yl)thieno[2,3-c]pyridine-5-carboxamide;
- N-5-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,2-c]pyridine-2,5-dicarboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(pyrrolidin-1-ylcarbonyl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperidin-1-ylcarbonyl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperazin-1-ylcarbonyl)thieno[2,3-c]pyridine-5-carboxamide;
- 20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(4-methylpiperazin-1-yl)carbonyl]thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(morpholin-4-ylcarbonyl)thieno[2,3-c]pyridine-5-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(thiomorpholin-4-ylcarbonyl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(aziridin-1-ylcarbonyl)thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(azetidin-1-ylcarbonyl)thieno[2,3-c]pyridine-5-carboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-formylthieno[2,3-c]pyridine-5-carboxamide;

- 2-acetyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(trifluoroacetyl)thieno[2,3-c]pyridine-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(phenyl)sulfonyl]thieno[2,3-c]pyridine-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylsulfonyl)thieno[2,3-c]pyridine-5-carboxamide;
- 5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}thieno[2,3-c]pyridine-10 2-carboxylic acid;
- methyl 5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}thieno[2,3-c]pyridine-2-carboxylate;
- isopropyl 5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}thieno[2,3-c]pyridine-2-carboxylate;
- 15 2,2,2-trifluoroethyl 5-{[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl}thieno[2,3-c]pyridine-2-carboxylate;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-vinylthieno[3,2-c]pyridine-6-carboxamide;
- 20 4-methyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,2-c]pyridine-6-carboxamide;
- 4-methylthio-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,2-c]pyridine-6-carboxamide;
- 4-methoxy-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,2-c]pyridine-6-25 carboxamide;
- 4-chloro-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-ethynylthieno[3,2-c]pyridine-6-carboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-prop-1-ynylthieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-hydroxyprop-1-ynyl)thieno[3,2-c]pyridine-6-carboxamide;

- methyl 3-(6-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl)thieno[3,2-c]pyridin-2-yl)prop-2-ynoate;
- 2-(6-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl)thieno[3,2-c]pyridin-2-yl)prop-2-ynoic acid;
- 5 2-(3-amino-3-oxoprop-1-ynyl)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-cyanothieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-chlorothieno[3,2-c]pyridine-6-
- 10 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-fluorothieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-iodothieno[3,2-c]pyridine-6-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-trifluoromethylthieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-mercaptothieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylthio)thieno[3,2-c]pyridine-6-
- 20 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylamino)thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(formylamino)thieno[3,2-c]pyridine-6-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[formyl(methyl)amino]thieno[3,2-c]pyridine-6-carboxamide;
- 2-(acetylamin)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,2-c]pyridine-6-carboxamide;
- 2-(acetyl(methyl)amino)-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,2-
- 30 c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(trifluoroacetyl)amino]thieno[3,2-c]pyridine-6-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(benzoylamino)thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(diethylamino)thieno[3,2-c]pyridine-6-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(diisopropylamino)thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(pyrrolidin-1-yl)thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopyrrolidin-1-yl)thieno[3,2-c]pyridine-6-carboxamide;
- 10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperidin-1-yl)thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopiperidin-1-yl)thieno[3,2-c]pyridine-6-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(morpholin-4-yl)thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxomorpholin-4-yl)thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(thiomorpholin-4-yl)thieno[3,2-c]pyridine-6-carboxamide;
- 20 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxothiomorpholin-4-yl)thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperazin-1-yl)thieno[3,2-c]pyridine-6-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(2-oxopiperazin-1-yl)thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methylpiperazin-1-yl)thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methyl-2-oxopiperazin-1-yl)thieno[3,2-c]pyridine-6-carboxamide;
- 30 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(3-oxopiperazin-1-yl)thieno[3,2-c]pyridine-6-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(4-methyl-3-oxopiperazin-1-yl)thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(cyclopropylamino)thieno[3,2-c]pyridine-6-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[dimethylamino]thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-pyrrole-1-yl)thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-imidazol-1-yl)thieno[3,2-c]pyridine-6-carboxamide;
- 10 c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-1,2,4-triazol-1-yl)thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(1H-1,2,3-triazol-1-yl)thieno[3,2-c]pyridine-6-carboxamide;
- 15 N-6-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,2-c]pyridine-2,6-dicarboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(pyrrolidin-1-ylcarbonyl)thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperidin-1-ylcarbonyl)thieno[3,2-c]pyridine-6-carboxamide;
- 20 c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(piperazin-1-ylcarbonyl)thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(4-methylpiperazin-1-yl)carbonyl]thieno[3,2-c]pyridine-6-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(morpholin-4-ylcarbonyl)thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(thiomorpholin-4-ylcarbonyl)thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(aziridin-1-ylcarbonyl)thieno[3,2-c]pyridine-6-carboxamide;
- 30 c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(azetidin-1-ylcarbonyl)thieno[3,2-c]pyridine-6-carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-formylthieno[3,2-c]pyridine-6-carboxamide;
- 2-acetyl-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,2-c]pyridine-6-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(trifluoroacetyl)thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-[(phenyl)sulfonyl]thieno[3,2-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylsulfonyl)thieno[3,2-
- 10 c]pyridine-6-carboxamide;
- 6-[[[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl]thieno[3,2-c]pyridine-2-carboxylic acid;
- methyl 6-[[[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl]thieno[3,2-c]pyridine-2-carboxylate;
- 15 isopropyl 6-[[[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl]thieno[3,2-c]pyridine-2-carboxylate;
- 2,2,2-trifluoroethyl 6-[[[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-ylamino]carbonyl]thieno[3,2-c]pyridine-2-carboxylate; and a pharmaceutically acceptable salt thereof.
- 20
25. The compound according to claim 11, wherein (b) is 1,3-benzothiazole-6-yl, 1,3-benzothiazole-5-yl, 1,3-benzoxazole-6-yl, 1,3-benzoxazole-5-yl, benzimidazole-6-yl, benzimidazole-5-yl, 1,3-benzodioxole-5-yl, 1H-indazole-5-yl, 1H-indazole-6-yl, 1,2-benzisothiazole-6-yl, -yl, 1,2-benzisothiazole-6-yl, 1,3-benzothiazole-5-yl, 1,3-
- 25 benzothiazole-6-yl, 1,3-benzodioxole-5-yl, 1,3-benzodioxole-6-yl, 2H-isoinidole-5-yl, 2H-isoinidole-6-yl, 1H-benzimidazole-5-yl, 1H-benzimidazole-6-yl, [1,3]thiazolo[5,4-c]pyridine-6-yl, [1,3]thiazolo[4,5-c]pyridine-6-yl, [1,3]dioxolo[4,5-c]pyridine-6-yl, or [1,3]oxazolo[4,5-c]pyridine-6-yl, any of which is optionally substituted with up to 4
- substituents independently selected from F, Cl, Br, -CN, -NO₂, alkyl, substituted alkyl,
- 30 halogenated alkyl, alkenyl, substituted alkenyl, halogenated alkenyl, alkynyl, substituted alkynyl, halogenated alkynyl, heterocycloalkyl, substituted heterocycloalkyl, halogenated heterocycloalkyl, -OR₈, -SR₈, -NR₈R₈, -NR₈C(O)R₈, or

phenyl optionally substituted with up to 4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅.

26. The compound of claim 25, wherein the compound is selected from
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1H-indazole-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1H-indazole-6-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-methyl-1H-indazole-6-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-methyl-1H-indazole-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethyl-1H-indazole-6-carboxamide;
10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethyl-1H-indazole-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1,2-benzisothiazole-6-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1,2-benzisothiazole-5-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethyl-1,2-benzisothiazole-6-
carboxamide;
15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-ethyl-1,2-benzisothiazole-5-
carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-methyl-1,2-benzisothiazole-6-
carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-3-methyl-1,2-benzisothiazole-5-
20 carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-methyl-1,3-benzothiazole-6-
carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-methyl-1,3-benzothiazole-5-
carboxamide;
25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-ethyl-1,3-benzothiazole-6-
carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-ethyl-1,3-benzothiazole-5-
carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-methyl-1,3-benzodioxole-5-
30 carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-ethyl-1,3-benzodioxole-5-
carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2,2-dimethyl-1,3-benzodioxole-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2H-isoindole-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2H-isoindole-6-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1H-benzimidazole-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1H-benzimidazole-6-carboxamide;
- N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl][1,3]thiazolo[5,4-c]pyridine-6-carboxamide;
- N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl][1,3]thiazolo[4,5-c]pyridine-6-carboxamide;
- N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl][1,3]dioxolo[4,5-c]pyridine-6-carboxamide;
- 10 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl][1,3]oxazolo[4,5-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1H-imidazo[4,5-c]pyridine-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1,3-benzothiazole-5-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-bromo-1,3-benzothiazole-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-chloro-1,3-benzothiazole-5-carboxamide;
- 2-amino-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1,3-benzothiazole-5-
- 20 carboxamide;
- 2-(acetylamino-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1,3-benzothiazole-5-
- carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-methoxy-1,3-benzothiazole-5-
- carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-phenoxy-1,3-benzothiazole-5-
- carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(phenylthio)-1,3-benzothiazole-5-
- carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylthio)-1,3-benzothiazole-5-
- 30 carboxamide;
- 2-anilino-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1,3-benzothiazole-5-
- carboxamide;

- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-morpholin-4-yl-1,3-benzothiazole-5-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-piperazin-1-yl-1,3-benzothiazole-5-carboxamide;
- 5 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1,3-benzothiazole-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-bromo-1,3-benzothiazole-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-chloro-1,3-benzothiazole-6-
- 10 carboxamide;
- 2-amino-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1,3-benzothiazole-6-carboxamide;
- 2-(acetylamino-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1,3-benzothiazole-6-carboxamide;
- 15 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-methoxy-1,3-benzothiazole-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-phenoxy-1,3-benzothiazole-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(phenylthio)-1,3-benzothiazole-6-
- 20 carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-(methylthio)-1,3-benzothiazole-6-carboxamide;
- 2-anilino-N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-1,3-benzothiazole-6-carboxamide;
- 25 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-morpholin-4-yl-1,3-benzothiazole-6-carboxamide;
- N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-piperazin-1-yl-1,3-benzothiazole-6-carboxamide; or a pharmaceutically acceptable salt thereof.

30 27. The compound of claim 3, wherein W is (c).

28. The compound of claim 27, wherein (c) is isoquinolin-3-yl, quinoline-3-yl, 2,3-dihydro[1,4]dioxino[2,3-c]pyridine-7-yl, 2,3-dihydro-1,4-benzodioxine-6-yl,

- chromane-6-yl, 2H-chromene-6-yl, 2H-pyrano[2,3-c]pyridine-6-yl, 2H-pyrano[2,3-c]pyridine-7-yl, 3,4-dihydro-2H-pyrano[2,3-c]pyridine-6-yl, or 3,4-dihydro-2H-pyrano[2,3-c]pyridine-7-yl, any of which is optionally substituted with up to 4 substituents independently selected from F, Cl, Br, -CN, -NO₂, alkyl, substituted alkyl, halogenated alkyl, alkenyl, substituted alkenyl, halogenated alkenyl, alkynyl, substituted alkynyl, halogenated alkynyl, heterocycloalkyl, substituted heterocycloalkyl, halogenated heterocycloalkyl, -OR₈, -SR₈, -NR₈R₈, -NR₈C(O)R₈, or phenyl optionally substituted with up to 4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅.
29. The compound of claim 28, wherein each R₄ is independently H, lower alkyl, or substituted lower alkyl.
30. The compound according to claim 29, wherein R₆ is an amino protecting group.
31. The compound according to claim 29, wherein R₆ is H, or lower alkyl optionally substituted with up to 3 substituents independently selected from F, Cl, Br, I, -OH, -CN, -NH₂, -NH(alkyl), or -N(alkyl)₂.
32. The compound of claim 31, wherein R₁ is H or lower alkyl, and wherein R₂ is H or lower alkyl.
33. The compound of claim 32, wherein at least one R₄ is H and one R₄ is H or lower alkyl optionally substituted with 1 substituent selected from -OR₁₀, -SR₁₀, -S(O)R₁₀, -S(O)₂R₁₀, -OS(O)₂R₁₀, -NR₁₀R₁₀, -C(O)R₁₀, -C(O)OR₁₀, -C(S)R₁₀, -C(O)NR₁₀R₁₀, -CN, -NR₁₀C(O)R₁₀, -NR₁₀C(O)NR₁₀R₁₀, -S(O)₂NR₁₀R₁₀, -NR₁₀S(O)₂R₁₀, -NO₂, or phenyl optionally substituted with up to 4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅, provided that when said lower alkyl is optionally substituted, said lower alkyl can be further optionally substituted with up to 3 substituents independently selected from F, Cl, Br, and I, wherein R₁₀ is H, lower alkyl, or halogenated lower alkyl.

34. The compound according to claim 33, wherein R_1 , R_2 , and each R_4 is H.
35. The compound according to claim 34, wherein the compound is N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]isoquinoline-3-carboxamide; or a
5 pharmaceutically acceptable salt thereof.
36. The compound according to claim 34, wherein the compound is N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-methylisoquinoline-3-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-methylisoquinoline-3-carboxamide;
10 N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-methoxyisoquinoline-3-carboxamide; N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-trifluoromethylisoquinoline-3-carboxamide; N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-chloroisoquinoline-3-carboxamide; N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-bromoisoquinoline-3-carboxamide; N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-fluoroisoquinoline-3-carboxamide; N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-iodoisoquinoline-3-carboxamide; N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-ethynylisoquinoline-3-carboxamide; N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-cyanoisoquinoline-3-carboxamide; N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-ethenylisoquinoline-3-carboxamide; N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-6-nitroisoquinoline-3-carboxamide; N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]2,3-dihydro-1,4-benzodioxane-6-carboxamide; N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]chromane-6-carboxamide; or a
20 pharmaceutically acceptable salt thereof.
- 25 37. The compound of claim 3, wherein W is (d).
38. The compound of claim 37, wherein each R_4 is independently H, lower alkyl, or lower substituted alkyl.
- 30 39. The compound according to claim 38, wherein R_6 is an amino protecting group.

40. The compound according to claim 38, wherein R_6 is H, or lower alkyl optionally substituted with up to 3 substituents independently selected from F, Cl, Br, I, -OH, -CN, -NH₂, -NH(alkyl), or -N(alkyl)₂.
- 5 41. The compound of claim 40, wherein R_1 is H or lower alkyl, and wherein R_2 is H or lower alkyl.
42. The compound of claim 41, wherein at least one R_4 is H and one R_4 is H or lower alkyl optionally substituted with 1 substituent selected from -OR₁₀, -SR₁₀,
10 -S(O)R₁₀, -S(O)₂R₁₀, -OS(O)₂R₁₀, -NR₁₀R₁₀, -C(O)R₁₀, -C(O)OR₁₀, -C(S)R₁₀,
-C(O)NR₁₀R₁₀, -CN, -NR₁₀C(O)R₁₀, -NR₁₀C(O)NR₁₀R₁₀, -S(O)₂NR₁₀R₁₀,
-NR₁₀S(O)₂R₁₀, -NO₂, or phenyl optionally substituted with up to 4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅, provided that when said lower alkyl is optionally substituted, said lower alkyl can be further optionally substituted
15 with up to 3 substituents independently selected from F, Cl, Br, and I,
wherein R₁₀ is H, lower alkyl, or halogenated lower alkyl.
43. The compound according to claim 42, wherein R_1 , R_2 , and each R_4 are H.
- 20 44. The compound of claim 43, wherein (d) is thieno[3,4-c]pyridin-6-yl, furo[3,4-c]pyridin-6-yl, 2-benzothiophen-5-yl, 2-benzothiophen-6-yl, 2-benzofuran-5-yl, or 2-benzofuran-6-yl, any of which is optionally substituted with up to 4 substituents independently selected from F, Cl, Br, -CN, -NO₂, alkyl, substituted alkyl, halogenated alkyl, alkenyl, substituted alkenyl, halogenated alkenyl, alkynyl,
25 substituted alkynyl, halogenated alkynyl, heterocycloalkyl, substituted heterocycloalkyl, halogenated heterocycloalkyl, -OR₈, -SR₈, -NR₈R₈, -NR₈C(O)R₈, or phenyl optionally substituted with up to 4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅.
- 30 45. The compound according to claim 44, wherein the compound is N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]thieno[3,4-c]pyridine-6-carboxamide; or a pharmaceutically acceptable salt thereof.

46. The compound according to claim 44, wherein the compound is N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]furo[3,4-c]pyridine-6-carboxamide, N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-benzofuran-5-carboxamide; N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]-2-benzothiophen-5-carboxamide; or a pharmaceutically acceptable salt thereof.

47. The compound of claim 3, wherein W is (e).

48. The compound of claim 47, wherein (e) is [1]benzothieno[2,3-c]pyridin-3-yl, [1]benzothieno[3,2-c]pyridin-3-yl, [1]benzofuro[3,2-c]pyridin-3-yl, [1]benzofuro[2,3-c]pyridin-3-yl, dibenzo[b,d]thiophen-2-yl, or dibenzo[b,d]furan-2-yl, any of which is optionally substituted with up to 4 substituents independently selected from F, Cl, Br, -CN, -NO₂, alkyl, substituted alkyl, halogenated alkyl, alkenyl, substituted alkenyl, halogenated alkenyl, alkynyl, substituted alkynyl, halogenated alkynyl, heterocycloalkyl, substituted heterocycloalkyl, halogenated heterocycloalkyl, -OR₈, -SR₈, -NR₈R₈, -NR₈C(O)R₈, or phenyl optionally substituted with up to 4 substituents independently selected from F, Cl, Br, I, R₁₃, and R₁₅.

49. The compound of claim 48, wherein each R₄ is independently H, lower alkyl, or substituted lower alkyl.

50. The compound according to claim 49, wherein R₆ is an amino protecting group.

51. The compound according to claim 49, wherein R₆ is H, or lower alkyl optionally substituted with up to 3 substituents independently selected from F, Cl, Br, I, -OH, -CN, -NH₂, -NH(alkyl), or -N(alkyl)₂.

52. The compound of claim 51, wherein R₁ is H or lower alkyl, and wherein R₂ is H or lower alkyl.

53. The compound of claim 52, wherein at least one R₄ is H and one R₄ is H or lower alkyl optionally substituted with 1 substituent selected from -OR₁₀, -SR₁₀, -S(O)R₁₀, -S(O)₂R₁₀, -OS(O)₂R₁₀, -NR₁₀R₁₀, -C(O)R₁₀, -C(O)OR₁₀, -C(S)R₁₀,

- C(O)NR₁₀R₁₀, -CN, -NR₁₀C(O)R₁₀, -NR₁₀C(O)NR₁₀R₁₀, -S(O)₂NR₁₀R₁₀,
-NR₁₀S(O)₂R₁₀, -NO₂, or phenyl optionally substituted with up to 4 substituents
independently selected from F, Cl, Br, I, R₁₃, and R₁₅, provided that when said lower
alkyl is optionally substituted, said lower alkyl can be further optionally substituted
5 with up to 3 substituents independently selected from F, Cl, Br, and I,
wherein R₁₀ is H, lower alkyl, or halogenated lower alkyl.

54. The compound according to claim 53, wherein R₁, R₂, and each R₄ are H.
- 10 55. The compound according to claim 54, wherein the compound is N-[(1S, 2R,
4R)-7-azabicyclo[2.2.1]hept-2-yl]dibenzo[b,d]thiophene-2-carboxamide; N-[(1S, 2R,
4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothieno[2,3-c]pyridine-3-carboxamide; N-[(1S,
2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzothieno[3,2-c]pyridine-3-carboxamide; N-
[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]dibenzo[b,d]furan-2-carboxamide; N-
15 [(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuro[3,2-c]pyridine-3-carboxamide;
N-[(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl]benzofuro[2,3-c]pyridine-3-
carboxamide; or a pharmaceutically acceptable salt thereof.
56. A pharmaceutical composition comprising a compound according to any one
20 of claims 1-55, an anti-psychotic agent, and a pharmaceutically acceptable excipient.
57. The pharmaceutical composition according to claim 56, wherein said
compound and said agent are to be independently administered rectally, topically,
orally, sublingually, or parenterally for a therapeutically effective interval.
58. The pharmaceutical composition according to claim 56, wherein said
25 compound is administered in an amount of from about 0.001 to about 100mg/kg of
body weight of said mammal per day.
59. The pharmaceutical composition according to claim 56, wherein said
compound is administered in an amount of from about 0.1 to about 50mg/kg of body
weight of said mammal per day.
- 30 60. The pharmaceutical composition according to claim 56 comprising a
compound according to any one of claims 1-55 and a pharmaceutically acceptable
excipient.

61. The pharmaceutical composition according to claim 60, wherein said compound is administered rectally, topically, orally, sublingually, or parenterally for a therapeutically effective interval.
62. The pharmaceutical composition according to claim 60, wherein said
5 compound is administered in an amount of from about 0.001 to about 100mg/kg of body weight of said mammal per day.
63. The pharmaceutical composition according to claim 60, wherein said compound is administered in an amount of from about 0.1 to about 50mg/kg of body weight of said mammal per day.
- 10 64. Use of a compound according to any one of claims 1-55 for the preparation of a medicament for treating a disease or condition, wherein the mammal would receive symptomatic relief from the administration of a therapeutically effective amount of $\alpha 7$ nicotinic acetylcholine receptor agonist.
- 15 65. The use according to claim 64, wherein the disease or condition is cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), or senile dementia.
- 20 66. The use according to claim 64, wherein the disease or condition is schizophrenia or psychosis.
67. The use of claim 66, wherein the mammal would receive symptomatic relief
25 from the administration of a therapeutically effective amount of $\alpha 7$ nicotinic acetylcholine receptor agonist and an anti-psychotic agent for a therapeutically effective interval.
68. The use according to claim 64, wherein the disease or condition is depression,
30 anxiety, general anxiety disorders, or post traumatic stress disorder.
69. The use according to claim 64, wherein the disease or condition is attention deficit disorder, or attention deficit hyperactivity disorder.

70. The use according to claim 64, wherein the disease or condition is mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems in general and associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, Parkinson's disease, tardive dyskinesia, Pick's disease, dysregulation of food intake including bulimia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependant drug cessation, Gilles de la Tourette's Syndrome, age-related macular degeneration, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain.

71. A method for treating a disease or condition in a mammal in need thereof, wherein the mammal would receive symptomatic relief from the administration of an $\alpha 7$ nicotinic acetylcholine receptor agonist comprising administering to the mammal a therapeutically effective amount of a compound according to any one of claims 1-55.

72. The method according to claim 71, wherein the disease or condition is cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), or senile dementia.

73. The method according to claim 71, wherein the disease or condition is schizophrenia or psychosis.

74. The method of claim 73, wherein the mammal would receive symptomatic relief from the administration of a therapeutically effective amount of $\alpha 7$ nicotinic acetylcholine receptor agonist and an anti-psychotic agent for a therapeutically effective interval.

75. The use according to claim 71, wherein the disease or condition is depression, anxiety, general anxiety disorders, post traumatic stress disorder.

76. The use according to claim 71, wherein the disease or condition is attention deficit disorder, or attention deficit hyperactivity disorder.

77. The method according to claim 71, wherein the disease or condition is mood
5 and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems in general and associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, Parkinson's disease, tardive dyskinesia, Pick's disease, dysregulation of food intake including
10 bulimia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependant drug cessation, Gilles de la Tourette's Syndrome, age-related macular degeneration, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 02/25959

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D519/00 A61K31/4025 A61P25/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BANNON A W ET AL: "BROAD-SPECTRUM, NON-OPIOID ANALGESIC ACTIVITY BY SELECTIVE MODULATION OF NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 279, no. 5347, 1998, pages 77-81, XP000906771 ISSN: 0036-8075 the whole document	1-77
Y	WO 96 06093 A (UNIV VIRGINIA ; SHEN T Y (US); HARMAN W DEAN (US); HUANG DAO FEI (U) 29 February 1996 (1996-02-29) page 9 -page 13; examples 63-92 page 108 -page 129; claims 1-34 --- -/--	1-77

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

13 November 2002

Date of mailing of the international search report

27/11/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Papathoma, S

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/25959

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5 998 429 A (MACOR JOHN ET AL) 7 December 1999 (1999-12-07) cited in the application column 1 -column 2 column 6 -column 9; claims 1,3,4,7,9-12; example 3	1-77
Y	WO 01 60821 A (ASTRAZENECA AB ;PHILLIPS EIFION (US); SCHMIESING RICHARD (US)) 23 August 2001 (2001-08-23) cited in the application page 1 -page 6; claims 1-3,6,10,19,31-36	1-77

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 02/25959

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9606093 A	29-02-1996	US 5817679 A	06-10-1998
		AU 708112 B2	29-07-1999
		AU 3540695 A	14-03-1996
		CA 2196979 A1	29-02-1996
		CN 1163613 A ,B	29-10-1997
		EP 0778835 A1	18-06-1997
		HU 77938 A2	30-11-1998
		JP 2002504883 T	12-02-2002
		US 6255490 B1	03-07-2001
		WO 9606093 A1	29-02-1996
US 5998429 A	07-12-1999	AT 1219081 T	15-06-2002
		AU 706944 B2	01-07-1999
		AU 2238797 A	10-09-1997
		BR 9707616 A	27-07-1999
		CN 1211983 A ,B	24-03-1999
		CZ 9802659 A3	16-02-2000
		DE 69713295 D1	18-07-2002
		EE 9800250 A	15-02-1999
		EP 0885221 A1	23-12-1998
		HK 1017357 A1	03-08-2001
		HU 9901273 A2	28-07-1999
		IL 125620 A	13-09-2001
		JP 2000505452 T	09-05-2000
		NO 983711 A	13-08-1998
		NZ 331145 A	28-02-2000
		PL 328614 A1	01-02-1999
		WO 9730998 A1	28-08-1997
		SK 102798 A3	11-01-1999
		TR 9801642 T2	23-11-1998
		US 6054464 A	25-04-2000
		ZA 9701082 A	25-08-1997
WO 0160821 A	23-08-2001	AU 3259401 A	27-08-2001
		WO 0160821 A1	23-08-2001

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USTO)